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Multiple factors contribute to mother-to-child transmission (MTCT) of HIV-1, including 
virological, obstetric and biological factors. Other possible contributory determinants for high 
MTCT rates include immunological factors such as host genetics and viral genetic variations. 
Despite several therapeutic, prophylactic and obstetric interventions to reduce the proportion 
of infants infected during labour and delivery, mechanisms for intrapartum HIV-1 
transmission remain elusive and current interventions, could, therefore remain sub-optimal. 
Much controversy has surrounded the correlation of HIV-1 RNA (viral load) in the systemic 
and genital compartments of women.  
 
The influence of short-term antiretroviral (ARV) drugs on genital tract HIV-1 is also unclear. 
At the time the present study was initiated, a regimen of maternal intrapartum and neonatal 
postpartum single-dose Nevirapine (sdNVP) was the standard of care for the prevention of 
mother-to-child transmission (PMTCT). In most low and middle-income countries, including 
South Africa, sdNVP has been documented as effective intrapartum HIV-1 prevention based 
on plasma pharmacokinetic levels, decreased viral loads (HIV-1 RNA) and reduced rates of 
intrapartum transmission, yet operational studies continue to report high intrapartum 
transmission rates despite the administration of sdNVP. As a result perinatal HIV-1 




The primary aim of this study was to describe the pharmacological dynamics of Nevirapine in 
association with virological and immunological risk factors for intrapartum HIV-1 
transmission in a South African PMTCT programme where sdNVP was the standard of care. 
 
Methods:  
Following regulatory approval from the Biomedical Research Ethics Committee at the 
University of KwaZulu-Natal (UKZN), one hundred and twenty pregnant HIV-infected 
women who received the sdNVP regimen for prevention of mother-to-child HIV-1 
transmission were enrolled between April-December 2006 at King Edward VIII Hospital 
(KEH) in Durban. Blood and cervicovaginal lavage (CVL) samples were collected from 
women at pre-NVP (during pregnancy) and post-NVP dosing (during labour/delivery). In 
addition to infant blood sampling at birth (post-NVP), postnatal infants were assessed at four 
and six weeks postnatally. Pharmacological laboratory investigations involved measurement 
of NVP drug concentration by Tandem Mass spectrophotometry. Virological investigations 
comprised HIV-1 RNA (viral load) quantitation, HIV-1 drug resistance testing (HIV-1 
transmitting women only) and HIV-1 DNA PCR testing (infants only). Immunological 
investigations were only undertaken in a selected case-control subset of HIV-1 transmitting 
women and their infants. In this component, laboratory investigations included the 
determination of CCL3 and CCL3-L1 gene copy numbers, identification of single nucleotide 
polymorphisms (SNP’s) and haplotype characterisation of the CCL3 gene. All women were 




One hundred and twenty women were enrolled onto this study. Of these, 110 women delivered 
117 live infants (103 singletons and 7 twin pairs). Twelve (10.9%) women transmitted HIV-1 
to their infants, while 95 (86.0%) were classified as non-transmitters. As a result of seven twin 
deliveries, the infant cohort comprised of 117 infants in total. Following two separate DNA 
PCR tests, HIV-1 infection was identified in 14 (11.9%) of study infants while the remaining 
90 (76.9%) were exposed-uninfected. HIV infection status remained unknown for 13 infants 
due to infant demise (1.7%), lost to follow-up (7.7%) or study withdrawal (1.7%).  
 
During active labour (sampling that was best representative of the intrapartum phase) and 
within 20 hours of dosing, the median NVP concentration of 1070 ng/ml in the maternal 
systemic compartment was almost 44 times higher than the NVP levels detected in the genital 
compartment [24.5 ng/ml] (p < 0.001). NVP drug levels were below the 100 ng/ml therapeutic 
target in seven (13.7%) of 51 plasma and in all 39 CVL samples. While no significant 
association was found between NVP concentration in the systemic compartment and HIV-1 
transmission (p = 0.4), this association was statistically significant in the genital compartment 
(p = 0.02). The median plasma NVP level detected among infants at birth was 83 times above 
the IC50 WT (10 ng/ml) and eight times higher than the 100 ng/ml therapeutic target for NVP.  
More than 71.0% of the infants achieved NVP drug levels above the therapeutic target.  
 
In general, higher levels of HIV-1 RNA (viral load) were observed in maternal plasma when 
compared to CVL. Following intrapartum sdNVP dosing, reduction in HIV-1 RNA levels did 
occur, however ≥80.0% of the women experienced no change to their HIV-1 RNA levels in 
both systemic and genital compartments during active labour. These findings were further 
 xxvi
supported by the strong correlation observed when comparing pre and post-NVP HIV-1 RNA 
levels in both maternal systemic [r = 0.81, p < 0.0001] and genital compartments [r = 0.80, p < 
0.0001] during active labour. HIV-1 transmitting women had significantly higher viral loads 
than their non-transmitting counterparts in systemic and genital compartments, before and 
after intrapartum sdNVP administration. In terms of perinatal transmission this observation 
was only statistically significant for plasma (p = 0.02) and not CVL (p = 0.7). Maternal viral 
load was inversely correlated with maternal CD4 cell counts in both systemic and genital 
compartments. Almost 40.0% of women in this study had at least one type of STI detected 
during pregnancy. Maternal STI’s were detected in four (66.6%) intrapartum transmitting 
women and in 38 (38.8%) of non-transmitting women. No significant association was 
observed between the presence of maternal STI’s and the risk for intrapartum MTCT (p = 0.2, 
RR: 2.90, 95% CI: 0.60-15.40). The presence of maternal STI’s was associated with higher 
median viral loads in both systemic and genital compartments of all women, independent of 
intrapartum HIV-1 transmission.  
 
Despite trial-like conditions and optimal sdNVP dosing, the overall MTCT rate in this 
exclusively formula-fed cohort was 11.9%, of which 50.0% were in utero and 50.0% were 
intrapartum HIV-1 transmissions. In utero and intrapartum MTCT rates were 5.9% and 5.9% 
respectively.   
 
Discussion/Conclusion:  
Detectable CVL HIV-1 RNA that correlated well with plasma HIV-1 RNA, in conjunction 
with sub-optimal NVP drug concentration in maternal CVL during active labour, suggests that 
intrapartum HIV-1 infected women continue to act as reservoirs for both vertical and 
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horizontal HIV-1 transmission throughout the duration of pregnancy. These findings confirm 
that the role of sdNVP in PMTCT was primarily one of infant prophylaxis. This was further 
supported by relatively unchanged maternal HIV-1 RNA (viral load) during active labour, in 
both systemic and genital compartments.  
 
Early identification of women who need highly active antiretroviral therapy (HAART), and 
initiation of such therapy as early as possible during pregnancy, not only benefits maternal 
health but remains the best prophylaxis against mother-to-child HIV-1 transmission. Universal 
access to HAART and improving strategies to optimize coverage of the current dual ARV 
regimen sdNVP and Zidovudine for PMTCT remain urgent research priorities in several 
resource-limited settings. Ongoing STI counseling, intensive screening/testing of women and 
their partners together promotion of condom usage, safer sex practices and aggressive STI 
treatment are simple interventions with tremendous impact for PMTCT in resource-limited 
settings. 
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CHAPTER ONE: REVIEW OF LITERATURE 
1.1 HIV/AIDS: A global and local perspective 
According to the latest global summary of the Acquired Immune Deficiency Syndrome 
(AIDS) epidemic by the United Nations, an estimated 33 million (30.3 - 36.1 million) people 
were living with Human Immunodeficiency Virus (HIV-1) by the end of 2007 (UNAIDS, 
2008a). Sub-Saharan Africa remains one of the most seriously affected regions of the world, 
accounting for 67.0% of all people living with HIV-1 and 72.0% of AIDS-related deaths in 
2007 (Fig 1). This region along with several of the world’s HIV-1 epicenters (India, China, 




Fig 1: Adults and children estimated to be living with HIV-1 (UNAIDS, 2008a) 
 
Global estimate = 33 million 
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Fig 2: Subtype diversity of HIV-1 infections prevalent worldwide (Spira et al, 2003) 
 
Women, in particular (68.0%), continue to endure an extremely disproportionate burden of the 
HIV/AIDS crisis all across this continent (UNAIDS, 2008a). The South African HIV-1 
experience appears to be similar in its disproportionate and devastating impact upon women, 
particularly those of child-bearing potential. In a survey by the Human Sciences Research 
Council, women aged between 15-24 years were four times more likely to be HIV-1 infected 
than their male counterparts (Shisana et al, 2005). From inception in the early 1990’s, the 
annual national survey of HIV-1 and Syphilis prevalence (Fig 3), undertaken by the National 
Department of Health, has continued to indicate that HIV-1 prevalence among antenatal clinic 
attendees is no longer increasing exponentially but stabilizing at a high value (Department of 
Health, 2007).               
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Fig 3:  National HIV-1 prevalence among antenatal attendees in South Africa  
     from 1990-2006 (Department of Health, 2007) 
 
While the national antenatal HIV-1 prevalence rate was ~30.2% in 2005, considerable inter-
provincial discrepancy was observed (Fig 4) with some provinces being more badly affected 
than others. In 2005, KwaZulu Natal (KZN) province had the highest antenatal prevalence 
while the Western Cape (15.7%) province demonstrated the lowest HIV-1 prevalence 
(Department of Health, 2007).                   
 
Fig 4: Provincial HIV-1 prevalence among antenatal attendees in South Africa  
(Department of Health, 2007) 
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HIV-1 prevalence among antenatal attendees ranged from 13.0% (< 20 years); 28.0% (20-24 
years); 38.7% (25-29 years); 37.0% (30-34 years); 29.6% (35-39 years) to 21.3% among 
women aged 40 years and above (Department of Health, 2007). 
 
1.2 HIV-1 and pregnancy 
Worldwide more than 3.28 million pregnant women infected with HIV-1 are estimated to give 
birth annually. While studies have shown that pregnancy does not adversely affect HIV-1 
disease progression or survival, observational studies have strongly implicated HIV-1 in the 
reduction of fertility and a variable rate of adverse pregnancy outcomes such as increased 
spontaneous miscarriage, low birth weight and still-birth (Langston et al, 1995; Rollins et al, 
2007). 
 
1.3  Mother-to-child transmission of HIV-1 
As the number of HIV-1 infected women has dramatically increased over the years, so has the 
number of perinatally-acquired infections, with the majority of paediatric infections being 
attributable primarily to mother-to-child transmission (MTCT). MTCT occurs when a 
pregnant HIV-1 infected woman transmits or passes the virus onto her baby; either during the 
course of pregnancy, at the time of labour/delivery or postnatally through breastfeeding. 
 
Each year an estimated 700 000 infants become HIV-1 infected, mainly through MTCT. 
Around 90.0% of these infections take place in Sub-Saharan Africa, South Asia or South East 
Asia. In sharp contrast, MTCT has been almost eradicated in resource-rich countries through 
the effective implementation of evidence-based interventions. These interventions have 
encompassed; accessibility to antiretroviral (ARV) therapy, safe obstetric practices, effective 
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voluntary testing and counseling (VCT) and the widespread availability of safe breast-milk 
substitutes (European collaborative study, 2005; UNAIDS, 2005). The use of evidence-based 
interventions has resulted in vertical transmission rates that vary from less than 5.0% in 
resource-rich countries to greater than 30.0% in resource-limited countries without access to 
ARV interventions and with prolonged breastfeeding practices (Chersich et al, 2006; McIntyre 
and Gray, 2002). Access to HAART, modified obstetric practices and the use of exclusive 
formula feeding are some of the improved interventions which have further reduced MTCT 
rates to less than 2.0% (Fig 5) in resource-rich countries (Mofenson and McIntyre, 2000; 
Coovadia, 2004; McIntyre and Gray, 2002). 
 
 
                        
Fig 5: Effect of evidence-based interventions on MTCT rates (McIntyre and Gray, 2002) 
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1.3.1 Timing and pathogenesis of MTCT 
MTCT is known to occur in utero (Brossard et al, 1995; Lewis et al, 1990), intrapartum 
(Mofenson, 1997) and postpartum through breastfeeding (Leroy et al, 1998). In the absence of 
any evidence-based intervention, 15.0%-45.0% of women will transmit HIV-1 to their 
children; (5.0-10.0%) in utero, (10.0-20.0%) intrapartum and (5.0-20.0%) postpartum [De 
Cock et al, 2000].  MTCT rates can vary from 15-30% without breastfeeding and can reach 
30-45% with prolonged breastfeeding depending on population and regional diversities 
(Moodley and Coovadia, 2008). 
 
The precise mechanism and timing of in utero transmission is presently unknown, however 
studies have shown that these infections may occur in the last two months of pregnancy, hence 
the administration of ARV drugs during the last trimester of pregnancy may reduce in utero 
infections (Luzuriaga, 2007). Similarly the mechanism for intrapartum HIV-1 transmission is 
not well understood but may occur due to transplacental microtransfusions (Kwiek et al, 2006) 
or by infection via mucosal exposure to maternal blood or cervicovaginal secretions (Van de 
Perre, 1999). While multiple factors contribute to MTCT of HIV-1, viraemia in plasma and 
genital fluids of HIV-1 infected pregnant women has been documented to correlate strongly 
with intrapartum HIV-1 transmission (Gaillard et al, 2000). Observations such as the 
differential rate of infection for vaginally delivered twins, protective effects offered by 
caesarean sections, the association between perinatal transmission and prolonged rupture of 
membranes all suggest that a newborns exposure to HIV-1 present in cervicovaginal secretions 
and blood while passing through the birth canal may be a very important determinant of 
intrapartum transmission (Chuachoowang et al, 2000). While use of elective caesarean 
sections prior to the onset of labour is known to reduce the risk of intrapartum transmission, 
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factors such as prolonged rupture of membranes and chorioamnionitis increase the risk of 
intrapartum transmission (Landesman et al, 1996). Postnatally, the most significant risk factor 
for MTCT is breastfeeding (McIntyre and Gray, 2002). Studies have shown that breastfeeding 
transmission may occur within the first few months of life (Miotti et al, 1999; Nduati et al, 
2000). Specific risk factors during breastfeeding include: cracked nipples, mastitis (breast 
inflammation), high breastmilk viral load (John et al, 2001); low CD4 cell count and high 
plasma viral load (John-Stewart et al, 2004). Local studies by Coutsoudis and others have 
found that mixed infant feeding (breastmilk and replacement feeds) also increases the risk of 
HIV-1 transmission (Coutsoudis et al, 1999). The ZVITAMBO study group confirmed the 
observations by Coutsoudis and others (1999) and also provided additional data distinguishing 
the magnitude of risk of HIV transmission or death associated with different breastfeeding 
patterns (Illiff et al, 2005). 
 
1.3.2 Risk factors for MTCT 
MTCT may be influenced by a multitude of maternal risk factors that consist of virological, 
immunological, obstetric and biological factors. 
Virological factors include; plasma viral load (HIV-1 RNA), one of the strongest predictors of 
MTCT, HIV-1 drug resistance, increased genital HIV-1 secretion, viral genotype and 
phenotype (European collaborative study, 1992; Mofenson, 1997).  
Immunological factors ; A wide range of novel and fascinating studies on immune factors such 
as; maternal autologous neutralizing antibodies (Dickover et al, 2006); antibodies to HIV-1 
gp120 epitopes including V3 loop (Scarlatti et al, 1993; Rossi et al, 1989); Leukemia 
inhibitory factors (Patterson et al, 2001; Tjernlund et al, 2003); CC chemokines [CCL3, CCL4 
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and CCL5] (Cocchi et al, 1995); CXCL12 (Farquhar et al, 2005); Lewis X component found 
in human breast milk (Naarding et al, 2005) and human secretory leukocyte protease inhibitors 
(Doumas et al, 2005) suggests that these innate immune factors appear to be involved in the 
protection of HIV-1 exposed, uninfected infants (Gray et al, 2007).  
Obstetric factors include; gestational age, rupture
 
of membranes for greater than four hours 
prior to labour, placental abruption, amniocentesis, episiotomy, chorioamnionitis and mode of 
delivery [caesarean section (C/S) vs. normal vaginal delivery (NVD)] (Mandelbrot et al, 
1996). An elective caesarean section before the onset of labour reduces the risk of perinatal 
transmission (European Mode of Delivery Collaboration, 1999), while an emergency 
caesarean section performed in labour for prolonged or difficult labour has been associated 
with increased HIV-1 transmission rates (Kind et al, 1998). Presence of vaginal lacerations 
during labour or preterm
 
delivery has been associated with prolonged membrane rupture and 
may increase fetal exposure to maternal blood and body fluids, thereby increasing the risk for 
HIV-1 transmission (Landesman et al, 1996; Kuhn et al, 1999). Twin pregnancy has been 
associated with an increased risk of pregnancy complications such as premature rupture of 
membranes and preterm labour, which are also well known risk factors for MTCT 
(Mandelbrot et al, 1996). While there have only been a few studies on the influence of 
multiple pregnancies on perinatal HIV-1 transmission, current available data has suggested 
that MTCT occurs most often among first-born twins (Park et al, 1987; Goedert et al, 1991; 
Duliège et al, 1995). 
Biological risk factors such as high antenatal prevalence of sexually transmitted infections 
(STI’s) have been linked to adverse pregnancy outcomes (Moodley and Sturm, 2000) and also 
been implicated in facilitating HIV-1 transmission (Pham-Kanter et al, 1996; Taha et al, 1998; 
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Moodley et al, 2002). An estimated 340 million new cases of curable STI’s occur globally 
each year in women aged between 15-49 years (WHO, 2001). The various sites of commonly 
occurring STI’s are illustrated in Fig 6, while Table I highlights local and global prevalence 
rates of these infections. Since 1995, STI’s have been managed syndromically in South Africa 









Fig 6: STI infection sites in the female genital tract (WHO, 2005) 
 
 - 10 - 
Table І: Global and local prevalence of STI’s 
 









Chlamydia trachomatis 10-25% 3-5% 
Bacterial vaginosis 20-40% 15-50% 
Treponema pallidum 0-3% 10% 
Neisseria gonorrhoeae 3-18% 3-5% 
Trichomonas vaginalis 8-16% 15-50% 
Candida albicans _ 20-40% 
Human papillomavirus 20-60% No data 
Herpes simplex virus 2-12% No data  
**
(Pham-kanter et al, 1996; Kharsany et al, 1997; Johnson et al, 2005b) 
 
Other factors associated with increasing the risk of MTCT include; acquisition of STI’s or 
new HIV-1 infections due to unprotected sexual intercourse (Bulterys et al, 1997), advanced 
maternal disease (Blanche et al, 1994); advanced maternal age (Mayaux et al, 1995); infant 
gender (European collaborative study, 2004), breastfeeding (European collaborative study, 
1992), low birth weight and prematurity (Landesman et al, 1996). Maternal cigarette smoking 
during pregnancy has been associated with a three-fold increased risk of MTCT among 
women with low CD4 cell counts (Burns et al, 1994). Similarly, the use of various illicit drugs 
such as cocaine, heroin, opiates or methadone lowers maternal immunity and increases the risk 
for preterm delivery and MTCT (Bulterys et al, 1997; Rodriguez et al, 1996).  
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1.3.2.1 Viral burden in various body compartments 
The amount of free-virus (HIV-1) in body fluids such as saliva, tears, breast milk and urine 
has been estimated to be 10-100 times lower than the amount of virus typically found in blood 
samples (Table II). While some body fluids may contain only small amounts of free-virus, all 
body fluids contain virus-infected cells. In genital secretions, these virus-infected cells have 
been shown to be a major source of HIV-1 transmission, with the risk of sexual transmission 
of HIV-1 being dependant upon the quantity of virus-infected cells present in genital 
secretions (Levy, 2007).  
 
Table ІІ: HIV-1 (Viral burden) in various bodily fluids (Levy, 2007) 
 
Bodily fluids (cell-free) Viral burden estimates (IP/ml) 
Blood plasma 10-50 
Serum 10-50 
Saliva < 1 
Semen 10-50 
Breast milk < 1 
Vaginal/cervical secretions < 1 
Tears < 1 
Ear secretions 1-10 
Urine < 1 
Footnote: *IP/ml: number of Infectious Particles per millilitre 
Pilcher and others conducted a study wherein they compared HIV-1 RNA levels in various 
bodily fluids (Fig 7) during primary versus established infection. HIV-1 RNA in blood and 
cerebrospinal fluid were significantly higher during primary infection, while cervicovaginal 
lavage and saliva were not significantly different among both groups (Pilcher et al, 2001). One 
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of their major study findings was that primary HIV-1 infection was a dynamic process of 
dissemination to diverse tissue compartments, which resulted in the early establishment of 
viral reservoirs and shedding into oral and genital fluids. These investigators confirmed that 
HIV-1 was shed into genital fluids early during primary infection and have suggested that like 
blood, dissemination into the oral cavity and female genital tract most probably occurs by the 
time of onset of symptoms. Those authors also state that while ARV’s may be effective in 
viral suppression in these compartments, it was unlikely to limit the initial dissemination to 




Fig 7: HIV-1 RNA levels in various body compartments/ fluids during primary infection 
(shaded-boxes) versus established infection (open-boxes) (Pilcher et al, 2001) 
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1.4 The female genital tract: an independent reservoir for HIV -1 
HIV-1 was first isolated from the genital tract of women more than two decades ago (Wolfsy 
et al, 1986; Vogt et al, 1986). Anatomical sources, the hormonal cycle and a wide array of 
sampling techniques have made evaluation of the female genital tract quite complex (Coombs 
et al, 2003; Galvin and Cohen, 2006). 
 
1.4.1 Sites of HIV-1 shedding 
Genital tract HIV-1 has been detected as cell-free in addition to cell-associated forms (Wolfsy 
et al, 1986; Vogt et al, 1986; Hart et al, 1999) in the vagina, cervix and upper genital tract 
(Farrar et al, 1997; Johnstone et al, 1994). The primary targets for male-female HIV-1 sexual 
transmission are immune cells of the lower female genital tract. These include dendritic cells, 
macrophages, T cells and epithelial cells (Coombs et al, 2003; Nicol and Nuovo, 2005; 








                        
                       
Fig 8a: Uterus of a woman of reproductive age (WHO, 2006a) 
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1.4.2 Sampling methods 
Sampling methods for the female genital tract remain un-standardised at the present time and 
range from conventional swabbing techniques, cervicovaginal lavage (CVL) collection to 
more recent techniques of direct aspirates of cervical mucous, cytobrush, tampons and Sno-
strip wicking (Coombs et al, 2003).  
While direct aspirates, CVL and swabbing techniques collect cell-free and cell-associated 
virus, Sno-strip wicking collects cell-free virus and cytobrushes collect mainly cell-associated 
virus (Coombs et al, 2003).  
There are several advantages and disadvantages to consider when selecting a genital sampling 
collection method. Variability of assay results is a function of; sampling method, assay type 
and biological variation within the compartment being sampled (Brambilla et al, 1999). The 
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general approach to “sampling choice” should always proceed from the least intrusive to the 
most intrusive method (Coombs et al, 2001). 
CVL sampling can be performed in any clinical setting and involves flushing the cervical os 
(Figs 8a; 8b) with 10 ml of sterile non-bacteriostatic saline and aspirating the resulting fluids 
(Kovacs et al, 1999; 2001; Hart et al, 1999; John et al, 2001). Compared to other methods, 
CVL yields a greater sample volume allowing more assays to be performed on a single 
sample. The introduction of a dilution factor when using CVL samples in various assays and 
interpretation of such data has traditionally attracted much criticism as it results in virus or 
antibody levels becoming more dilute, hence making standardization of the sample volume 
problematic. Several researchers have reported their results by use of a standardized 
denominator. The use of “per milliliter of lavage fluid” has been a widely accepted method 
utilized in several publications (John et al, 2001; Kovacs et al, 1999; Cu-Uvin et al, 2006). A 
few researchers have proposed the addition of 10 mmol/l lithium chloride to the CVL wash 
buffer as a means of standardizing sample volume (Bélec et al, 1995; Mohamed et al, 1997). 
Whilst such methods have been tested with success on spiked samples in a research laboratory 
setting, such methodology is yet to be routinely performed on clinical samples. In general, 
studies have shown that CVL samples are representative of cells shed from the cervix, vagina 
and uterus (Fig 8a; 8b). While epithelial cells and granulocytes are frequently found, 
lymphocytes and macrophages are found less often (Hill and Anderson, 1992; Howell et al, 
1997). Cells known to be permissive for HIV-1 infection include epithelial, stromal and 
Langerhans cells (Hill and Anderson, 1992; Howell et al, 1997; Collins et al, 2000).  
Sno-strip wicking is another commonly employed sampling technique. Such sampling allows 
for localization and collection of a defined volume of genital fluid from a specific anatomical 
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location such as the vaginal fornix, endocervix or exocervix (Fig 8a; 8b) with little or no 
disruption of the epithelial surface, while permitting concentration and detection of a lower 
level of virus or antibody (Coombs et al, 2003). While this technique may be an optimum 
method for collecting a known volume of sample, the volume of sample is relatively small, 
thereby restricting sample usage to just a single assay only (Coombs et al, 2001). With 
specific reference to HIV-1 RNA detection in the female genital tract, the greatest assay 
variability has been mainly observed with CVL samples while the least assay variability was 
noted with Sno-strip wicking (Coombs et al, 2001). Detection and quantitation of HIV-1 RNA 
was greatest in the cervix (Nuovo et al, 1993) and least in the vagina (John et al, 2001; 
Coombs et al, 2001; Iversen et al, 1998).  
1.4.3 Factors influencing genital HIV-1 RNA (viral load) 
Plasma HIV-1 RNA concentration both quantitatively and qualitatively is known to be the 
most important determinant for the prediction of genital HIV-1 shedding, even among women 
receiving ARV therapy. Other factors that influence HIV-1 shedding in this compartment 
include, genital viral discordance (lack of correlation between plasma and genital HIV-1 
RNA), sexually transmitted infections (Wang et al, 2001), micronutrient supplementation 
(Mostad et al, 1997; McClelland et al, 2004), subtype (John-Stewart et al, 2005), oral 
contraceptive use (Mostad et al, 1997) and pregnancy (Clemetson et al, 1993). Several studies 
have demonstrated that genital HIV-1 shedding increases incrementally with plasma HIV-1 
RNA concentration (Cu-Uvin and Caliendo, 1997; Hart et al, 1999; Iversen et al, 1998; 
Kovacs et al, 1999; 2001; Goulston et al, 1998). Various clinical trials have reported an 
association between genital HIV-1 shedding and micronutrient supplementation. Mostad and 
others found that reduced vitamin A levels were associated with increased vaginal HIV-1 
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shedding (Mostad et al, 1997). Similarly a randomized placebo-controlled trial undertaken in 
Kenya found that selenium and multivitamins resulted in a higher prevalence of quantifiable 
HIV-infected cells in vaginal (but not cervical) swab samples, compared with the placebo arm 
(McClelland et al, 2004). Prevalence of HIV-1 infected cells, HIV-1 RNA in genital 
secretions; breast milk and the risk of MTCT were compared among subtypes A, C and D in a 
cohort of HIV-1 infected pregnant women in Kenya. In this study, (41.0%) of pregnant 
women infected with subtype C were more likely to shed HIV-1 infected vaginal cells than 
those women infected with subtypes A (19.0%) and D (8.0%). These findings have suggested 
that HIV-1 subtypes could also influence mucosal shedding of HIV-1 (John-Stewart et al, 
2005). 
 
1.4.4 Detection and quantitation of genital HIV-1 RNA  
Several studies have detected cell-free and/or cell-associated  HIV-1 RNA in the female 
genital tract with detection rates ranging from 9.0%-80.0% (Coombs et al, 2001; Kovacs et al, 
2001; Tuomala et al, 2003; Chuachoowang et al, 2000; Quinn et al, 2000). 
HIV-1 RNA was detected in most female genital samples with incomplete plasma viral load 
suppression (Kovacs et al, 1999; 2001) and in 20.0% of samples from women with complete 
plasma viral HIV-1 RNA suppression (Coombs et al, 2001). Several studies have found 
association between detectable whole CVL HIV-1 RNA, cell- free HIV-1 RNA and plasma 
HIV-1 RNA (Clemetson et al, 1993; John et al, 1997; Hart et al, 1999; Goulston et al, 1998; 
Iversen et al, 1998; Mostad et al, 1997; Cu-Uvin et al, 1998). Kovacs and others demonstrated 
that HIV-1 RNA was detected more often and at significantly higher levels in cell-associated 
compared to the cell-free component of CVL (Kovacs et al, 1999). Whole unfractionated CVL 
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comprising of mainly cell-associated HIV-1 RNA correlated with plasma HIV-1 RNA in 
studies by Cu-Uvin and Caliendo (1997). In contrast, Hart and co-workers showed that most 
of the HIV-1 RNA was accounted for in the cell-free fraction and not in the cell-associated 
fraction. Both components appeared to correlate with plasma HIV-1 RNA (Hart et al, 1999).  
Two studies found no association between plasma HIV-1 RNA levels and the ability to detect 
HIV-1 in the genital tract (Mbopi-Kéou et al, 2000; Rasheed et al, 1996).  The dilution factor 
in cell-free HIV-1 CVL RNA was proposed as a possible reason for the lack of association 
between these two compartments. 
1.4.4.1 Plasma vs. genital HIV-1 RNA  
Fiore and others reported that plasma HIV-1 RNA failed as markers of infectivity of genital 
secretions after they observed cervicovaginal shedding occurring in 25.0% of women who had 
undetectable plasma virus (Fiore et al, 2003). Similar observations were reported by (Coombs 
et al, 1998; Mbopi-Kéou et al 2000; Spinillo et al, 2001; Debiaggi et al, 2001 and Günthard et 
al, 2001). 
A Spanish study undertaken by Garcia-Bujalance and others reported a lack of correlation 
between vaginal and plasma HIV-1 RNA of pregnant women, therefore women with 
undetectable plasma HIV-1 RNA were still at risk of transmitting the virus vertically during a 
normal vaginal delivery (Garcia-Bujalance et al 2004). Chuachoowang and co-workers 
reported that HIV-1 RNA level in the genital tract of pregnant women close to term, increased 
the risk of perinatal transmission even though the plasma HIV-1 RNA level was low 
(Chuachoowang et al 2000). Studies have shown that the higher the HIV-1 RNA levels were 
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in maternal plasma, the greater the likehood that HIV-1 will also be found in maternal 
cervicovaginal secretions.  
Several studies reported positive correlations between systemic and genital tract HIV-1 RNA 
levels (Mostad et al, 1997; Iversen et al, 1998; Goulston et al, 1998; Kovacs et al, 1999; Hart 
et al, 1999; Cu-Uvin and Caliendo, 1997; 2006; Andréoletti et al, 2003; Si-Mohamed et al, 
2000). 
A longitudinal study to determine the patterns of HIV-1 RNA in paired plasma and CVL 
sample measurements of non-pregnant women over a 36 month period found that CVL HIV-1 
RNA levels were generally lower than plasma levels. The authors confirmed an occasional 
discordance (5.0%) when CVL HIV-1 RNA exceeded plasma HIV-1 RNA. They suggest that 
it may be possible that women with undetectable plasma HIV-1 RNA were less likely to 
express genital tract virus and therefore less likely to transmit HIV-1. Where plasma HIV-1 
RNA correlated strongly with CVL RNA levels, it may be concluded that genital tract cell-
free HIV-1 RNA may be more dependent on changes in plasma HIV-1 RNA than on changes 
in the local genital environment as compared with cell-associated HIV-1 DNA that may 
derived from local genital reservoirs (Cu-Uvin et al, 2006).  
The mucosal hypothesis for intrapartum HIV-1 transmission has been supported by an 
increased risk of transmission with higher levels of cell-free and cell-associated HIV-1 RNA 
in cevicovaginal secretions independent from maternal plasma HIV-1 RNA (Chuachoowang et 
al, 2000; John et al, 2001; Tuomala et al, 2003). A significant relationship was observed 
between cervical or vaginal HIV-1 RNA levels and perinatal infection. Infant exposure to 
HIV-1 infected cells in maternal genital secretions has been shown to be an important 
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determinant for intrapartum HIV-1 transmission (John et al, 2001). This was also confirmed in 
a study undertaken in Thailand in which researchers investigated plasma and CVL HIV-1 
RNA levels in relation to MTCT in a randomized placebo-controlled trial of short-course 
Zidovudine therapy. In this study, a perinatal HIV-1 transmission rate of 28.7% was observed 
among those women with quantifiable CVL HIV-1 RNA and high plasma HIV-1 RNA. Those 
women without quantifiable CVL HIV-1 RNA (cell-free and cell-associated) and low plasma 
HIV-1 RNA had a perinatal transmission rate of 1.0% (Chuachoowang et al, 2000). Both 
studies have shown that high CVL HIV-1 RNA increases the risk of perinatal transmission at 
both high and low levels of virus in plasma (Chuachoowang et al, 2000; John et al, 2001). 
 
1.5 Interventions for the prevention of MTCT 
The United Nations (UNAIDS, 2005) currently recommends a three-pronged strategy for the 
reduction of pediatric HIV-1 infection and disease: 
• prevention of HIV-1 infection among women of child-bearing potential 
• prevention of unwanted and unplanned pregnancies among HIV-1 positive women 
• prevention of MTCT during pregnancy, labour and delivery, and breastfeeding  
ARV drug therapy forms only a single component in a broader spectrum of evidence-based 
interventions proposed for PMTCT (UNAIDS, 2005). Other interventions include: 
• improved availability, quality, and use of maternal and child health services 
• HIV-1 voluntary counseling and testing (VCT) 
• infant feeding options 
• caesarean sections  
• maternal care and support 
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1.5.1 Antiretroviral (ARV) therapy 
Several large, randomised, controlled clinical trials performed to date have successfully 
demonstrated the effectiveness of ARV’s in the prevention of MTCT as long-term treatment 
or short-term prophylaxis in breastfed (Appendix 1) and non-breastfed populations (Appendix 
2). Most of these ARV regimens have been based on drugs such as Zidovudine (ZDV), 
Lamivudine (3TC), Nevirapine (NVP) or a combination of these drugs in either short or long-
course regimens. 
 
1.5.1.1   Zidovudine (ZDV) monotherapy 
Almost 15 years ago, a randomized, placebo-controlled clinical drug trial (PACTG 076) 
successfully demonstrated the efficacy of ARV drug therapy for PMTCT. In this study, a long-
course ZDV regimen initiated from 14 weeks gestation until delivery in the mother and for six 
weeks in the infant significantly reduced MTCT by 67.0% in a non-breastfed population 
(Connor et al, 1994). Despite the PACTG 076 regimen being hailed as one of the most 
noteworthy advances in PMTCT, successful implementation of this regimen has been confined 
to resource-rich countries due to its complexity and cost. The Perinatal HIV Prevention Trial 
(PHPT-1) conducted in Thailand examined different durations of antenatal and neonatal ZDV 
regimens in a non-breastfed population (Lallemant et al, 2000). These investigators concluded 
that shorter antenatal therapy with ZDV was much more efficacious than longer antenatal 
therapy. Investigators of the CDC Côte d’Ivoire trial reported a 37.0% reduction in MTCT 
following their assessment of a short regimen of antenatal (from 36 weeks gestation) and 
intrapartum ZDV against a placebo in a breastfed cohort (Wiktor et al, 1999). In this study, 
MTCT rates (at three months) of 16.5% and 26.0% were noted in the ZDV and placebo groups 
respectively. Researchers of the ANRS 049 DITRAME study (Côte d’Ivoire/Burkino Faso) 
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evaluated a short-course regimen of antenatal (from 36 weeks), intrapartum and postpartum 
(one week) ZDV versus a placebo in a breastfed cohort. On the whole, efficacy in reducing 
MTCT was reported as 38.0%. At six months, MTCT rates were 18.0% and 27.0% in the ZDV 
and placebo arms respectively (Dabis et al, 1999).  
 
1.5.1.2   Combination therapy  
Mandelbrot and others investigated a regimen of (ZDV) and Lamivudine (3TC) from 32 
weeks (in pregnancy) and continued in infants until six weeks postpartum in the French ANRS 
075 study. They concluded that the addition of 3TC reduced MTCT rates from 6.8% to 1.6% 
at 18 months (Mandelbrot et al, 2001). Similarly, the PETRA trial was a four-armed study 
undertaken in South Africa, Tanzania and Uganda wherein investigators reported a 67.0% 
reduction in MTCT at six weeks among breastfeeding women when a regimen of ZDV and 
3TC was commenced from 36 weeks and continued until one week post-delivery in both 
women and their infants (PETRA study team, 2002). 
 
1.5.1.3   Nevirapine (NVP) vs. ZDV or ZDV and 3TC 
An effective, easily administered and cost-effective ARV regimen encompassing maternal and 
infant safety, tolerability and optimal protection from HIV-1 transmission was sought as a 
suitable alternative intervention for reduction of MTCT in resource-constrained countries.  
Several properties such as potent antiviral activity, excellent bioavailability, rapid oral 
absorption, long half-life and the ability to rapidly cross the placental barrier into the fetus 
(Cheeseman et al, 1993; 1995; Havlir et al, 1995) have made the intrapartum and neonatal 
sdNVP regimen an extremely attractive therapeutic option for reducing MTCT in resource-
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poor settings. Kinetic analysis has shown that NVP was able to penetrate cell-free virions and 
inactivate virion-associated reverse transcriptase in situ; properties useful in the inactivation of 
cell-free virions in the genital tract and breast milk (Zhang et al, 1996). 
Mirochnick and co-workers conducted the ACTG 250 trial, the first study that evaluated the 
safety, toxicity and pharmacokinetics of sdNVP during pregnancy (Mirochnick et al, 1998). 
They demonstrated that an oral 200 mg dose administered to women during labour, followed 
by a single 2 mg/kg dose to the infant (48-72 hours) was well-tolerated, non-toxic, had a long 
half-life (36.8-65.7 hours) and high bioavailability. In addition, NVP drug concentration 
exceeding the 100 ng/ml therapeutic target was achieved in the newborn. These findings were 
thereafter also confirmed by the HIVNET 006 trial. Researchers reported that high plasma 
concentration that was ten times the NVP concentration required to inhibit viral replication by 
50.0% (IC50) was attainable with sdNVP. In addition, this Ugandan study performed on a 
predominantly breastfed cohort also reported good drug penetration into colostrum and breast 
milk with sdNVP prophylaxis (Musoke et al, 1999). 
The benchmark HIVNET 012 study undertaken in Uganda was an extremely successful 
perinatal HIV-1 prevention clinical trial which further substantiated the safety and efficacy of 
intrapartum and neonatal sdNVP when compared with a short-course of ZDV (Guay et al, 
1999). Similar to HIVNET 006, the potent sdNVP regimen used in HIVNET 012 trial 
successfully maintained NVP serum concentrations above 100 ng/ml therapeutic target in 
infants. This regimen also reduced the risk of perinatal HIV-1 transmission in this 
breastfeeding population by 50.0% during the first 14-16 weeks of life (Guay et al, 1999). The 
sdNVP regimen was found to be simple, well tolerated and cost effective (Marseille et al, 
1999). Apart from the low occurrence of adverse side-effects, subsequent follow-up data (18 
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months) from this study provided concrete evidence of its sustained efficacy with a continued 
HIV-1 free survival benefit maintained well into infancy (Jackson et al, 2003). The South 
African Intrapartum Nevirapine Trial (SAINT) demonstrated similar safety and efficacy when 
investigators compared a short-course sdNVP regimen to a short-course combination regimen 
of intrapartum/postpartum (seven days) ZDV and 3TC. Overall efficacy in preventing HIV-1 
infection was estimated as 50.6% for the sdNVP regimen and 58.8% for the ZDV/3TC 
combination. The SAINT trial was particularly relevant for MTCT reduction in developing 
countries as this study further substantiated the findings of the HIVNET 012 study by 
extending similar observations across populations, regions and clades (Moodley et al, 2003). 
The SAINT trial encompassed analysis of both formula and breastfed infants and verified the 
safety, affordability and efficacy of the short-course intrapartum and neonatal sdNVP regimen 
in a resource-constrained setting. The timing of maternal NVP dosing during labour was 
another very significant issue addressed by this trial, with the odds of an intrapartum HIV-1 
infection found to increase by three-fold when the maternal sdNVP dose was ingested less 
than two hours prior to delivery (Moodley et al, 2003). Findings from the HIVNET 012 and 
SAINT trials provided compelling evidence in support of the sdNVP regimen for reduction of 
vertical HIV-1 transmission. These  significant research findings have since been successfully 
translated into the World Health Organisation’s (WHO) endorsement of this regimen as one of 
several recommended ARV regimens for PMTCT in resource-limited settings (WHO, 2006b). 
 
1.5.1.4   Addition of sdNVP to ZDV regimens 
The PHPT-2 trial conducted among non-breastfeeding women in Thailand determined the 
effect of adding NVP (intrapartum or sdNVP intrapartum plus neonatal sdNVP) to a ZDV 
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regimen (from 28 weeks, with one week ZDV). Compared to ZDV alone (6.3%), transmission 
rates were significantly reduced (2.8% in sdNVP intrapartum and 1.9% for intrapartum and 
neonatal NVP) by addition of sdNVP to the ZDV regimen (Lallemant et al, 2004). In Malawi, 
an open-labelled trial (Taha et al, 2004) examined the efficacy of adding one week of neonatal 
ZDV to the HIVNET 012 regimen. Investigators found that additional ZDV did not confer any 
significant benefit at six weeks and reported MTCT rates of 14.1% (sdNVP only) and 16.3% 
(sdNVP and ZDV)  [Taha et al, 2004]. The ANRS 1201 DITRAME PLUS (Ivory Coast and 
Burkino Faso) was an open-labeled study that compared (ZDV + sdNVP) with (ZDV + 3TC + 
sdNVP). The MTCT rate at six weeks was 6.5% in the group receiving (ZDV + sdNVP), 
while the group receiving (ZDV + 3TC + sdNVP) had an MTCT rate of 4.7%. No difference 
was noted between transmission rates of breastfed and non-breastfed infants at six weeks of 
age (Dabis et al, 2005).  
 
1.5.1.5   Infant-only ARV prophylaxis 
The benefit of neonatal ZDV was first demonstrated by Wade and others (Wade et al, 1998). 
In this study, the transmission rate was 6.1% in women who received the full ACTG 076 
regimen, 10.0% in those who only received ZDV during the intra-and postpartum periods was 
10.0% and 26.6% in women who did not receive any ZDV.   
 
A few African studies successfully demonstrated that it was still beneficial to provide ARV 
treatment to HIV-1 exposed-infants in the form of post-exposure prophylaxis or PEP in the 
following situations ; there was no access to antenatal care, infants were born at home, women 
were missed by PMTCT and when maternal intrapartum ARV therapy was missed or not 
possible. In Malawi, investigators of the NVAZ trial (Taha et al, 2003) evaluated a PEP 
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regimen of sdNVP and one week of ZDV administered to the infants of untreated mothers in a 
breastfeeding population. The MTCT rate observed at 6-8 weeks was 15.3% with combination 
therapy and 20.8% with sdNVP alone. This study indicated that dual therapy of sdNVP 
coupled with one week of ZDV given to the infant was far superior to providing sdNVP alone 
(Taha et al, 2003). In the South African PEP study, investigators compared neonatal sdNVP 
with six weeks of ZDV among infants whose mothers received no ARV therapy (Gray et al, 
2005). PEP study investigators reported an overall MTCT rate of 16.3% by 12 weeks of age 
and concluded that an infant-only sdNVP regimen was as efficacious as six weeks of ZDV 
therapy (Gray et al, 2005). The Mashi study performed in Botswana demonstrated that 
maternal sdNVP may not be needed to reduce MTCT in the setting of maternal ZDV and 
infant ZDV plus sdNVP. Investigators observed similar infant HIV infection rates at age six 
weeks irrespective of whether the women received sdNVP (4.3%) or placebo (3.7%) (Shapiro 
et al, 2006).  
 
1.5.1.6   Current standard of care for PMTCT in low-income countries  
The current standard of care for PMTCT of HIV-1 involves a dual regimen of maternal ZDV 
starting from 28 weeks and intrapartum sdNVP in women. Infant prophylaxis presently entails 
sdNVP at birth, followed by a seven day short-course of ZDV therapy (Appendix 3a). In the 
absence of maternal ARV therapy during labour (Appendix 3b), infant ARV regimens of 
either sdNVP alone or (sdNVP + four weeks of ZDV) are recommended by the WHO as 
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Some of the key MTCT lessons learnt to date include: (Dao et al, 2007) 
• combination ARV regimens are more effective than monotherapy 
• longer duration of ARV prophylaxis is usually more effective 
• efficacy of intrapartum ARV regimens is diminished over time in breastfeeding 
populations  
• addition of sdNVP improves the efficacy of other short-course ARV regimens 
• relative importance of maternal sdNVP in the context of short-course ZDV regimens 
remains unclear. Infant only post-exposure prophylaxis is only a valid alternate 
therapeutic option for PMTCT in instances when maternal ZDV is received for an 
inadequate duration or when infants receive ZDV for four weeks  
 
1.5.1.7   ARV coverage for PMTCT 
In 2007, ~33.0% of pregnant HIV-1 infected women received ARV drugs for PMTCT. Figure 
9a illustrates the estimated ARV drug coverage for PMTCT observed in low and middle-
income countries in 2007 (UNAIDS/WHO/UNICEF, 2008b). Variable ARV coverage was 
noted among the ten countries (including South Africa) with the largest number of HIV-1 
infected pregnant women. While ARV coverage in Thailand has been very encouraging 
(92.0%), some African countries including South Africa (57.0%), Mozambique (46.0%); 
Kenya (69.0%); Guyana (43.0%) have indicated fair to reasonable coverage. However, 
countries like India, Democratic Republic of Congo, Nigeria and Ethiopia were able to 
achieve 10.0-15.0% ARV coverage (UNAIDS/WHO/UNICEF, 2008b). In 2007, ARV drug 
coverage among infants born to HIV-1 infected women in low and middle-income countries 
was estimated to be less than 20.0% (UNAIDS/WHO/UNICEF, 2008b). 
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Fig 9a: ARV coverage for PMTCT in low and middle-income countries  
(UNAIDS/WHO/UNICEF, 2008b) 
 
In 2007, data on ARV drug regimens for PMTCT (provided by 60 countries) revealed that 
almost 50.0% of women received NVP monotherapy; 26.0% received a dual ARV regimen; 
and 8.0% received a triple ARV combination (UNAIDS/WHO/UNICEF, 2008b). Data from 
Sub-Saharan African (provided by 44 countries) indicated that women on treatment received 
NVP monotherapy (50.0%); dual regimen (27.0%) and a triple ARV combination (6.0%) 
(UNAIDS/WHO/UNICEF, 2008b).  
Despite a host of successful ARV drug regimens, uuniversal access to HAART is still not a 
reality in most resource-limited countries where the rates of MTCT continue to escalate 
(Chersich et al, 2006). The use of NVP alone or in combination with ZDV (Fig 9b), therefore 
remains the mainstay of PMTCT programmes in several low-resource settings (Fowler et al, 
2007). 
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Fig 9b: Distribution of ARV regimens received by pregnant HIV-1 infected women in low and middle-
income countries (UNAIDS/WHO/UNICEF, 2008b) 
 
1.5.1.8   Pharmacology of NVP 
Structurally, NVP (Viramune
®
) is a member of the dipyrido-diazepinone group of chemical 
compounds. This potent non-nucleoside reverse transcriptase inhibitor or NNRTI was 
developed by Boehringer Ingelheim Pharmaceuticals (Viramune
®
, 2005). NNRTI’s are a class 
of ARV drugs that bind directly to the HIV-1 reverse transcriptase enzyme and prevent RNA 
from changing into DNA (Richman et al, 1991; Merluzzi et al, 1990; Hargrave et al, 1991). 
 
NNRTI’s have shown a high degree of specificity for the reverse transcriptase of HIV-1, but 
are not effective against that of HIV-2, even with their high homology (Wu et al, 1991).   Four 
NNRTI’s are currently approved by the Food and Drug Administration (FDA) for use in the 
treatment of HIV-1 infection. These include NVP, Efavirenz (EFV), Delavirdine (DLV)   and 
Etravirine (FDA, 2009).  Figure 10 illustrates the mechanism of action for the NNRTI class of 
 - 30 - 
compounds. An NNRTI such as NVP attaches directly to the reverse transcriptase enzyme at a 
specific location, near the active site and causes a structural change that disrupts the formation 
of the active site and leads to weakened polymerisation activity (Immunopaedia, 2008). 
 
NVP is a potent ARV that is readily absorbed after oral administration (> 90.0%) and has a 
half-life of ~45 hours (Riska et al, 1999). It is non-ionised at physiologic pH, is distributed 
widely and evenly throughout the body, and is highly lipophilic. It is approximately 60.0% 
bound to plasma proteins. More than 80.0% of the NVP dose is bio-transformed via P450 
oxidation to hydroxylated metabolites that are subsequently largely excreted in urine as 
glucuronides. Only a small fraction of the dose (< 3.0%) is excreted unchanged in urine (Sabo 
et al, 2000). NVP has been shown (in vitro) to block an early event in the viral replication 
cycle, completely inhibiting replication if administered within 24 hours of infection, but 
having no effect on protein production or viral release (Koup et al, 1991).  
 
 
Fig 10: Mechanism of action of NNRTI drugs (Immunopaedia, 2008) 
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1.5.1.9   NVP detection methods 
 
a)  Qualitative Methods 
Thin layer chromatography: 
Thin layer chromatography (TLC) is a fast, inexpensive method for the qualitative 
measurement of NVP in plasma. Studies have shown that TLC methods were able to reliably 
detect the presence of NVP concentration of greater than or equal to 100 ng/ml in human 
plasma (Dubuisson et al, 2004).  This study made use of spot detection by TLC plates and was 
able to detect NVP concentrations as low as 60 ng/ml. The 100 ng/ml concentration was 
selected as the limit of detection due to the robustness of the spot detection at this 
concentration, compared to a lower concentration.  
 
b)   Quantitative Methods 
High performance liquid chromatography with ultraviolet absorbance: 
The use of high performance liquid chromatography (HPLC) with ultraviolet (UV) absorbance 
detection was validated for the simultaneous quantitative determination of three currently 
prescribed NNRTI’s (EFV, DLV and NVP). Studies have found HPLC with UV absorbance to 
be a very accurate, precise, simple and highly reproducible method for NNRTI quantitation in 
human plasma (Rezk et al, 2002). A study comparing protease inhibitors (PI’s) and NNRTI’s 
has shown that HPLC with UV absorbance can be successfully applied for reliable and 
accurate ARV quantitation in samples of maternal plasma and direct aspirates of 
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High performance liquid chromatography and solid phase extraction: 
The majority of the published methods for NVP quantitation in plasma have relied upon solid 
phase extraction of ~200-600 µl of sample, followed by HPLC (Pav et al, 1999; Marchei et al, 
2002; Marzolini et al, 2002; Rezk et al, 2004). Recent modification to this method to increase 
detection sensitivity has permitted the accurate quantitation of smaller sample volumes such as 
clinical neonatal samples (Silverthorn and Parsons, 2006). Shorter run times and lower levels 
of detection have made this method an attractive cost and time-efficient option for application 
in several research settings (Kagaayi et al, 2005).  
 
Liquid chromatography Tandem Mass spectrophotometry: 
An overall NVP recovery of 92.4% was achieved by the use of Liquid chromatography 
Tandem Mass spectrophotometry (LC-MS-MS). This sensitive and rapid method was 
developed for the measurement of NNRTI (NVP) levels in HIV-1 infected human plasma. In 
this method, the analyte and internal standard was isolated from plasma by a simple perchloric 
acid precipitation of plasma proteins followed by centrifugation. Two linear calibration curves 
were then used to determine NVP concentration (Chi et al, 2003).  Laurito and others (2002) 
found the application of the LC-MS-MS method in sdNVP bioequivalence studies to be 
reliable and adequate. Lowest limit of quantification, inexpensive liquid-liquid extraction, 
faster run times and high specificity were some of the advantages cited in favour of LC-MS-
MS over other HPLC methods. In addition, the LC-MS-MS method was applied with much 
success for NVP quantitation in samples of paediatric saliva (Rakhmanina et al, 2007), 
oropharyngeal and cervicovaginal secretions (Harms et al, 2005; Kunz et al, 2007) and dried 
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1.5.1.10   Quantitation of NVP in the female genital tract 
While quantitation of NVP drug concentration (following single dosing) has been widely 
reported in breast milk and plasma studies (Mirochnick et al, 1998; 2000; 2003, Muro et al, 
2005; Musoke et al, 1999), limited data were currently available for NVP drug measurements 
in cervicovaginal secretions from HIV-1 infected pregnant women. The mucosal hypothesis 
for intrapartum HIV-1 transmission is supported by a higher risk of transmission with higher 
levels of cell-free and cell-associated HIV-1 in cervicovaginal secretions independent from 
maternal plasma HIV-1 RNA (Chuachoowang et al, 2000; John et al, 2001; Tuomala et al, 
2003). In their study to analyze the extent of intrapartum transmission after mucosal exposure 
of the fetus to HIV-1 in the context of sdNVP, Kunz and others quantified NVP concentration 
in infant oropharyngeal secretions using liquid chromatography/Tandem-Mass 
spectrophotometry methods (Kunz et al, 2007). In this study, no intrapartum HIV-1 
transmission was observed after mucosal exposure of the fetus to HIV-1. Investigators found 
that a high concentration of NVP was rapidly achieved in the oropharyngeal secretions of 
babies after a single dose which also contributed to the drug’s effectiveness (Kunz et al, 
2007). 
 
In a study carried out in Uganda, a high concentration of NVP was detected in maternal 
cervicovaginal secretions (median = 742 ng/ml) and oropharyngeal secretions of babies after 
sdNVP administration to the mother (Harms et al, 2005). Sno-strips were used to collect 
maternal cervicovaginal secretions and NVP concentration was determined by LC-MS-MS 
methods. Significant positive correlation was noted between maternal plasma concentration 
(median = 1742 ng/ml) and infant plasma concentration (1291 ng/ml) (Harms et al, 2005). 
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Studies have also found that differential penetration of ARV drugs in the female genital tract 
could alter the rates of vertical and heterosexual transmission and influence the efficacy of 
post-exposure prophylaxis. In a study of non-pregnant HIV-1 infected women by Min and 
others, cervicovaginal fluid samples were collected by direct aspiration methods (Min et al, 
2004). ARV drug concentration (NNRTI and PI) were assayed at two collection points using 
HPLC/UV detection. Measurable drug concentration for all ARV drugs, with the exception of 
Ritonavir and Saqinavir were found in samples of cervicovaginal fluid (CVF). Of the NNRTI 
drugs assayed, CVF samples had the highest concentration of NVP (Min et al, 2004). In 
contrast, findings of poor NNRTI drug penetration into CVF were previously cited by 
Ellerbrock et al, 2001 and Tirado et al, 2004. Cohen and co-workers reported that the 
penetration of antiviral agents into the female genital tract was dictated by the degree of 
protein binding and a drug’s affinity for albumin and α1-acid glycoprotein. High protein-bound 
drugs (> 80.0%) were recovered at a lower concentration in genital tract secretions compared 
to plasma drug levels (Cohen et al, 2007).  
 
Kashuba and others profiled the concentration of ARV drugs based on extracellular and 
intracellular genital tract exposure relative to blood plasma concentration (Fig 11). Using 
novel pharmacokinetic methods, these researchers found that despite high plasma 
concentration, the corresponding concentration of high-protein bound drugs such as the 
NNRTI’s remained remarkably low in the genital tract (Kashuba, 2006; Cohen et al, 2007). 
When compared to blood plasma, the NNRTI’s were also detected at a lower concentration in 
CVF samples using LC-MS-MS quantitation methods (Kwara et al, 2008).   
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Fig 11:  ARV drug concentration in the female genital tract relative to blood plasma 
concentration [ratio of genital fluid to plasma]. NNRTI drugs: EFV, DLV  
and NVP. (Kashuba, 2006; Cohen et al, 2007) 
 
1.5.2      Other interventions for PMTCT 
1.5.2.1   Modified obstetric practice 
MTCT rates of 2.0% with ARV and 10.4% without ARV were observed among women who 
delivered by elective C/S. In contrast, MTCT rates of 7.3% with ARV and 19.0% without 
ARV were noted among women who delivered vaginally (European mode of delivery 
collaboration, 1999).     
While the use of an elective C/S prior to the onset of labour and rupture of membranes has 
been widely advocated as a highly effective evidence-based intervention against intrapartum 
HIV-1 transmission (European mode of delivery collaboration, 1999), there have also been 
conflicting reports regarding its clinical utility among HIV-1 infected women. In a meta-
analysis conducted by Read and others, the use of the elective C/S over the NVD translated 
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into a 50.0% reduction of risk among women who were not on HAART or had high plasma 
viral load (Read and Newell, 2006). Data from the WITS study reported an association 
between maternal morbidity and use of elective C/S (Read et al, 1999) among HIV-1 infected 
women. Similarly the ACTG 185 trial also found an increased rate of infectious complications 
among HIV-1 infected women who had surgical deliveries (Mofenson et al, 1999a). Despite 
its potential risks, an elective C/S negates the possibility of premature rupture of membranes 
and also minimizes an infant’s exposure to contaminated vaginal fluids during a normal 
vaginal delivery. Guidelines from the Centre for Disease Control (CDC) have stated that these 
risks were not of significant frequency or severity to outweigh the potential benefits of 
reduced transmission. The CDC recommends that an elective C/S be offered to all women 
provided they were made aware and understood the risks and benefits of such procedures 
(CDC 2002).   
1.5.2.2   Infant feeding methods 
Breastfeeding is considered the most ideal food for infants due to its age appropriate nutritive 
value and protective immune factors. However, the transmission of HIV-1 from breast milk 
was found to account for a 14.0% risk of transmission (Dunn et al, 1992). Breastfeeding 
continues to remain one of the leading contributing factors to high HIV-1 transmission rates in 
Africa, with increasing concerns over its direct influence on the efficacy of ARV prophylactic 
regimens and ultimately infant survival.  
 
A longer duration of breastfeeding has been shown to enhance HIV-1 transmission; however 
early weaning has been associated with adverse impact on growth, morbidity and mortality. 
While breastfeeding may be a key determinant for the discrepancy in MTCT rates between 
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resource-rich and resource-limited countries; safer replacement feeding options are not always 
available in resource-limited settings. In many of these poverty-stricken regions, the increase 
in infant morbidity and mortality associated with formula-feeding may far outweigh any 
reduction in the risk of HIV-1 transmission. A randomized controlled trial that compared 
breastfeeding and replacement feeding in Nairobi reported that 44.0% of the HIV-1 infection 
in the breastfed group was attributable to breastmilk. In addition, study investigators observed 
that HIV-free survival was significantly reduced among those infants who were breastfed 
(Nduati et al, 2000). A local vitamin A supplementation study undertaken by Coutsoudis and 
others reported an increased rate of HIV-1 infection in their mixed-fed group while similar 
rates of transmission at 3-6 months was observed between the breastfed and formula-fed 
infants (Coutsoudis et al, 2001). Researchers of the ZVITAMBO study group reported that 
early exclusive breastfeeding substantially reduced breastfeeding-associated HIV transmission 
(Illiff et al, 2005). International guidelines have recommended that HIV-1 infected pregnant 
women be provided with all the necessary information to enable an informed decision 
pertaining to the risks and benefits of breastfeeding vs. replacement feeding (McIntyre and 
Gray, 2002). The WHO recommends “exclusive breastfeeding for six months” which has been 
defined as only providing breastmilk from birth and the avoidance of all other liquids and 
solids except drops or syrups, drugs, vitamins and mineral supplements (WHO, 2002). 
Potential modification of infant feeding practices includes; complete avoidance of 
breastfeeding, early cessation, pasteurization of breastmilk and refraining from breastfeeding 
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1.6 Other MTCT determinants  
1.6.1   NVP: timing of maternal and neonatal dosing 
The presence of a protective concentration of NVP at the time of delivery and during the first 
few days of an infant’s life are most likely crucial to the efficacy of the two-dose regimen in 
the absence of other ARV therapy. While the sdNVP regimen is easily administered, wide 
variability in the timing of the dose relative to delivery is a known occurrence. While no 
disparity was observed in the pharmacokinetics of NVP between pregnant and non-pregnant 
women (Mirochnick et al, 2001), studies have reported reduced maternal NVP absorption 
during the time of labour and delivery (Mirochnick et al, 1998; 2000; Musoke et al, 1999).  
 
Cases of reduced NVP plasma levels during pregnancy were reported (Haberl et al, 2004) and 
more recently from a comparison study of steady-state pharmacokinetics of NVP in men, non-
pregnant women and women in late pregnancy. In this study Von Hentig and others observed 
that pregnant women exhibited an increased NVP clearance and lower plasma concentration 
than non-pregnant women (Von Hentig et al, 2006). In contrast, findings from a small clinical 
drug trial (PACTG 1022) confirmed that steady-state plasma NVP concentration during the 
second and third trimester of expectant mothers was equivalent to those outside of pregnancy 
(Aweeka et al, 2004). 
 
Mirochnick and others have previously recommended that the maternal NVP dose be 
administered as early in labour as possible to maximize the time available for drug absorption 
and distribution across the placenta (Mirochnick et al, 2001). In a Zambian study of HIV-1 
infected women, the rate of perinatal HIV-1 transmission was higher when the period between 
maternal NVP ingestion and delivery was less than one hour (Stringer et al, 2003b). 
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Investigators of the SAINT trial also reported similar observations. They found that the odds 
of an intrapartum HIV-1 infection increased three-fold when the maternal sdNVP dose was 
ingested less than two hours prior to delivery (Moodley et al, 2003). In analysis of cord blood 
samples collected during the HIVNET 012 trial, Jackson and others observed a pattern of 
increased perinatal HIV-1 transmission in cases where the maternal NVP dose was ingested 
within two hours before delivery (Jackson et al, 2006). The authors did, however, 
acknowledge that their finding was not statistically significant due to the small number of 
patients in this particular subset. In a similar cord blood analysis, investigators of PACTG 316 
trial recommended the inclusion of an additional NVP dose to the infant (48-72 hours) after 
the initial birth NVP dose, in the event of the infant being born less than two hours after 
maternal intrapartum NVP dosing (Mirochnick et al, 2003). In contrast, an observational 
analysis by the HIVNET 024 trial performed at four sites in Africa demonstrated that variation 
in the timing of maternal and neonatal NVP dosing did not influence the risk for MTCT, 
provided dosing occurred within reasonable proximity to delivery. Investigators also reported 
that repeat dosing of infants as previously suggested by Mirochnick et al (2003) may not be 
necessary as long as the maternal dose was administered within 48 hours of delivery and the 
infant dose was given within 72 hours of birth (Chi et al, 2005).  
 
While several local and international studies have successfully demonstrated the efficacy of 
the intrapartum and neonatal postpartum sdNVP regimen for PMTCT, data regarding 
operational efficacy has been limited. Findings of poor sdNVP efficacy in reducing or 
preventing MTCT in a real-life setting were reported by a group of Kenyan researchers 
(Quaghebeur et al, 2004). In contrast, Colvin and others concluded that the sdNVP regimen 
was effective following their evaluation of three PMTCT sites in South Africa. Despite their 
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findings, the authors also emphasised that implementation could be sub-optimal if the regimen 
was introduced into an already weakened health care system (Colvin et al, 2007).  
The prolonged elimination half-life of sdNVP has been established to be ~61.3 hours [range 
27-90 hours] from pharmacokinetic studies on HIV-1 infected pregnant women (Mirochnick 
et al, 1998; Musoke et al, 1999), implying that plasma NVP may still be detectable in mothers 
several days after delivery. Muro and others reported a median half-life of 56.7 hours in their 
cohort of healthy non-pregnant HIV-1 uninfected female volunteers. Although this study was 
conducted in the Netherlands, their finding of NVP being associated with persistent drug level 
detection beyond three weeks after single dose administration was extremely valuable in the 
context of NVP drug resistance (Muro et al, 2005). The PHPT-2 trial undertaken in Thailand 
reported a significant NVP concentration in maternal plasma samples during the postpartum 
period, following intrapartum sdNVP in addition to ZDV prophylaxis. This trial demonstrated 
that plasma NVP concentration (around the IC50) may persist in some women for as long as 
four weeks after intrapartum sdNVP dosing (Cressey et al, 2005).   
 
1.6.2   NVP drug resistance 
Notwithstanding its significant impact and proven success, use of NVP monotherapy or in 
combination with other ARV drugs remains shrouded in much controversy due to the 
development and emergence of NVP-induced drug resistance (NVP
R
) mutations.  
 
A drug resistance mutation against an NNRTI is an amino-acid change that reduces the 
binding affinity of a drug such as NVP to the enzyme so that the enzyme activity resumes 
(Immunopaedia, 2008). A single point mutation as illustrated earlier (Fig 10) in the viral 
codon may result in high-level resistance to one or more NNRTI’s (Cressey et al, 2005). 
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Plasma is the main source of virus when investigating HIV-1 drug resistance in clinical 
settings. As the half-life of HIV-1 in plasma is ~ six hours, only actively replicating virus can 
be isolated from this source. The sequence of plasma virus therefore represents the 
quasispecies most recently selected by the ARV therapy (Perelson et al, 1996). The presence 
of drug mutations is normally detected through population-based or clonal sequencing. 
Complementary analysis has recently been provided by several research teams through the use 
of more sensitive drug resistance assays. Methods have included; Sensitive real-time PCR for 
K103N and Y181C (Johnson et al, 2005a; Loubser et al, 2005), Allele-specific RT-PCR for 
K103N (Palmer et al, 2005), LigAmp and TyHRT (Flys et al, 2006).  
 
The evidence for the emergence of NNRTI-associated drug resistance dates back to the 1990’s 
(Merluzzi et al, 1990; Richman et al, 1991; Dueweke et al, 1993). Transmission of drug 
resistant HIV-1 variants occurs through sexual contact and from mother-to-child (Yerly et al, 
1999; Colgrove et al, 1998; Neihues et al, 1999). Development of NNRTI drug resistance has 
been shown to decrease the effectiveness of this class of ARV drug (Richman et al, 1991) and 
this type of drug resistance is also relatively transmissible (Leigh-Brown et al, 2003). Effects 
on the mother include a decreased rate of virologic suppression (Jourdain et al, 2004). The 
archiving of resistant variants in biological reservoirs may have a detrimental impact on 
mother or infant by impairing future responses to NNRTI-containing regimens (Lockman et 




 has been detected in a considerable proportion of women and infants following sdNVP 
intake for PMTCT. As a consequence, trials like HIVNET 012 have been subjected to critical 
medical review (Cohen et al, 2004; Hammer, 2005). Appendix 4a highlights drug resistance 
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findings from a selection of African studies and clinical drug trials designed with a regimen of 
intrapartum and neonatal sdNVP. A meta-analysis of published studies and conference 
proceedings (between 1997 and 2006), estimated the prevalence of NVP
R
 as ~ 35.7% in 
women and 52.6% in infants following sdNVP intake for PMTCT (Arrivé et al, 2007). This 
analysis also found that rates of NVP
R
 were further reduced to ~ 4.5% in women and ~16.5% 
in children with the inclusion of a short-course postpartum ARV regimen (Arrivé et al, 2007).  
Appendix 4b tabulates prevalence of NVP
R
 among mothers and infants participating in trials 
containing sdNVP treatment arms in addition to other ARV treatment arms. Worth mentioning 
are the extremely high rates of NVP
R
 observed among infants in the Treatment Options 
Preservation Study (TOPS) [77.8%] and SAINT (52.5%) trials. In contrast to the high NVP
R
 
rate in their sdNVP treatment arm, the TOPS study investigators reported a drastically reduced 
rate (12.5%) in their treatment arm that contained a regimen of sdNVP and four days of 
Combivir (McIntyre et al, 2005). 
 
A host of virological, pharmacological and immune factors have been implicated in playing 
significant roles in the development of NVP
R
 including; plasma HIV-1 RNA (Eshleman et al, 
2001), NVP drug concentration, metabolism and clearance (Chaix et al, 2007), CD4 cell 
count, clade diversity, viral subtype, viral fitness, and immune selective pressure (Spira et al, 
2003; Eshleman et al, 2005a; Page-Shafer et al, 2006). 
 
NVP resistant HIV-1 was selected independently in infants following sdNVP dosing. 
Emergence of drug resistance among infants has been attributed to a longer length of NVP 
exposure by the infants compared to their mothers. In the intrapartum and neonatal sdNVP 
regimen, infants were theoretically dosed twice (once through placental transfer of maternally 
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administered NVP and again in a dose following birth) (Eshleman et al, 2001). While the risk 
of maternal and infant toxicity with intrapartum and neonatal sdNVP has been shown to be 
minimal, data from HIVNET 012 has provided evidence for the development of NVP
R
 
mutations among women with active viral replication during the period in which sdNVP was 
taken (Eshleman et al, 2001). Similarly, findings from the PACTG 316 sub-study concluded 
that NVP
R
 mutations could be detected after sdNVP in women receiving standard ARV 
therapy as well as in patients who had virus with no detectable mutations prior to receiving the 
NVP dose. While their study found a low rate (14.7%) of NVP
R
 prevalence (new mutations) 
among women, their study served to confirm that mutations could also be found among 
women receiving combination therapy with HAART (CD4 > 400 µl/ml) as well as at any level 
of replicating virus (Cunningham et al, 2002; Chaix et al, 2004). Studies in South Africa, 
Thailand and Botswana have evaluated virologic treatment response following sdNVP. These 
studies found no significant difference in virologic response for women who commenced 
treatment more than six months after sdNVP exposure. Two studies found poor response rates 
in women when treatment was initiated within 6 months of sdNVP exposure (McConnell et al, 
2007). While most genotypic assessments were performed at 6-8 weeks (Appendix 4a and 4b), 
some studies have shown successful detection of drug resistance mutations as early as four 
weeks (Chaix et al, 2004; 2006) and at ten days post sdNVP exposure (Jourdain et al, 2004).  
 
Light at the end of the dim NVP
R
 tunnel comes in the form of reports of fading drug resistance 
observed in studies on women and infants in Africa (Eshleman et al, 2001; Eure et al, 2006). 
In a Ugandan study, women with drug resistance at 6-8 weeks lacked detectable drug 
resistance when re-assessed at 12-24 months (Eshleman et al, 2001). Similar reports from 
South African and Cote d’I’voire studies corroborated the fading of NVP-induced resistance 
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mutations over time, with no significant impact on MTCT after twelve months (Kantor et al, 
2003; Martinson et al, 2004; 2006; Eure et al, 2006). The TOPS conducted in SA reported a 
reduction in the development of NVP
R
 when both the mother and infant received a short 
course of [CBV] or Combivir (ZDV plus 3TC) in addition to sdNVP (McIntyre et al, 2005). 
Sequence analysis of maternal samples collected at six weeks revealed reduced rates of NVP
R
; 
11.9 % (sdNVP and 4 days CBV) and 10.3% (sdNVP and 7 days CBV) while prevalence of 
NVP
R
 was more than 60.3% their sdNVP containing arm. A similar outcome was observed 
among the infant cohort; 12.5% with (sdNVP and 4 days CBV) and no NVP
R
 with (sdNVP 
and 7 days CBV) and 77.8% with sdNVP use only (McIntyre et al, 2005). In another study by 
Eshleman et al (2006), the development of NVP
R
 in infants was lowest (27.0%) when infants 
received (sdNVP and ZDV) and maternal sdNVP was avoided. When both mothers and 
infants received sdNVP, NVP
R
 among infants was (87.0%) and when infants received (sdNVP 
and ZDV) a rate of 57.0% NVP
R
 was observed (Eshleman et al, 2006). 
 
The most common drug resistant mutation associated with sdNVP has been K103N in mothers 
and Y181C in infants (Chaix et al, 2006; Eshleman et al, 2001; Gordon et al, 2004; Martinson 
et al, 2004; Sullivan, 2002). HIVNET 012 and PACTG 316 found K103N to be the most 
frequently detected mutation (Cunningham et al, 2002; Eshleman et al, 2001). The PHPT-2 
trial in Thailand reported the K103N, G190A and Y181C as the most frequently detected drug 
mutations in their trial (Jourdain et al, 2004). The NVP Resistance study undertaken by 
Martinson and others involved genotypic analysis of samples collected from PMTCT cohorts 
in Soweto and KZN. Investigators reported maternal drug mutations in their study to include 
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1.6.3 Chemokines and HIV-1 
The connection between HIV-1 and the chemokine system over a decade has greatly advanced 
our knowledge and understanding of the biology, pathogenesis and disease progression of 
HIV-1. Chemokines are a small group of chemotactic cytokines (CC) which play a key role in 
the recruitment, activation and trafficking of leukocytes to the sites of infection, resulting in an 
enhanced local inflammatory response. In addition, these inflammatory proteins also modulate 
cytokine production by T helper cells (Menten et al, 2002).  
 
The three chemokines: MIP-1α (CCL3); MIP-1 β (CCL4) and RANTES (CCL5) were 
identified as the major HIV-1 suppressive factors produced by CD8+ T cells (Cocchi et al, 
1995). The identity of a second HIV-1 cellular co-receptor, CXCR4 was shown to be a 
chemokine receptor-like molecule (Feng et al, 1996). Samson and others (1996a) cloned a 
second receptor (CC-CK45) for CCL3. This clone CC-CK45, was later renamed CCR5 in new 
nomenclature. Soon after its discovery, CCR5 was shown to be essential for entry of HIV-1 
strains into permissive cells (Murphy et al, 2000).  
 
Genetic studies of exposed, uninfected participants by Samson et al (1996b) showed the first 
conclusive evidence of genetically based resistance to HIV-1 infection by the discovery of a 
32-bp deletion within the coding sequence of the CCR5 gene (CCR5-∆32). This allele 
exhibited a higher frequency in Europe and was extremely rare among East Asians, Native 
Americans and Africans. This so-called lucky defect was shown to confer a high degree of 
protection against HIV-1 in homozygotes. Although no resistance to HIV-1 was seen in 
CCR5-∆32 heterozygotes, the rate of disease progression was significantly delayed. Quillent 
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and others identified a polymorphism in exposed uninfected subjects (m303, which introduced 
a premature stop codon in the CCR5 gene), reaffirming the central role played by CCR5 in 
HIV-1 physiology (Quillent et al, 1998). 
 
1.6.3.1   Role of chemokines in MTCT 
The inflammatory chemokines; CCL3, CCL4 and CCL5 are the natural ligands for CCR5, a 
chemokine receptor used by (R5) HIV-1 other than CD4 to gain entry into leukocytes (Deng et 
al, 1996; Dragic et al, 1996). By virtue of binding to CCR5 these chemokines have the ability 
to block replication of macrophage-trophic (R5) viruses’ in vitro (Cocchi et al, 1995). This 
discovery raised the probability that these molecules could contribute to protective immunity 
against HIV-1 in vivo. Evidence for this hypothesis was shown in prototype HIV-1 vaccine 
studies performed in rhesus macaques, where CC production by CD8 T cells was correlated 
with protective immunity (Lehner et al, 1996; Heeney et al, 1998). Elevated production of 
these chemokines was also observed in persons who remained uninfected despite multiple 
high risk sexual encounters (Paxton et al, 1996; Zagury et al, 1998) Apart from regulating 
cell-mediated immunity, these chemokines also play a role in chemotaxis (Matsukawa et al, 
2000). 
 
Naturally occurring host genetic variants of chemokine and chemokine receptor genes have 
demonstrated the crucial role of these molecules in altering the host immune response to HIV-
1 (O’Brien and Nelson, 2004). Investigators have, therefore speculated that the setting present 
in infants at birth was conducive to providing protection from HIV-1 and could explain why 
majority of HIV-1 exposed infants somehow escape infection despite the absence of ARV 
 
 
- 47 - 
intervention. This was supported by a study demonstrating the over expression of CCL3, 
CCL4 and CCL5 in a small number of exposed-uninfected infants, suggesting that these 
chemokines may mediate non-cytolytic inhibition of infection during perinatal HIV-1 
exposure  (Wasik et al, 1999). 
 
Genome duplication is an important mechanism in human evolution and genetic adaptation. 
Identification of various polymorphisms or duplications of chemokine or chemokine receptor 
genes that exert variable effect on HIV-1 disease progression demonstrated that the rate of 
disease in each individual was not necessarily determined by a single genetic polymorphism, 
but rather by the combined effects of divergent or multiple genes, which are further modulated 
by the genetic background of the racial group (Lusso, 2006). As segmental duplications over-
represent genes involved in immunity, duplications are thought to benefit host immunity 
(Bailey et al, 2002).  
 
CCL3-L1 is the most potent ligand for CCR5 and provides an excellent example of the 
benefits of gene duplication. CC chemokine ligand 3-like or CCL3-L1 is one of the two active 
genes (CCL3/LD78α) and (CCL3-L1/ LD78 β) that code for CCL3. Although CCL3 and 
CCL3-L1 share a 94.0% sequence similarity (Nakao et al, 1990), they encode functional 
proteins that are biologically different. While CCL3 occurs in two copies per diploid genome 
(p.d.g), CCL3-L1 is found in variable copies (p.d.g) in different individuals (Menten et al, 
2002). By binding to CCR5 and promoting its sequestration (Fig 12), CCL3-L1 can block 
HIV-1 replication. As a CCR5 agonist, CCL3-L1 can also promote T cell activation and 
migration, enhancing both cellular immunity and generalized immune activation. Genetic 
polymorphisms thought to determine the amount of CCR5 and CCL3-L1 have complex effects 
 
 
- 48 - 
on HIV-1 pathogenesis that include control of viraemia and cellular immunity, as well as 
effects that are independent of both (Lederman and Sieg, 2007). 
 
                 
Fig 12: CCL3-L1 HIV-1 blocking mechanism. By binding to CCR5 and promoting its sequestration, 
CCL3-L1 can block HIV-1 replication. As CCL3-L1 levels rise, more CCR5 receptors are filled, 
thereby blocking the virus’s ability to infect a host cell (Lederman and Sieg, 2007). 
 
The CCL3-L1 gene dose, therefore affects the risk for HIV-1 acquisition and disease 
progression because as levels of CCL3-L1 rise (Fig 12), more CCR5 receptors are filled, 
thereby blocking the virus’s ability to infect a host cell. In addition, an increase in the number 
of CCL3-L1 copies was associated with a decrease in the proportion of CD4 cells that express 
CCR5 and a lower expression of CCR5 decreases the likelihood of HIV-1 infection 
(Lederman and Sieg, 2007). Individuals with CCL3-L1 gene copy numbers above the 
population median were less susceptible to HIV-1 acquisition (Townson et al, 2002). In a 
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landmark study that investigated the influence of CCL3-L1 gene-containing segmental 
duplications on HIV/AIDS susceptibility, Gonzalez and others observed  wide variability in 
the average number of CCL3-L1 gene copies (Fig 13) across diverse human populations that 
extended across a range of continents (Gonzalez et al, 2005).  
 
Compared to non-African individuals, African individuals had significantly higher CCL3-L1 
gene copy numbers. Gene copy medians, determined among various African populations 
ranged from five gene copies p.d.g in the (Bantu Pedi, Bantu Zulu and Bantu Sotho) to six 
gene copies p.d.g in the Bantu Tswana population (Gonzalez et al, 2005). Gonzalez and others 
(2005) also observed significant inter-individual and inter-population differences in the copy 
number of a segmental duplication encompassing the gene encoding CCL3-L1. While adults 
and children bearing a higher copy number of CCL3-L1 gene relative to their population 
median were at a reduced risk of HIV-1 infection, those possessing a gene copy number lower 
than the population median were associated with enhanced HIV/AIDS susceptibility 
(Gonzalez et al, 2005).  
 
The relationship between CCL3-L1 gene dose and altered HIV/AIDS susceptibility points to a 
central role for CCL3-L1 in HIV/AIDS pathogenesis. However, the association between 
CCL3-L1 gene dose and HIV/AIDS susceptibility exists only when viewed in the context of 
an individual’s ethnicity and geographic ancestry. It also indicates that the differences in the 
dose of immune response genes may constitute a genetic basis for the variable responses to 
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Fig 13: Distribution of CCL3-L1 gene copy numbers among human populations (Gonzalez et al, 2005) 
 
A significant discovery by Gonzalez and others was that Argentinean children with CCL3-L1 
gene copy numbers less than their population median had  a higher risk of acquiring HIV-1 
vertically whereas those with copy numbers greater than the population median had a lower 
risk (Gonzalez et al, 2005). Local studies in SA have since confirmed these findings. Infants 
who displayed a deficient production phenotype were at an increased risk of acquiring HIV-1; 
hence CCL3-L1 plays an important role as an “HIV-1 susceptibility factor” in the South 
African population (Kuhn et al, 2007; Meddows-Taylor et al, 2006).  
 
The influence of sdNVP on the relationship between maternal-infant CCL3-L1 gene copies 
and perinatal HIV-1 transmission was investigated by Kuhn and co-workers. They confirmed 
the dose dependent relationship between duplications of the CCL3-L1 gene and perinatal HIV-
1 transmission (Kuhn et al, 2007). In their study, the median number of CCL3-L1 gene copy 
numbers was reported to be four to five p.d.g in the context of the southern African black 
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population. Infants with fewer gene copies were more likely to acquire HIV-1 from their 
mothers and conversely those infants with more gene copies were less susceptible. This 
finding was however restricted to detection only in the absence of maternal NVP or with high 
maternal viral load (Kuhn et al, 2007). No association was found between CCL3-L1 gene 
copies and perinatal transmission if mothers took sdNVP. NVP could therefore possess anti-
viral and immunomodulatory properties which partially change the role of CCR5 and its 
ligands in HIV-1 transmission (Kuhn et al, 2007).  
 
Local NICD researchers performed a detailed single nucleotide polymorphism (SNP) and 
haplotype characterization of the CCL3 and CCL3-L1 genes (Paximadis et al, 2007). SNP 
(Fig 14) refers to a DNA sequence variation that occurs when a single nucleotide (A, C, T, G)  
in the genome (or other shared sequence) differs between members of a species (or between 
paired chromosomes in an individual) [Hall, 2007]. 
 
 
Fig 14: Single nucleotide (C/T) polymorphism (Hall, 2007) 
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Paximadis and others investigated the role of a unique CCL3 haplotype (CCL3-Hap-1) in 
respect to HIV-1 susceptibility and MTCT (Paximadis et al, 2007). They achieved this by 
targeting a seven-SNP haplotype (Hap-1) identified in CCL3. This haplotype known to 
harbour a SNP haplotype in the core promoter region along with two downstream SNP’s has 
been previously associated with a reduced risk of HIV-1 acquisition in African Americans 
(Gonzalez et al, 2001). Paximadis and co-workers investigated this relationship further in their 
study which included four South African MTCT transmission cohorts (Paximadis et al, 2007). 
They found that CCL3-Hap-1 was significantly associated with a high CCL3-L1 gene copy 
number only in infants and not in the corresponding mothers. A crucial outcome from their 
study was the low Hap-1 representation found among infants who were infected in utero as 
opposed to intrapartum. These extremely novel findings suggest that the role of CCL3 in 
protection could vary for different modes of HIV-1 transmission.  
 
1.6.4   CD4 cell counts and MTCT 
Maternal immune depletion has been shown to correlate with vertical transmission (Luzuriaga, 
2007; Mofenson et al, 1999b). Decreased CD4 T cell counts are a measure of worsening 
immune
 
deficiency and have been associated with enhanced perinatal
 
HIV-1 transmission. A 
low CD4 T cell count may result
 
from a high viral load and may therefore not be an 
independent
 
risk factor for vertical acquisition of HIV-1 (Mofenson et al, 1999b). Revised 
guidelines from the WHO currently recommends that HAART be considered for those patients 
(clinical stage I and II) with a CD4 cell count below 350  µl/ml, especially if closer to 200-250 
µl/ml (WHO, 2006b). 
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1.7   Study rationale, hypotheses, aims and objectives 
Despite therapeutic, prophylactic and obstetric interventions to reduce the proportion of 
infants infected during labour and delivery, mechanisms for intrapartum HIV-1 transmission 
remain elusive and current interventions could therefore remain sub-optimal. Much 
controversy has surrounded the correlation of HIV-1 RNA (viral load) in the systemic and 
genital compartments. The influence of short-term ARV drugs on genital tract HIV-1 is also 
unclear.  
 
At the time the present study was initiated, a regimen of maternal intrapartum and neonatal 
postpartum sdNVP was the standard of care for the prevention of mother-to-child transmission 
of HIV-1. In most low and middle-income countries, including South Africa, sdNVP has been 
documented as effective intrapartum HIV-1 prevention based on plasma pharmacokinetic 
levels, decreased viral loads (HIV-1 RNA) and reduced rates of intrapartum transmission, yet 
operational studies continue to report high intrapartum transmission rates despite the 
administration of sdNVP. As a result perinatal HIV-1 transmission remains a significant 
public health concern in several African countries. 
 
 
The hypotheses for the PIVD study included the following: 
 
 
1) The pharmacokinetics of sdNVP when used routinely for the indication of prevention 
of intrapartum HIV-1 transmission in a public health setting is comparable to Phase I 
and II controlled studies.  
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2) The mechanism of action of sdNVP in potentially preventing intrapartum transmission 
is through infant postexposure prophylaxis and reduction of viral load (HIV-1 RNA) in 
maternal plasma and cervical secretions.  
3) Expression of specific CCL3 and CCL31 “Susceptibility genes” in mothers serve as 
“early warning” markers for intrapartum HIV-1 transmission despite the provision of 
sdNVP.  
 
The primary aim of this study was to describe the pharmacological dynamics of Nevirapine in 
association with virological and immunological risk factors for intrapartum HIV-1 
transmission in a South African PMTCT programme where sdNVP was the standard of care. 
 
This was accomplished through the following objectives: 
 
Primary: 
1) Determination of NVP drug concentration in maternal plasma and CVL samples in the 
peripartum period 
2) Determination of neonatal drug concentration following dosing at birth 
3) Quantitation and correlation of maternal HIV-1 RNA (viral load) in plasma and 
cervicovaginal lavage (CVL) samples at pre and post-NVP dosing 
 
Secondary: 
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2) Investigation of host genetics in a subset of confirmed HIV-1 infected infants and their 
mothers by determination of CCL3 and CCL3-L1 gene copy numbers, identification of 
single nucleotide polymorphisms and haplotype characteristation of the CCL3 gene 
3) Investigation of unique clinical characteristics that determine the presence of NNRTI 
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CHAPTER TWO: METHODOLOGY 
2.1 Regulatory and institutional approvals 
Prior to commencement, this present received regulatory approval from the Provincial 
Department of Health (KZN) and permission to conduct this study at KEH was obtained from 
hospital management. Full ethical approval from the Biomedical Research Ethics Committee 
at Nelson R Mandela School of Medicine (UKZN) was received on 15
th
 February 2006 and 
patient screening officially commenced in April 2006. The ethics reference number for this 
study is H004/05.    
 
2.2  Study description 
2.2.1  Study design and setting 
The PIVD study was a laboratory based study of a cohort of pregnant women attending the 
maternity and child health services at KEH. This public sector, tertiary care referral hospital is 
located in Durban, KZN (South Africa). Samples were processed and stored at the Women’s 
Health and HIV Research Unit (WHHRU study laboratory), Doris Duke Medical Research 
Institute (DDMRI), UKZN. All laboratory assays were performed at the Department of 
Virology (IALCH), CAPRISA and Hasso Plattner Molecular laboratories in Durban 
[Virological]; Department of Clinical Pharmacology, University of Cape Town 
[Pharmacokinetics]; and the AIDS VIRUS UNIT (Cell Biology), National Institute of 
Communicable Diseases (NICD), Johannesburg [Immunology and Host Genetics].  
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2.2.2    Standard of care for PMTCT at KEH 
PMTCT refers to the prevention of mother to child HIV-1 transmission programme. Fig 15 
provides a brief overview of the comprehensive package of services offered at KEH. At the 
time the present study (2006-2007), all pregnant women were offered voluntary counselling 
and testing. If confirmed HIV-1 positive by HIV-1 antibody testing (HIV-1 ELISA), a CD4 
cell count was performed. Women with lower CD4 cell counts (< 200 cells/µl) were screened 
for eligibility for HAART (drug adherence training, pill buddies or partners etc.) and 
commenced on a regimen of Lamivudine (3TC), Stavudine (d4T) and NVP during pregnancy. 
HIV-1 infected women with a CD4 cell count of ≥ 200 cells/µl were offered a prophylactic 
ARV drug regimen consisting of  single dose (200 mg tablet) NVP issued at 28 weeks 
gestational age for self-administration during labour to prevent MTCT. A single dose (0.6 ml) 






























Fig 15: Overview of PMTCT services (adapted from PMTCT site manual, 2005) 
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2.2.3    Study population 
Pregnant women (between the ages of 18-39 years) who tested HIV positive by rapid tests and 
who decided to only formula feed their infants were screened for their study eligibility during 
the period April-December 2006. The total sample size comprised of one hundred and twenty 
mother-infant pairs. The PIVD study was designed with the primary objective of describing 
the pharmacological and virological dynamics of a single dose of NVP for the prevention of 
mother-to-child transmission of HIV-1 within a routine PMTCT program setting. Previously 
described controlled pharmacokinetic studies with sample sizes that ranged from  
50 -150 participants served as a guide for sample size determination in the present study 
(Mirochnick et al 1998, Musoke et al, 1999). Likewise similar virological studies investigating 
CVL HIV-1 RNA levels (viral loads) also assessed cohorts of 40-100 participants (Kovacs et 
al, 1999, Hart et al, 1999, Garcia-Bujalance et al, 2004, Kunz et al, 2007). Where the size of 
sample subsets were not adequately powered to address statistical relationships e.g. CCL3-L1 
gene copy expression and intrapartum HIV-1 transmission, this has been duly mentioned in 
the text under study limitations (page 187). In anticipation of the small number of HIV-1 
infected infants, we intended providing a description of our unique observations to steer the 
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2.2.4   Inclusion and exclusion criteria  




 Confirmed HIV-1 positive (HIV-1 antibody testing) 
 Decided to only formula feed infant (i.e. to exclude postnatal exposure to HIV-1) 
 Willing to attend post-delivery infant assessments (i.e. to continue follow up until six  
weeks post-delivery) 
 Must be ARV naïve (i.e. no previous exposure to NVP or other ARV drugs) and not 
require HAART 




 HIV-1 negative 
 Refusal to participate  
 Decided to only breastfeed infant 
 Unable to return for post-delivery infant assessments  
 Previous or current ARV exposure OR  require HAART 
 High risk patients [TB, cardiac, other] 
 < 18 and > 39 years of age 
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2.3   Screening and enrollment procedures    
2.3.1 Confirmation of maternal infection status  
Antenatal records of potential participants were screened for HIV-1 status. As part of PMTCT 
standard of care, maternal HIV-1 status was confirmed by routine antibody testing (HIV-1) 
through the use of a 4
th
 generation HIV-1 and p24 antigen combo ELISA kit (Elecsys HIV 
combi cobas
®
, Roche Diagnostics, Mannheim) at the Department of Virology (IALCH, 
Durban). 
  
2.3.2 Maternal CD4 cell counts 
Similarly antenatal records of potential participants were examined for maternal CD4 cell 
count results. As part of PMTCT standard of care, all CD4 cell testing was performed 
routinely at a central laboratory service (Department of Virology, IALCH, Durban).  
 
2.3.3 Maternal socio-demographic information  
Study participants were interviewed on their socio-demographic characteristics such as 
maternal age, gestational age, marital status, level of education and employment status. 
Antenatal records also served as a tool to verify pertinent inclusion criteria such as age, 
residence within a 10 km radius, no current or previous ARV exposure etc. 
 
2.3.4 Informed consent 
Study counseling and informed consent was supervised by the candidate (study investigator) 
and undertaken by two isi-Zulu speaking research assistants. Counseling was carried out in the 
language preferred by the participants, with either the ethics-approved isi-Zulu or English 
versions of the informed consent document being signed by all participants. One copy of the 
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informed consent document was retained by the study investigator and one copy was given to 
the study participant. All participants were given a patient information leaflet and made aware 
of their option to withdraw consent at any time during the course of the study if they so 
desired. 
  
2.3.5 Data collection 
Specific data pertaining to the medical history of a participant (antenatal, obstetric and 
paediatric clinical chart notes) was documented into a patient case report form or CRF 
(Appendix 5). Confirmation of maternal NVP intake (during labour) was self-reported by all 
study participants and verified through the use of PMTCT NVP registers and clinical records. 
Infant NVP dosing (at birth) was verified through review of clinical records and PMTCT NVP 
registers. All maternal data was collected from study enrolment up to maternal 
labour/delivery. All infant data was collected from birth to six weeks of age (completion of all 
study endpoints).  
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2.4  Sample collection, processing and storage 
Blood and cervicovaginal lavage samples (CVL) were collected from women at pre and post-
NVP dosing, while blood samples were obtained from infants (post-NVP dosing) by either 
nurses or medical officers/registrars stationed at the antenatal clinic, labour ward facility or 
paediatric nursery of KEH (during the study period). These sampling points were defined as 
follows:  
 
• Pre-NVP dose sampling: maternal sampling performed during pregnancy (≥ 28 weeks 
gestational age), prior to single NVP dosing in labour. 
 
• Post-NVP dose sampling: maternal sampling performed during active labour or after 
delivery and after administration of single dose NVP. Samples from infants were also 
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2.4.1 Blood: (maternal and infant) 
Maternal and infant whole blood samples were collected by venipuncture in sterile vacutainer 
tubes (4 ml) which contained EDTA as the anticoagulant (Beckton Dickinson, UK). After 
transport to the WHHRU study laboratory (DDMRI), whole blood was pipetted into 
appropriately labeled cryovials (Greiner, Germany) as 200 µl (infant) and 1000 µl (maternal) 
sample aliquots. Whole blood aliquots were stored in a -70
o
C freezer at the WHHRU study 
laboratory (DDMRI) until required for genotyping investigations as per study event schedule 
(Table III).  
 
All remaining whole blood samples were centrifuged at 800 - 1600 rpm for 20 minutes at 
room temperature. Plasma was carefully removed and transferred into appropriately labeled 
cryovials (Greiner, Germany) as 200 µl (infant) and 1000 µl (maternal) sample aliquots. All 
plasma aliquots were stored in a -70
o
C freezer at the WHHRU study laboratory (DDMRI) 
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2.4.2 Cervicovaginal lavage (CVL)  
The purpose of this collection procedure was to obtain a washing of virus and cells from the 
ectocervix and fluid from the posterior vaginal fornix for virological and pharmacokinetic 
assessments.  
 
Fig 16: CVL sampling region (adapted from WHO, 2006a) 
 
 Ten millilitres of sterile pH 7.2 Phosphate Buffered Saline (PBS) [Gibco©, Invitrogen™, UK] 
was drawn into a sterile medical syringe (Becton Dickinson, UK). After careful insertion of a 
lubricated speculum into the vagina, the PBS-filled syringe was slowly introduced through the 
speculum at the opening of the cervical os (Fig 16). The syringe was not inserted into the 
cervical os. A continuous stream of PBS was aimed directly at and onto the cervical os to 
bathe the cervix and ectocervix. Once the fluid pooled into the posterior fornix, it was 
aspirated back into the same syringe. This wash procedure was repeated a further two times 
using the same fluid. No additional PBS was added to the sample. The pooled fluid 
(cervicovaginal lavage or CVL) was finally aspirated and transferred to a sterile 15 ml 
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polypropylene tube (Delta labs, Spain). Samples were transported on ice to the WHHRU study 
laboratory (DDMRI) within 4 - 6 hours of collection (ACTG, 2004a). The total sample volume 
and presence of blood contamination was recorded in the patients CRF. Dipstick analyses 
using urine dipsticks (Uricheck, RapiMED diagnostics, SA) was performed to measure pH and 
estimate the level of blood contamination. CVL samples were briefly vortexed to ensure equal 
sample distribution. CVL was stored as whole unfractionated samples in 1000 µl aliquots in a 
-70
o
C freezer in appropriately labelled cryovials (Greiner, Germany) until required for 
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2.4.3 Dried blood spots: (infants only) 
Blood was collected onto the filter cards either from a syringe or directly from the 
venepuncture site. The skin on an infant’s heel was first cleaned with an alcohol swab. Once 
all residual alcohol had evaporated, a heel-prick was performed by a PMTCT medical officer 
by carefully puncturing the infant heel with a sterile lancet (Fig 17a). A filter collection card 
(Schleicher & Schuell Bioscience, Dassel, Germany) was held gently against a large drop of 
blood and a sufficient amount of blood was allowed to soak through to fill a single pre-printed 
circle on the filter card (Fig 17b). This process was repeated to completely fill as many of the 
pre-printed circles as possible. An example of a valid dried blood spot sample is shown in Fig 
17c. After filter collection cards were appropriately labeled with the infant’s study 
identification (PIVD number) and date of sample collection, they were carefully placed onto a 
rack and allowed to air-dry completely (Fig 17d). Once thoroughly dried, each filter card was 
placed into separate zip-lock plastic bags to prevent cross-contamination (Fig 17e). Dried 
blood spot samples were transported to the WHHRU study laboratory (DDMRI) and stored at 
-20
o
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2.5      Laboratory investigations 
2.5.1 Infant HIV-1 infection status and prediction of timing of infection 
 
Six weeks of age: 
At six weeks of age, all HIV-1 exposed infants received standard of care HIV-1 DNA PCR 
testing to establish their infection status. Samples were sent to the Virology Laboratory 
(IALCH, Durban) where they were batch-tested. The typical turn-around time for obtaining 
laboratory results ranged from 6 - 14 weeks.  
 
Birth and Four weeks of age: 
Confirmation of all HIV-exposed uninfected infants at four weeks and prediction of timing of 
infection in HIV-infected infants at birth and four weeks was performed by the author using 
HIV-1 DNA PCR under supervision at the Department of Virology (IALCH). Samples were 
batch tested approximately 8 - 12 months after sample collection. 
 
Principle of the HIV DNA PCR test: 
The MagNA Pure LC DNA Isolation kit III (Roche Diagnostic Systems, Branchburg, NJ, 
USA) was utilized for automated DNA extraction from infant dried blood spot samples. After 
DNA extraction, a slightly modified AMPLICOR HIV-DNA test, version 1.5 (Roche 
Diagnostic Systems, Branchburg, NJ, USA) was used for amplification and detection of 
proviral HIV-1 DNA. The Amplicor HIV-1 DNA test is a qualitative test that involves sample 
preparation, PCR amplification of target DNA using HIV-1 specific complementary primers, 
and nucleic acid hybridization of amplified products and detection of probe-bound amplified 
DNA products by colorimetric determination.  
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Sample preparation: 
A 0.5 cm diameter circle (50 µl sample volume) was cut from each filter paper spot (dried 
blood spot) using a sterile fine-point scissors. A new pair of sterile scissors was used for each 
infant sample. The dried blood spot was further cut into smaller slices and then placed into an 
appropriately labeled 1.5 ml eppendorf tube.  
 
DNA extraction: 
An automated protocol [MagNA Pure LC DNA Isolation kit III (Bacteria, Fungi), Roche 
Diagnostic Systems, Branchburg, NJ, USA] was used for extraction of proviral DNA from 
dried blood spot samples. A bottle of Proteinase K was first reconstituted with 1200 µl of 
Elution buffer. A stock reagent was prepared by dispensing 9100 µl Bacterial Lysis buffer, 
1400 µl of Proteinase K and 35 µl of Internal control into a 50 ml blue capped centrifuge tube 
(Greiner, Germany). This tube was inverted ~25 times to mix, and then allowed to stand on a 
bench for ~ 5 minutes until all air bubbles had dissolved. A 300 µl volume of Stock Reagent 
was dispensed into each eppendorf tube containing dried blood spot samples. Once dried 
blood spots were completely immersed in the stock reagent, all tubes were thoroughly 
vortexed for 10 seconds. Samples were placed onto a heating block for 10 minutes at 65
o
C. 
Following incubation, samples were removed from the heating block and vortexed. Samples 
were placed back onto the heating block for further ten minute incubation at 65
o
C. After 
vortexing, samples were placed directly onto a 95
o
C heating block for ten minutes. All tubes 
were then centrifuged at 5000 rpm for one minute at room temperature. After centrifugation, 
150 µl of sample was transferred into a MagNA pure sample cartridge. Sample cartridges were 
loaded onto the MagNA Pure LC instrument (Roche Diagnostic Systems, Branchburg, NJ, 
USA) and the batch run commenced. 
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DNA amplification and detection: 
DNA extracts (50 µl) obtained from the above protocol were then amplified and detected by 
using the Amplicor HIV-1 DNA test, version 1.5 (Roche Diagnostic Systems, Branchburg, NJ, 
USA) according to the manufacturer’s instructions. Fig 18 illustrates the process of DNA 




Fig 18: DNA amplification using polymerase chain reaction (NIH, 2009) 
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Interpretation of results: 
HIV DNA PCR testing was performed on all HIV-1 exposed infants at age six weeks 
according to the standard of care at KEH during the study period April – December 2006. 
Using CDC guidelines, all study infants were confirmed to be HIV-1 infected only after they 
tested PCR positive for HIV DNA on two separate occasions (CDC, 1995). Similarly the 
absence of HIV infection among HIV-1 exposed uninfected infants was confirmed with two 
separate DNA PCR tests i.e birth and 6 weeks or 4 and 6 weeks. The various permutations 
listed in Table V were used as a guide to estimate the timing of HIV-1 transmission from 
mother-to-child. 
 
Table IV: Estimating the timing of HIV-1 infection 
 











 Positive Positive Positive  In utero 
HIV-1 Positive  Positive  In utero 
DNA PCR Negative Positive Positive  Intrapartum 
 Negative Negative Positive Positive Intrapartum 
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On receipt of the six week DNA PCR results, the attending PMTCT clinician proceeded as 
follows: 
 
• If infants were HIV-1 negative (after two separate DNA PCR tests), they were 
discharged from the PMTCT clinic at KEH and mothers were advised to continue with 
regular infant check-ups at their local district health clinics.  
 
• If infants were HIV-1 positive, they were re-tested using DNA PCR. If results were 
confirmed positive by the second test (two consecutive results), infants were referred to 
the ARV rollout programme for management and treatment.  
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2.5.2 HIV-1 RNA quantitation (viral load) 
Testing was performed by the candidate under supervision of medical technologists at the 
Caprisa Research laboratory based at the DDMRI (Durban). 
 
Principle: 
A commercially available nucleic acid amplification COBAS AmpliPrep/COBAS TaqMan 
HIV-1 test (Roche Diagnostic Systems, Branchburg, NJ, USA) was used for the quantitation 
of HIV-1 RNA. The COBAS AmpliPrep instrument enabled automated sample preparation 
and COBAS TaqMan analyzer allowed automated amplification and detection.  
 
The COBAS system involved three major steps: 
♦ Sample preparation for HIV-1 RNA isolation 
♦ Reverse transcription of the target RNA to generate complementary DNA (cDNA) 
♦ Simultaneous PCR amplification of target cDNA and detection of cleaved dual-
labelled oligonucleotide detection probe specific to the target 
 
Frozen aliquots of plasma (maternal and infant) and whole unfractionated cervicovaginal 
lavage were allowed to thaw to room temperature. Samples were thoroughly vortexed and a 
sample volume of 1000 µl was used for each patient. The high positive, low positive and 
negative external controls included in the kit were also run for every batch of samples assayed. 
Plasma and genital HIV-1 RNA levels were quantified in several batch runs according to the 
manufacturer’s instructions (COBAS AmpliPrep/COBAS TaqMan HIV-1 test, Roche 
Diagnostic Systems, Branchburg, NJ, USA).  
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Interpretation of results: 
The limit of quantitation for this assay ranged from 40 - 10 000 000 copies/ml. HIV-1 RNA 
concentration for samples, and controls were determined automatically by the COBAS 
TaqMan analyzer. Samples with “Target not detected” were reported as HIV-1 RNA 
undetectable. Samples with HIV-1 RNA values below the assay limit were reported as < 40 
copies/ml. Samples with HIV-1 RNA values above the specified assay range were diluted 
(using the original sample) accordingly with kit provided HIV-1 negative human EDTA-
plasma and the test was repeated.  The reported result was then multiplied by the dilution 
factor. 
 
HIV-1 RNA concentration was expressed as the number of HIV-1 RNA copies per millilitre 
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2.5.2.1      Estimation of blood contamination in CVL samples 
Pre and post-NVP dose maternal CVL samples were visually examined for blood 
contamination and by the use of urine reagent strips (Uricheck-9, RapiMED Diagnostics, SA) 
for measurement of whole blood and haemoglobin. This was performed to determine blood 
derived HIV-1 RNA in CVL. Estimation of the amount of blood plasma present in CVL was 
determined using a previously described method by Hart et al (1999). Haemoglobin (Hb) 
concentrations were used to calculate blood volumes in CVL samples. Four Hb levels were 
defined on the Uricheck-9 reagent strips: 10, 25, 50 and 250 erythrocytes/microlitre. Test 
sensitivity ranged from 0.015 - 0.062 mg Hb/100 ml. The amount of plasma virus in a CVL 
sample was estimated by using the following series of calculations: 
 
a) Total amount of Hb in a CVL sample (mg Hb lavage) was determined using the equation:  
mg Hb lavage = (Hb signal lavage x 0.01) x (volume lavage) 
 
The Hb signal lavage was the Hb level (mg Hb/100 ml) estimated from the Uricheck-9 reagent 
strip, and volume lavage was the total volume of CVL sample in milliliters. 
 
b) As the Hb concentration in peripheral blood (mg Hb blood /100 ml blood) was known and the 
amount of Hb in CVL (mg Hb lavage) was determined using the above calculation, the blood 
volume in CVL samples was then calculated using the equation:  
Volume Lblood = (mg Hb lavage) ÷ (mg Hb blood/100 ml blood) 
 
c) Blood plasma volume (plasma lavage) in CVL samples was calculated using the volume of 
blood in CVL samples (vol Lblood) and the peripheral blood heamatocrit in the equation:  
(Plasma lavage) = (1- haematocrit) x (vol Lblood) 
 
d) Blood plasma virus in CVL samples (plasma HIVlavage) was calculated using the volume of 
plasma in CVL samples (plasma vol lavage) and the virus concentration in plasma (HIV RNA 
copies plasma/plasma vol) in the equation:   
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2.5.3 NVP quantitation (pharmacokinetic assessments) 
Principle: LC-MS-MS 
Tandem Mass spectrophotometry (MS-MS) is a sensitive analytical method used for the 
identification of organic compounds in mixtures. The first mass spectrophotometer serves to 
ionize all components of the mixture and selects a major ion (molecular ion of the compound 
of interest). These ions were fragmented and the resulting fragment ions were separated and 
mass analyzed in the second mass spectrophotometer (Biemann, 1993). Use of liquid 
chromatography with Tandem Mass spectrophotometry (LC-MS-MS) improves the rate of 
sample analysis, assay sensitivity and data quality. Figure 19 illustrates the mode of operation 
of a mass spectrophotometer (Clark, 2000). A sample was introduced into the ionization 
source of the instrument. Once inside the ionization source, the sample molecules were 
ionized. These ions were extracted into the analyzer region of the mass spectrophotometer 
where they were separated according to their mass (m)-to-charge (z) ratios (m/z). The 
separated ions were detected and a signal was then sent to a data system where the m/z ratios 
were stored together with their relative abundance for presentation in the form of an m/z 
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Fig 19: Mode of operation of a mass spectrophotometer (Clark, 2000) 
 
Procedure: NVP quantitation assay 
NVP drug concentration levels were quantified by the candidate using a validated Tandem 
Mass spectrophotometry method (LC-MS-MS), under the supervision of laboratory staff at the 
Division of Clinical Pharmacology, Department of Medicine, Groote Schuur 
Hospital/University of Cape Town. This assay procedure was performed with minor 
modifications as per previously described method (Cohen et al, 2008). 
 
a) Reagents:  
NVP reference drug was obtained from Aspen Pharmacare (SA). Aspen NVP (generic) was 
formulated in SA under license of the Boehringer-Ingelheim group of companies (Aspen 
Pharmacare (Pty) Limited, Sandton, SA). 
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Using the reference drug above, NVP stock solution of [1 mg/ml] was freshly prepared as per 
procedures described in Appendix 6. NVP stock solution was used to prepare NVP working 
standard solutions of 10 µg/ml and 100 µg/ml respectively (Appendix 6). NVP calibration 
standards (S1 - S10) were prepared by spiking drug-free human plasma with an appropriate 
amount of NVP working standard solution to obtain final concentrations of 100, 200, 500, 
800, 1000, 1300, 1500, 2000, 5000 and 10 000 ng/ml respectively (Appendix 6).  
 
Reserpine (Sigma, St Louis, MO) served as the internal standard. Low (C1), medium (C2) and 
high (C3) quality control samples of NVP were also prepared by spiking drug-free human 
plasma with 300, 1800 and 9000 ng/ml of NVP working standard solution respectively 
(Appendix 6). These quality controls covered the range of the standard curve and were 
randomly interspersed among unknown patient samples during each sample run.  
 
b) NVP precipitation method:  
Frozen patient samples [maternal plasma, maternal CVL and infant plasma] were allowed to 
thaw at ambient temperature. A 50 µl volume of NVP calibration standard (S1 - S10), quality 
control sample (C1, C2, and C3) and patient sample were each pipetted into appropriately 
labelled 2 ml eppendorf tubes. A calibrated Eppendorf Multipette was used to accurately 
dispense 200 µl of Protein Precipitation reagent [80% Methanol (MERCK, Germany): 20% 
0.2 M Zinc Sulphate (Sigma, St Louis, MO), Appendix 6], containing 150 µl Reserpine 
(Sigma, St Louis, MO)] into each eppendorf tube. All eppendorf tubes containing (patient 
samples, NVP calibration standards and quality controls) were vortexed (Vortex Genie, 
Scientific Industries) thoroughly for 10 seconds each. This was followed by a five minute 
sonnication step (Instrulab, Integral systems, SA). All tubes were centrifuged (Biofuge 13, 
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Sepatech) at 13 000 rpm for five minutes at room temperature. A 200 µl volume of the 
resulting supernatant was carefully transferred into a clean glass insert contained within clean 
glass vial (Agilent technology, Germany). Care was taken to avoid disturbing or dislodging 
the pellet during this transfer step. All glass vials were carefully capped, placed into an 
autosampler rack (Agilent technology, Germany) and then finally loaded onto the LC/MS/MS 
System. 
 
c) Instrument conditions: 
The LC/MS/MS System consisted of a linear Ion Trap Quadropole API 3200 Q-trap Mass 
Spectrophotometer (Applied Biosystems, Germany) attached to an HPLC 1200 Series (Agilent 
Technologies, Germany) using a 1200 binary pump (Agilent, Germany),  Gemini C18-RP 3 
µm particle size and a [50 x 2.00 mm 4 micron] Phenomenex fusion column. The mobile 
phase consisted of; Bottle A: 10% Methanol (MERCK, Germany) and Bottle B: 97% 
Methanol (MERCK, Germany) + 3% 10 mM Ammonium Acetate (MERCK, Germany) in 
Glacial Acetic acid (analytical grade, Pal Chemicals) [Appendix 6]. The run time was three 
minutes at an injection volume of 2 µl and a flow rate 600 µl/minute.  
 
Interpretation of results: 
On completion of each sample run, a standard curve was constructed by plotting peak height 
ratios of NVP to internal standard versus NVP concentration. The standard curve (Fig 20) was 
assessed for linearity [r value as close to 1 as possible]. Chromatograms of maternal (plasma 
and CVL) and infant (plasma) samples are shown in Figs 21 a-e. NVP concentrations were 
determined relative to the internal standard (Reserpine, Sigma, and St Louis, MO) and all 
results were reported in units of ng/ml. Patient samples with NVP levels above the assay range 
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were diluted, and then re-assayed to maintain assay specificity. NVP values of (< 10 ng/ml) 
for CVL samples and (< 100 ng/ml) for plasma samples were regarded as below the limit of 
quantification for this assay.   
 
Assay modifications: 
All maternal CVL samples were first assayed using the same set of calibration standards as 
used for blood plasma [range: 100 – 10 000 ng/ml]. NVP detection and quantitation in a vast 
majority of the CVL samples was below the limit of assay quantification (< 100 ng/ml). The 
range of the standard curve was therefore lowered to [10 ng/ml – 100 ng/ml] to improve the 
detection limits of the assay. Using the NVP reference drug from Aspen Pharmacare (SA), 
NVP stock solution of [1 mg/ml] was freshly prepared as per (Appendix 6). NVP working 
standard solutions of 1 µg/ml and 10 µg/ml were then prepared using the NVP stock solution. 
NVP calibration standards (S1 – S8) were prepared by spiking drug-free human plasma with 
an appropriate amount of NVP working standard solution to obtain final concentrations of 10, 
20, 30, 40, 50, 60, 80 and 100 ng/ml respectively. Low (C1), medium (C2) and high (C3) 
quality control samples of NVP were made up by spiking drug-free human plasma with 25, 55 
and 90 ng/ml of NVP working standard solution respectively. The final sample injection 
volume was 20 µl. All other assay parameters in respect of NVP precipitation, internal 
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r value = 0.99 









21a) Maternal Plasma: Pre-NVP dose 
21b) Maternal Plasma: Post-NVP dose 
Fig 21 (a-b): Chromatograms of Maternal Plasma at Pre-NVP (a) and Post-NVP (b) dosing 
Internal standard: 
Reserpine 
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21c) Maternal CVL: Pre-NVP dose 





Peak of interest: 
Nevirapine 
Fig 21(c-d): Chromatograms of Maternal CVL at Pre-NVP (c) and post-NVP (d) dosing 
 
 













21e) Infant plasma: Post-NVP dose 




Fig 21e: Chromatogram of Infant plasma at post-NVP (e) dosing 
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2.5.4 Screening for STI’s 
Principle of test: 
Wet mount microscopy was used for the direct microscopic examination of a wet preparation 
of cervicovaginal discharge. This WHO recommended method provided simple and rapid 
diagnosis of Trichomonas vaginalis, Bacterial vaginosis and Candida albicans infections 
(WHO, 2005). STI screening was performed on all study women (n = 120) during pregnancy 
at pre-NVP dosing. Following CVL collection, ~500 µl of sample was aliquoted into a clean 
eppendorf tube and transported immediately to the Global Clinical and Viral Laboratory 
(Durban) for wet mount microscopy assessments as per WHO guidelines (Appendix 7).  
 
Interpretation of Results: 
Laboratory reports were received on a weekly basis. If CVL samples indicated the presence of 
any STI (Trichomonas vaginalis, Candida albicans or Bacterial vaginosis), study participants 
were immediately contacted by telephone and urged to visit the antenatal clinic at KEH as 
soon as possible to commence with standard of care treatment (antibiotics) prior to their labour 
and delivery. 
 
 Standard of care for STI management at KEH: 
♦ Erythromycin (500 mg) x 7 days  
♦ Flagyl (400 mg) stat dose 
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2.5.5 HIV-1 drug resistance testing 
Testing was performed by the candidate under supervision of a medical research scientist at 
the Hasso Plattner Molecular Research laboratory (DDMRI), Durban. 
 
Sample, processing and storage 
HIV-1 drug resistance testing was only conducted on HIV-1 transmitting women [refers 
specifically to study participants who transmitted or passed the virus onto their unborn infant 
either during the course of pregnancy or at the time of delivery). Testing was performed on 
post-NVP dose maternal plasma samples. 
 
Principle: 
The procedure described below was adapted from the ACTG protocol, 2004b. The Viroseq™ 
HIV-1 Genotyping system (Celera Diagnostics, USA) was used to identify mutations in the 
pol gene of HIV-1.  In this system, the entire Protease gene and ~ two-thirds of the Reverse 
Transcriptase (RT) gene in the pol open reading frame were amplified. The amplicons were 
used as a sequencing template to generate sequence data. Genotypic analysis of this region of 
HIV-1 allows the study of the relationship between mutations and viral resistance to ARV 
drugs.   
The genotyping process involved:  
• isolation of HIV from plasma and purification of viral RNA  
• reverse transcription of the HIV genome using a single primer 
• PCR amplification of the protease and RT genes from the cDNA made during the reverse 
transcription reactions  
• direct sequencing of the PCR amplification product using custom sequencing mixes  
• identification of mutations in the protease and RT genes using the Viroseq
TM
 HIV-1 software   
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Sample Preparation: 
Maternal plasma samples and RNA diluents (kit) were allowed to thaw. A 500 µl volume of 
plasma was transferred into a pre-labeled tube (with orientation marks on one side of tube). 
Tubes were placed in a pre-cooled centrifuge (4
o
C) such that the orientation mark was facing 
the outside rim of the rotor. Samples were centrifuged for one hour at 25 000 rpm at 4
o
C. 
During centrifugation, 70% Ethanol was freshly prepared and viral lysis buffer (from kit) was 
thawed to room temperature. On completion of centrifugation, a fine-tip transfer Pasteur 
pipette was used to remove as much supernatant as was possible without disturbing the pellet. 
Thereafter 600 µl of viral lysis buffer was added to each tube and followed by thorough 
vortexing. Tubes were briefly centrifuged to sediment contents to the bottom of the tube. To 
ensure complete viral lysis, samples were allowed to stand at room temperature for ten 
minutes. This was followed by the addition of 600 µl of Isopropanol to each sample. Each 
tube was vortexed for 3-5 seconds, followed by 15 minutes of centrifugation with the 
orientation mark facing out, at 12500 - 16000 rpm at room temperature. On completion of 
centrifugation, a fine-tip transfer pipette was used to remove as much supernatant without 
disturbing the pellet. A 1000 µl volume of cold 70% Ethanol was added to each tube, followed 
by gentle vortexing for 3-5 seconds. All samples were centrifuged, with the orientation mark 
facing outwards, at 12500-15000 rpm for 5 minutes at room temperature. On completion of 
centrifugation, a fine-tip transfer pipette was used to remove as much supernatant without 
disturbing the pellet. Residual 70% Ethanol was removed and all tubes were allowed to air-
dry. Each pellet was re-suspended with cold RNA diluent. This step was dependant upon the 
specific viral load (HIV-1 RNA) of each maternal sample. If HIV-1 RNA was > 15000 
copies/ml, 100 µl of RNA diluent was added. Alternatively if HIV-1 RNA of the sample 
ranged between 2000-15000 copies/ml, a 50 µl volume of RNA diluent was added. Pellets 
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were then re-suspended by vortexing vigorously for 10 seconds. Samples were then quick 
spun allowing liquids to settle at the base of each tube. Samples were stored at -80
o
C until 
needed for RT-PCR. 
 
RT-PCR: 
Using reagents provided in the kit, a PCR master mix (per reaction) was first prepared by 
combining PCR mix (29.5 µl), AmpliTaq Gold (0.5 µl) and UNG (1.0 µl). Positive and 
negative controls were included in each batch of extractions. RT master mix (volume/sample) 
was prepared by combining HIV RT Mix (8 µl), RNAse Inhibitor (1 µl), MuLV RT (1 µl) and 
0.4 µl (DTT). A 10 µl volume of cold sample RNA was aliquoted to a 0.2 ml PCR tube. All 
tubes were placed into a thermal cycler and the instrument was run on pre-set conditions under 
“viroseq-rt program”. The instrument was paused after the 42
o
C/5min step and tubes were 
removed from the thermal cycler. RT mix (10 µl) was added into each reaction tube. Samples 
were returned to the thermal cycler and “RT reaction” was resumed. Samples were held at 4
o
C 
for at least 10 minutes, thereafter PCR master mix (30 µl) was added to each sample. Samples 
were reloaded into the Thermal Cycler and run according to the pre-set instrument conditions 
under the “viroseq-pcr” program. Samples were stored at -20
o
C until analyzed. 
 
Purification of Viroseq products: 
Microcon-100 Spin columns were inserted into the Microcon 1.5 ml collection tubes (kit 
provided) for each maternal sample. A 300 µl of KCL (200mM) was carefully added to the top 
of each column without touching the membrane. The entire 50 µl PCR reaction was loaded to 
the centre of the KCL-filled column. All caps were secured and columns were centrifuged for 
15 minutes at 450 – 550 rpm. Thereafter 300 µl of sterile filtered deionised water was added to 
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the top of each column without touching the membrane. Caps were secured and the columns 
were centrifuged for 15 minutes at 450 – 550 rpm. After caps were removed, 35 µl of sterile 
filtered deionised water was added to the centre of each column. The columns were inverted in 
new tubes and spun for 5 minutes at 450 – 550 rpm. All columns were removed and discarded. 
Microtubes now contained approximately 40 -50 µl of purified PCR product. A mini agarose 
gel (1%) containing 0.5 µg/ml of Ethidium Bromide was prepared (Appendix 9). Five 
microlitres of the purified PCR product was mixed with 1 µl of Gel Loading Buffer (supplied 
with the kit) in a tube. A volume of 6 µl of the DNA Mass Ladder (supplied with the kit) was 
loaded into lane 1 of the agarose gel. Thereafter the entire 6 µl of the sample [purified PCR 
product and gel loading buffer] was loaded into the remaining wells of the agarose gel. The 
agarose gel was electrophoresed at 10 V/cm until the loading dye migrated at least 5 cm into 
the gel. The gel (Fig 22) was examined under UV light and the quantity of PCR products in 
each sample were estimated by comparing the intensity of each band to the intensities of the 
DNA Mass Ladder. Thereafter PCR products were diluted to an optimal concentration (as per 
manufacturer’s instructions and briefly vortexed for 3-5 seconds. 
 
Fig 22: Gel image after electrophoresis; DNA Mass Ladder (lane 1), maternal samples (lanes 2-9) 
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Sequencing Reactions: 
Primer mix reactions were set up in an optical 96-well reaction plate (Applied Biosystems, 
USA). A 12 µl volume of each primer mix (A, B, C, F, G and H) was added to an empty well. 
Thereafter 8 µl of the diluted purified PCR product was also added into each of the 6 wells 
from above step. The reaction plate was vortexed 3-5 seconds, and then quick spun for 5 – 10 
seconds. Samples were loaded onto a thermal cycler and run on max mode using the program 
“seq” on the GeneAmp 9700.  A thermal profile of 25 cycles permitted: denaturation of DNA 
at 96
o
C (10 seconds), primer annealing 50
 o





Purification of sequencing products: 
Stock solution (per reaction) was made by combining 2 µl of 3 M Sodium acetate pH 4.6 and 
50 µl of 100% Ethanol (MERCK, Germany). A volume of 55 µl of Stock solution was added 
to each sequencing reaction. An adhesive cover was used to seal the reaction plate before 
vortexing. The reaction plate was centrifuged at 3000 rpm for 20 minutes. Thereafter the 
adhesive cover was removed and the reaction plate was inverted onto folded paper towel. The 
reaction plate and paper towel was centrifuged at 150 rpm for 5 minutes. A 150 µl volume of 
freshly prepared 70% Ethanol was immediately added into each well to prevent drying out of 
the well. The reaction plate was centrifuged at 3000 rpm for 5 minutes. The reaction plate was 
once again inverted onto folded paper towel. The reaction plate and paper towel was 
centrifuged at 150 rpm for one minute. Thereafter the reaction plate was allowed to dry at 
room temperature (~5 minutes). Dried pellets were then re-suspended with 10 µl of 
Formamide (from kit) and allowed to denature at 95
o
C for 3 minutes on the GeneAmp 9700 
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under program “denature”. Samples were then loaded onto the ABI 3100 automatic sequencer 
(Applied Biosystems, USA) and run according to manufacturer’s instructions. 
 
Interpretation of results: 
All resulting sequences were assembled using Sequencher software (Gene Codes Corporation, 
USA) and examined in a multiple alignment with standard subtype references (Clustal X) 
available from (http://www.clustal.org). Aligned sequences were uploaded to the University of 
Stanford drug resistance database website available from (http://hivdb.stanford.edu/) for 
identification of drug resistance mutations. Drug resistance reports from two study patients 
indicating the presence and absence of NNRTI drug resistance mutations are shown in 
appendices 8a and 8b respectively. Phylogenetic analysis was then conducted using the 
Neighbour-joining method with Kimura's two-parameter model of distance calculation. 
Bootstrap analysis was performed with 100 replicas to rule out mislabeling of samples and to 
also confirm the absence of contamination. The virus subtype was determined by neighbour-
joining reconstruction using reference sequences of RT and Protease pol genes from the Los 
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 2.5.6 Host genetics and immunology 
All genotyping assays were conducted by the candidate under supervision of research 
scientists at the AIDS VIRUS UNIT (Cell Biology), National Institute of Communicable 
Diseases (NICD, Johannesburg). 
 
Sample collection, processing and storage 
Whole blood samples were collected from women during pregnancy (pre-NVP dosing) and 
from infants during their six week postnatal assessment. Maternal and infant whole blood was 
transferred into appropriately labeled cryovials and stored as 1000 µl (maternal) and 200 µl 
(infant) aliquots. All whole blood aliquots were stored at -70
o
C. Of these stored aliquots, a 
case-controlled matched subset of patients was then selected for genotyping. The subset 
included all HIV-1 transmitting mothers (n = 12) and their infected infants (n = 14) in 
conjunction with a matched control group of non-transmitting women (n = 28) and their HIV-
1 exposed-uninfected infants (n = 28). HIV-1 transmitting women were paired with HIV-1 
non-transmitting women (controls) according to demographic and clinical characteristics that 
included; CD4 cell count, HIV-1 RNA (viral load), maternal age and gestational age.  
 
Genotyping investigations included:  
 
♦ Determination of CCL3 and CCL3L1 gene copy number 
♦ Identification of Single nucleotide polymorphisms (SNP’s) and Haplotype characterisation of 
the CCL3 gene  
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Genomic DNA extraction and quantitation 
Genomic DNA was extracted from whole blood samples (maternal and infant) using the 
Qiagen QIAamp
®
 DNA mini kit (Qiagen, USA) according to the manufacturer’s instructions. 
Once extracted, purified DNA was stored in 2 ml eppendorf tubes at -20
o
C until required. 
DNA purity and concentration was measured using the NanoDrop (ND-1000) 
spectrophotometer. Absorbance’s were read at the following wavelengths (A230, A260 and A280) 
and DNA concentration was expressed in units of ng/µl. Fig 23 shows an example of a DNA 
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CCL3 and CCL3-L1 gene copy number determination 
CCL3 and CCL3-L1 gene copy numbers were determined by a real-time PCR assay as 
described by researchers at the NICD (Meddows-Taylor et al, 2006). This real time PCR assay 
made use of the following primers and probes which were synthesized at the University of 
Cape Town (UCT, SA):  
 
• β-Globin gene upstream primer  
• β-Globin gene downstream primer 
• β-Globin gene probe  
• CCL3-L1 gene upstream primer 
• CCL3 and CCL3-L1 genes downstream primer 
• CCL3 gene upstream and CCL3 probes  
 
Fig 24 illustrates a summary of the assay procedure. Frozen DNA (extracted) samples and 
aliquots of primers, probes, internal control (Flu-4, AIDS Virus unit, NICD, SA) and TaqMan 
Universal PCR Master Mix (Applied Biosystems, USA) were allowed to thaw on ice. Three 
eppendorf tubes were labelled as CCL3, CCL3-L1 and β-Globin respectively. A bulk mix of 
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Table V: Preparation of Bulk Mix 
 
 CCL3* CCL3-L1* β-Globin* 
CCL3 primer (forward) 31.5 µl 31.5 µl 31.5 µl 
CCL3-L1 primer (reverse) 31.5 µl 31.5 µl 31.5 µl 
Baxter water 59.5 µl 59.5 µl 59.5 µl 
CCL3 probe 17.5 µl 17.5 µl 17.5 µl 
* For 30 extracted samples 
 
PCR microtubes were placed onto a rack and appropriately labelled for DNA samples and two 
assay controls. FLU-4 was used as the internal control as it has a known CCL3 copy of two 
gene copies per diploid genome. Water was used as the negative control. TaqMan (17.5 µl) 
Universal PCR Master Mix [Applied Biosystems, USA] was added into each PCR tube and 
vortexed thoroughly. Extracted genomic DNA (3.5 µl) was added into each TaqMan 
containing tube. Thereafter 3.5 µl of FLU-4 was added into the control tube (internal control). 
Lastly 3.5 µl of water was added into the tube labeled negative control.  
 
A MicroAmp™ optical 96-well Reaction Plate with barcode (Applied Biosystems, USA) was 
prepared for PCR and placed onto a rack. Three reaction wells were run per DNA sample. 
Four microlitres of each primer and probe (CCL3, CCL3-L1 and β-Globin) was added into 
each allocated well respectively. Thereafter 6 µl of DNA/TaqMan mix was added into each of 
the three wells containing (CCL3, CCL3-L1 and β-Globin). Assay controls (internal and 
negative) were loaded onto the plate at the end. Fig 24 also illustrates the specific loading 
orientation of a single patient sample into a PCR reaction plate. Each row of the reaction plate 
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was then carefully capped with optical caps (Applied Biosystems, USA). The MicroAmp™ 
reaction plate was gently tapped to combine the primer/probe with patient DNA. The plate 
was thereafter loaded onto the ABI PRISM 7500 sequence detection system (Applied 
Biosystems, Netherlands) where Real-time PCR was performed according to the 
manufacturer’s protocol.  
 
Interpretation of results: 
For each sample; β-Globin, CCL3 and CCL3-L1 genes were amplified in duplicate, using ~ 20 
ng of genomic DNA. Using the relative quantification method and using Β-Globin as the 
endogenous control, CCL3 gene copy number was confirmed at two copies per diploid 
genome (p.d.g) for each sample. CCL3 was then used as the endogenous control to calculate 
the absolute CCL3-L1 gene copy number (using the relative quantification method) against a 
known copy control (Meddows-Taylor et al, 2006).  
 
The respective population median of CCL3-L1 gene copy among both maternal and infant 
samples was then calculated. Comparison of the absolute CCL3-L1 gene copy number relative 
to the population median was used to determine an association with HIV-1 susceptibility. 
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 Single nucleotide polymorphism and Haplotype characterisation of CCL3 and CCL3-L1  
 DNA sequencing of CCL3 and CCL3-L1  
 
One hundred nanograms of extracted genomic DNA was used in a PCR amplification 
designed to co-amplify the region spanning the core promoter, exon 1 and most of intron 1 of 
both the CCL3 and CCL3-L1 genes. The upstream primer was designed to bind a consensus 
region flanking the Alu element, which is present only in CCL3-L1, and the downstream 
primer was designed to bind the consensus region in intron 1, that is ~50 bp upstream from the 
start of exon 2. The primers thereby amplified two fragments, a CCL3 and CCL3-L1 specific 
amplicons (Meddows-Taylor et al, 2006). PCR was performed as per methods described by 
(Meddows-Taylor et al, 2006) using the Expand High Fidelity PCR System (Roche Diagnostic 
Systems, Branchburg, NJ, USA).  
 
After gel electrophoresis (Fig 25), amplicons were purified using the QIAquick
®
 gel extraction 
kit (using a microcentrifuge kit protocol) [QIAquick
®
 PCR Purification kit, Qiagen, USA] as 
per manufacturer’s instructions. Sequencing was carried out using four sequence-specific 
primers, designed to selectively sequence either the forward or reverse sequence of CCL3 and 
CCL3-L1 from the purified amplicon mixture. Sequencing reactions were set up using the Big 
Dye Terminator chemistry version 3.1 (Applied Biosystems, USA) and run on a 3100 genetic 
Analyser (Applied Biosystems, USA) according to the manufacturer’s instructions. Resulting 
sequences were assembled and analysed for the presence of single-nucleotide polymorphisms 
(SNP's) by using SEQUENCHER software version 4.14 (Gene Codes Corporation, USA) by 
alignment with published sequences by (Nakao et al, 1990). Sequence data has been included 
in Appendix 10. 
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Fig 25: Gel image after electrophoresis; DNA ladder (lane 1); patient samples (lanes 2-13) 
 
Investigation of a unique CCL3 Haplotype with respect to mother-to-child transmission 
 
A SYBR-Green Real-time PCR assay by (Paximadis et al, 2008) was used to detect CCL3 C/T 
promoter SNP at position -86 (Haplotype-1 representation). Samples were thawed and PCR 
reaction mixes (C and T) were prepared. The C mix was made up of [225 µl SYBR Green 
PCR master mix (Applied Biosystems, UK), 45 µl C-forward primer, 45 µl Reverse-2 and 45 
µl water]. T reaction mix was similar to the C reaction mix, with exception of 45 µl T-forward 
primer (instead of C-forward primer). All reaction mixes were vortexed, centrifuged then 
dispensed (8 µl per well) into C and T rows of a PCR reaction plate. Two microlitres of DNA 
was dispensed into each well. The PCR reaction plate was sealed with optical lids (MicroAmp, 
Applied Biosystems, USA). The reaction plate was briefly centrifuged before it was loaded 
onto a thermacycler using the following thermal profile [1 cycle, 10mins at 95
o
C, 50 cycles; 
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95
o
C (15 sec), 60
o
C (20 sec), 72
 o
C (1 min) and 1 dissociation cycle: 95
o





C (15 sec)].  
 
A real-time PCR assay developed by (Paximadis et al, 2008) using primers with 3′-end locked 
nucleic acids (LNA’s) designed over the SNP position [one primer with 3′-end C LNA and 
one with a 3′-end T LNA was used for identification of Homozygotes (C/C) and 
Heterozygotes (C/T) at position -86 in CCL3. All primers were manufactured at (UCT, SA) 
and included; Seq-alpha-IF, reverse-2, CCL3-Forward, Seq P1, Seq P2, Seq P3 and Seq-P4). 
While setup reactions were similar to conventional PCR, this real-time PCR measured the 
accumulation of PCR product via the fluorophore during the exponential stages of the PCR, 
rather than at the end point (as in conventional PCR). A real-time PCR thermal cycler 
(Applied Biosystems, USA) was used to measure the fluorescence in the reaction tubes. 
Fluorescence intensities were logged and data stored for each PCR cycle was then used to 
create amplification plots of (fluorescent signal detected - background) vs. cycle number to 
identify the threshold cycle or CT. The exponential increase of the product was used to 
determine the CT, i.e. the number of PCR cycles at which a significant exponential increase in 
fluorescence was detected and which was directly correlated with the number of copies of 
DNA template present in the reaction.  
 
Interpretation of results: 
Homozygote (Fig 26a) wild-types and mutants were detected by amplification plot shifts in 
threshold cycle CT values of approximately ten cycles whereas heterozygotes (Fig 26b) were 
detected by similar threshold values for each primer.  
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Fig 26a: Homozygote (C/C) at position -86 in CCL3 (A SYBR-Green real-time  





Fig 26b: Heterozygote (C/T) at position -86 in CCL3 (A SYBR-Green real time  
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2.6                Laboratory data: collation and capture 
All data collection was undertaken by the candidate. Prior to data capture, all patient CRF’s 
were thoroughly checked for accuracy and completeness by comparison with patient clinical 
records and laboratory reports. Clinical chart records of study participants were requested 
from the Medical Registry of KEH, photocopied and used to update and verify all patient data.  
 
Laboratory generated data were collated and filed into respective patient CRF’s as sample 
batches were assayed. Conversions and calculations were performed where necessary e.g. 
dilution factors, log transformations for HIV-1 RNA, calculations for CVL blood 
contamination etc. All transcribed laboratory results were cross-checked against original 
laboratory print-outs and reports. All clinical and laboratory data was captured by the 
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2.7 Statistical analysis 
Analysis was undertaken by the candidate with assistance from a senior Biostatistician (Dr CA 
Connolly at the Medical Research Council (Biostatistics unit, MRC, Durban). The following 
statistical software packages were utilized; Microsoft ® Excel 2003, InStat (GraphPad 
Software Inc, San Diego, USA) and Stata V9 (Stata Corporation, Texas, USA).  
 
To address the specific objectives of this study, data pertaining to in utero transmission were 
excluded from statistical analysis. 
 
Descriptive statistics such as proportions and medians were used to summarize continuous 
data (e.g. patient demography, maternal and infant characteristics etc). Weight for age z-scores 
were calculated using WHO reference tables for child growth standards (WHO, 2009). The 
unpaired t test was used for all continuous variable comparisons [normal distribution of data]. 
Categorical data (e.g. comparison of various CD4 categories among HIV-1 transmitting vs. 
non-transmitting women) were summarized by the use of contingency tables, and then 
analyzed with the Fisher’s exact test. The Mann-Whitney U test was used for analysis of all 
non-parametric data because of the unsymmetrical distribution of the data and small sample 
size (e.g. genotyping subset).  
 
Undetectable HIV-1 RNA (viral loads) were assigned a value of 10 copies/ml (1 log 10 
copies/ml) for CVL samples (Kovacs et al, 1999) and a value of 40 copies/ml (1.6 log10 
copies/ml) for plasma samples (Cobas AmpliPrep/Cobas TaqMan, 2006). All HIV-1 RNA 
(viral loads) were log10 transformed to obtain a more symmetrical distribution. Pearson’s 
correlation coefficient (r) was used to determine pair-wise linear associations between 
 
 
- 105 - 
variables (e.g. viral loads and CD4 cell counts). The strength of the correlation was interpreted 
as: r < 0.3 = weak correlation, r ≥ 0.3 - 0.7 = moderate correlation and r ≥ 0.7 - 1 = strong 
correlation.  
 
Statistical tests used during various data comparisons are shown in Table VI. All statistical 
tests were two-tailed and p values ≤ 0.05 were considered to be statistically significant. 
Interquartile ranges (IQR), odds ratio’s (OR), relative risk (RR) and 95% confidence interval’s 
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Table VI: Statistical tests 
 
Data comparisons Statistical test used 
Maternal age, gestational age, mode of delivery 
 vs. perinatal transmission 
 
Unpaired t test 
Rupture of membranes, infant weight, infant  
gender, STI  vs. perinatal transmission 
 
Fisher’s exact test 
**CCL3-L1 gene copy number in relation to 
 maternal parameters such as CD4 cell count, HIV-1  
RNA (viral load) etc 
 
Mann-Whitney U test 
**CCL3-L1 gene copy no vs. perinatal transmission 
 
Unpaired t test; Mann-Whitney U test 
Pearson correlation coefficient 
**CCL3-Hap 1 allelic representation in relation to 
maternal parameters such as CD4 cell count, HIV-1 
 RNA etc 
 
Mann-Whitney U test 
**CCL3-Hap 1 vs. perinatal transmission Mann-Whitney U test 
HIV-1 RNA (viral load) correlation: 
CVL vs. plasma 
Pre-NVP vs. Post NVP sampling 
 
Pearson’s correlation coefficient (r) 
NVP drug concentration (correlation) : 
CVL vs plasma 
Pre-NVP vs. Post-NVP sampling 
 
Pearson’s correlation coefficient (r) 
Maternal CD4 cell count (pre and post NVP) in 
 relation with maternal HIV-1 RNA 
 
Pearson’s correlation coefficient (r) 
STI vs. HIV-1 RNA Pearson’s correlation coefficient (r) 
STI vs. NVP concentration Pearson’s correlation coefficient (r) 
Maternal CD4 cell count and perinatal transmission Mann-Whitney U test 
NVP and perinatal transmission Fisher’s exact  
STI detection and perinatal transmission Fisher’s exact test 
HIV-1 RNA and perinatal transmission Unpaired t test, Mann Whitney U test 
 
Footnote: ** (case-control subset of maternal-infant pairs) 
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CHAPTER THREE: RESULTS 
3.1  Introduction 
In the present chapter, findings from all the laboratory investigations will be described and 
compared within the context of intrapartum HIV-1 transmission. 
 
3.2 Cascade of study events 
Six hundred pregnant women, who tested HIV-1 positive by rapid tests and received the single 
dose NVP regimen for the prevention of mother-to-child HIV-1 transmission (PMTCT) 
according to the standard of care at KEH (Durban, SA) were screened for study eligibility 
during the period April-December 2006. Of the total women screened, 120 (20.0%) were 
eligible for study participation. A flow diagram detailing all study events is shown in Fig 27.  
 
Fig 27 also highlights the various reasons that accounted for the large number of screening 
failure which occurred among 480 (80.0%) of pregnant women during the enrolment phase of 
this study. 
 
HIV-1 antibody testing (HIV-1 ELISA) of all study entrants provided confirmation of their 
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3.3 Study population 
3.3.1 Demography  
Isi-Zulu speaking participants (66.7%) made up the majority of the cohort (Table VII). The 
median age of study participants was 29 years (IQR: 18-39). More than 70.0% of participants 
received a secondary school education and 25.0% of all women were employed (Table VII). 
The majority of women (78.3%) were unmarried, among whom 33 (35.0%) were living with 
their partners. While 22 (18.3%) women were able to support themselves, others were 
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Table VII: Patient demography (n = 120) 
Patient characteristics:  Results n (%) 
Maternal age (years)*   
• < 20 5 (4.2) 
• 20-24 31 (25.8) 
• 25-29 35 (29.2) 
• 30-34 34 (28.3) 
• 35-39 15 (12.5) 
Ethnic sub-grouping:  
• Zulu 80 (66.7) 
• Xhosa 32 (26.7) 
• Sotho 3 (2.5) 
• Other 5 (4.1) 
Level of education:  
• Primary 33 (27.5) 
• Secondary 87 (72.5) 
Marital status:  
• Single 61 (50.8) 
• Married 26 (21.7) 
• Living with a partner 33 (27.5) 
Employment:  
• Employed 30 (25.0) 
• Unemployed 90 (75.0) 
Financial support:  
• Self-supported 22 (18.3) 
• Family 33 (27.5) 
• Boyfriend/husband/partner 65 (54.2) 
 
*Maternal age classification performed according to national survey (Department of Health, 2007) 
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3.3.2 Maternal clinical, laboratory and obstetric characteristics 
The median gestational age at study entry was 34 weeks (range: 28-39) with more than 100 
(80.0%) of the women having had their first antenatal consultation during their second 
trimester of pregnancy. 
 
Forty-seven (39.2%) of the total 120 women who were screened for the presence of 
asymptomatic STI’s had at least one type of STI detected during pregnancy (24-39 weeks 
gestational age). Three women (2.5%) presented with two concurrent types of STI. Candida 
albicans was the most frequently detected STI; 25 (20.8%) among women in this cohort. 
Trichomonas vaginalis was detected in 18 (15.0%) women while three (2.5%) women were 
positive for Bacterial vaginosis infections. One case (0.8%) of reactive Syphilis serology 
(Treponema pallidum) was observed among study women. Among the 47 women with 
detectable STI’s who were contacted to return for appropriate clinical management, 19 
(40.6%) sought treatment before delivery.   
 
Classification of maternal CD4 cell counts (Table VII) was performed according to the WHO 
CD4 criteria for initiation of ARV treatment in adults and adolescents (WHO, 2006c). The 
median and interquartile range (IQR) of CD4 cell counts among the 120 pregnant participants 
at study entry was 530 (cells/µl) [IQR: 246-497]. Nineteen (15.8%) of these women had a 
CD4 count of < 200 cells/µl and were eligible for antiretroviral therapy in admission into the 
ARV rollout programme at KEH. The median CD4 cell count among these women was 142 
cells/µl [range: 21-198].  All nineteen women were referred to the ARV rollout clinic (Philani 
Family Clinic, KEH) and commenced on a comprehensive eight-week ARV drug adherence 
training programme prior to labour and delivery. As at the final postnatal study visit at six 
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weeks, ARV treatment (3TC, d4T and NVP) was reported to have been initiated in four 
(21.0%) of the women prior to delivery, while the remaining 15 (78.9%) women had not 
commenced ARV treatment. The four women on ARV treatment withdrew from the study 
prior to delivery and are therefore excluded from the analysis. Reasons for not commencing 
therapy included various logistical constraints, advanced gestational age or some women were 
still in the process of completing their drug adherence training.  
 
Of the 120 women enrolled during pregnancy, 113 (94.2%) delivered at the study site for 
whom obstetric data were available. Women excluded from the study since baseline include 
three (2.5%) lost to follow-up and four (3.3%) who commenced ARV therapy before delivery. 
 
The median gestational age of women at delivery was 40 weeks [range: 31-43] and the median 
number of antenatal visits was nine visits prior to delivery as per patient clinical records. 
There was an almost equal distribution of normal vaginal deliveries (NVD) [n = 57] vs. 
caesarean section deliveries (n = 56). Of those delivering by caesarean section (C/S), 32.8% 
were elective and 16.8% were emergency (Table VIII). Duration of membrane rupture of 
greater than four hours prior to delivery occurred in 13 (18.0%) of women. Fewer women 
delivered their infants at pre-term (11.8%) compared to women delivering at full-term (86.4%) 
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Table VIII: Maternal clinical, laboratory and obstetric characteristics 
 
Previous obstetric history: n=120 
• Median Parity 1 (range:0-5) 
• Median Gravidity 2 (range: 1-6) 
• Miscarriages 10 (8.3%) 
• Termination of pregnancy 1 (0.8%) 
  
Current obstetric characteristics: Median (Range) 
Gestational age at first antenatal booking (weeks) 23 (8-36) 
Gestational age at study entry (weeks) 34 (24-39) 
Weight at first antenatal visit (kg) 69.6 (46.9-122.6) 
Weight at last antenatal visit (kg) 74.4 (49.1-128.4) 
Detection of maternal STI [n = 120] n (%) 
Treponema pallidum  1 (0.83) 
Bacterial vaginosis  3 (2.5) 
Candida albicans  25 (20.8) 
Trichomonas vaginalis  18 (15.0) 
*CD4 cell count (cells/µl) (pre-NVP dosing) [n = 120] n (%) 
• ≤ 200  19 (15.8) 
• 200-350 35 (29.2) 
• 350-500 37 (30.8) 
• ≥ 500 29 (24.2) 
Maternal outcomes [n = 120]  
• Total women who delivered at facility  113 (94.2%) 
• Withdrawn due to ARV treatment 4 (3.3%) 
• Lost to follow up (before delivery) 3 (2.5%) 
Gestational age at labour (weeks) 40 (31-43) 
Mode of delivery: [n = 113]# n (%) 
NVD 57 (50.4) 
Emergency (C/S) 19 (16.8) 
Elective (C/S) 37 (32.8) 
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Table VIII continued  
 
Duration of membrane rupture prior to delivery  [n = 73]** 
 
• 0-3 hours 45 (62.0) 
• ≥ 4 hours 13 (18.0) 
• Unknown 15 (20.0) 
Term of delivery: [n = 110] n (%) 
• Full-term (37- 41 weeks) 95 (86.4) 
• Pre-term (< 37 weeks) 13 (11.8) 
• Post-term (> 42 weeks) 2 (1.8) 
 
 
           Footnotes: 
           * As per WHO CD4 criteria for initiation of ART in adults and adolescents, (WHO, 2006c) 
               #
 includes three IUD’s that occurred at 33
+
, 38 and 40 weeks gestational age 
            ** 
Includes NVD and emergency deliveries 
 
 
 3.3.3  Paediatric clinical characteristics and outcomes 
 
Of the 120 women enrolled between June-December 2006, 110 women delivered 117 live 
infants comprising 103 singletons (93.6%) and seven pairs of twins (6.4%). Multiple 
pregnancies as risk factors for MTCT will be presented under ancillary study findings in 
section 3.5. Gender was almost equally distributed among the infant cohort; male (48.7%) and 
female (51.3%). The median infant birth weight was 3.1 kg and ranged from 1.2-4.1 kg. Table 
IX details all clinical characteristics and outcomes of the infant population. All infants in this 
study were exclusively formula-fed. One hundred and four (88.0%) of the infants were alive at 
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3.3.4 HIV-1 infection status and timing of MTCT  
Of the 110 women who delivered in this study, twelve (10.9%) transmitted HIV-1 to their 
infants, while 95 (86.4%) were classified as non-transmitters. The transmission status of three 
women remained unknown. As a result of seven twin births, the infant cohort comprised of 
117 infants in total. Following DNA PCR testing, HIV-1 infection was identified in 14 
(11.9%) infants while the remaining 90 (76.9%) were exposed-uninfected (Table IX). 
Infection status remained unknown for thirteen infants as a result of infant demise (1.7%), lost 
to follow-up (7.7%) or study withdrawal (1.7%) after delivery (Table IX). After confirmation 
of their infection status by two separate DNA PCR results, all HIV-1 infected infants were 
immediately referred to the ARV rollout programme at KEH or screened by the Paediatric 
AIDS Clinical Trial Group (PACTG) for potential participation in a clinical drug trial taking 
place at KEH.  
 
Viral characteristics of infants as measured by DNA and RNA PCR testing are shown in Table 
X. The overall MTCT rate in this non-breastfeeding population was 11.9% (CI: 6.70-19.00), 
of which seven (50.0%) were intrapartum and seven (50.0%) were in utero HIV-1 
transmissions. In utero and intrapartum MTCT rates were 5.9% each [95% CI: 1.68-10.28].  
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Table IX: Paediatric clinical characteristics and outcomes 
 
Infant characteristics Results 
Births:  (n) % 
• Total deliveries 110 (91.7) 
• Total live births 117 
• Singletons 103 (93.6) 
• Twin pairs  7 (6.4) 
Gender: (n = 117) n (%) 
• Male 57 (48.7) 
• Female 60 (51.3) 
Weight for age z-scores* Anthropometry: 
Weight  at:                            
Median weight  
(kg) Male  Female  
Birth 3.1 (1.2-4.1) -1 -0.7 
Four weeks 3.8 (2.0-5.5) -0.6 -1.5 
Six weeks 4.6 (2.6-8.0) -0.2 -0.2 
Median length at birth (cm) 47 (35.0-60.0) 
Median head circumference at birth (cm) 34 (28.0-38.0) 
Infant outcome by study completion (6 week-post delivery) (n = 117) n (%) 
Alive 104 (88.9) 
Demised; 2wks (n = 1);  4wks (n = 1) 2 (1.7) 
Lost to follow up; 4 weeks (n = 3); 6 weeks (n = 6) 9 (7.7) 
Withdrawn due to a change of infant feeding  mode of formula to breast 
at four weeks (n = 4) 
2 (1.7) 
Infection status as at 6 week study completion (n = 117) n (%) 
HIV-1 infected   14 (11.9) 
Exposed uninfected 90 (76.9) 
Unknown due to; infant demise; lost to follow-up or withdrawal  13 (11.1) 
 
Footnotes:  
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Table X: Viral characteristics of infants 
 In utero (n = 7) Intrapartum (n = 7) Exposed-uninfected (n = 90) 
DNA PCR    
Detection at birth HIV-1 positive (n = 7) HIV-1 negative (n = 7) HIV-1 negative (n = 90) 
Confirmation at 6 weeks HIV-1 positive (n = 7) HIV-1 positive (n = 7) HIV-1 negative (n = 90) 
RNA quantitation Median (range) Median (range)  
Birth  3.2 (2.5-5.6) n/a n/a 
≥ 4 weeks  5.7 (4.6-6.5) 5.2 (4.6-5.8) n/a 
 
Footnote:  
Analysis was not possible in 13 infants with unknown HIV-1 status due to; withdrawal due to breastfeeding (n=2), demise 
(n=2) or lost to follow-up (n=9)  
 
For the purpose of addressing the primary objectives of this study, all further investigations 
and evaluations include only the intrapartum infected infants and their mothers compared to 
the exposed-uninfected infants and their mothers.   
 
3.3.5 Maternal and infant characteristics as risk factors for intrapartum MTCT  
 
Table XI highlights various maternal clinical and obstetric characteristics as potential risk 
factors for intrapartum HIV-1 transmission. No statistically significant relationships were 
observed between maternal age (p = 0.24), gestational age at labour (p = 0.7) or parity (p = 
0.16) and the risk of intrapartum MTCT (Unpaired t test). Similarly no statistically significant 
association [p = 0.7, OR: 0.63, 95% CI: 0.10-3.30] was found between the mode of delivery 
and intrapartum MTCT. Preterm labour did not appear to increase the risk of intrapartum 
MTCT (p = 0.31, OR: 1.70, 95% CI: 0.70-3.70). Data was too sparse to ascertain statistical 
relationships between intrapartum MTCT and the premature membrane rupture of ≥ 4 hours 
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duration before labour (Table XI). Antenatal care as defined by the commencement of 
antenatal care and the number of antenatal visits did not differ between intrapartum HIV-1 
transmitting and non-transmitting women. The first antenatal consultation for HIV-1 
transmitting (75.0%) vs. non-transmitting (80.0%) women occurred during the second 
trimester of pregnancy (13-26 weeks gestation).  
 
Table XI also highlights the clinical characteristics of study infants in relation to intrapartum 
MTCT. The median birth apgar scores of nine and ten were comparable between intrapartum 
HIV-1 infected and exposed-uninfected infants at one and five minutes respectively. A 
statistically significant association was observed between intrapartum HIV-1 transmission and 
infants who weighed less than 2500 grams at birth (p = 0.04, OR: 6.80, 95% CI: 1.30-35.10). 
In contrast, infant gender was not associated with the risk of acquiring intrapartum HIV-1 (p = 
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Maternal Clinical and     
Obstetric: (n = 113) 
(n = 6) (n = 95)    
Mode of delivery:  n (%)  n (%)     
NVD (n = 55) 3 (5.5) 51 (92.7) 




Emergency C/S (n = 18) 0 (0) 15 (83.3) n/a   
Preterm labour  













PROM (n = 73) n (%)  n (%)  
≥ 4 hours (n = 13) 0 (0) 9 (69.2) 
 
0.02-7.60 








Paediatric: (n = 110) Intrapartum infected  
(n = 7) 
Exposed-uninfected  
(n = 90) 
p value OR 95% CI 
Apgar scores at 1 minute 9 9 0.8
*
 - -0.60 to 0.40 
Apgar scores at 5 minute 10 10 0.9
*
 - -0.40 to 0.50 
Infant birth weight:  n (%)  n (%) 
• < 2500 grams  3 (21.4) 9 (75.0) 









Infant gender:  n (%) n (%) 
• Male 5 (9.6) 47 (90.4) 









*Unpaired t test, **Fisher’s exact test, OR =odds ratio, CI: Confidence interval; PROM: Premature rupture of membranes 
 
Footnote:  
Among the 120 women enrolled; in utero transmitters (n=6), lost to follow-up (n=3 and on ARV’s (n=4) were 
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3.4 Laboratory findings: 
3.4.1     Pharmacological dynamics of NVP  
All data analysis pertaining to this laboratory component has been summarized in Table XII.  
 
Table XII: Summary of data analysis for NVP pharmacodynamics and intrapartum MTCT  
 
 
RESEARCH QUESTIONS WOMEN WOMEN INFANTS ENDPOINTS ILLUSTRATION 
PHARMACOKINETICS BASELINE PERIPARTUM    
1. NVP levels in systemic 
and genital compartments 
prior to NVP exposure 
Plasma: 120 
CVL: 120 
  Baseline Plasma vs.  
CVL NVP level  
Text 
2. NVP levels in systemic 
and genital compartments 
after NVP administration 
 Plasma: 113 
CVL: 72 
 Peripartum plasma vs  
CVL NVP level 
 
Text 
3. CVL NVP levels in 
relation to maternal sdNVP 
administration  
 CVL: 72  Maternal NVP level vs.  
time of sdNVP administration 
Text 
Fig 28 
4. NVP levels in infants in 
relation to their mother’s 
NVP level 
 Plasma: 100 Plasma: 
100 
Mum plasma NVP level  vs  
Infant NVP level 
Fig 29 
5. NVP levels in maternal 
systemic and genital 
compartments in relation to 
intrapartum MTCT   
 Plasma: 51 
CVL:  39 
(active labour 
only) 
 a) Mum Plasma NVP vs. 
Intrapartum MTCT  
       (45 NTM + 6 TM) 
b) Maternal CVL NVP 
vs. Intrapartum MTCT  
       (35 NTM+ 4 TM)  
Table XIV 
5. NVP levels in infants in 
relation to intrapartum 
MTCT 
  Plasma: 97 Infant plasma NVP vs 
Intrapartum MTCT (90 EU + 7 
IP) 
Table XV 
Footnotes: TM: Transmitting mother; NTM: non-transmitting mother 
                   IP: intrapartum infected infant; EU: exposed uninfected infant 
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3.4.1.1     Maternal pharmacokinetic analysis 
One hundred and thirteen of the 120 women enrolled, delivered at the health facility. Among 
the 113 women, 107 (94.7%) women self-administered their sdNVP during labour. The infants 
of three women, who did not take NVP, received two doses of NVP (0.6 ml) within 72 hours 
of delivery as the standard of care during the study. Other than the standard of care sdNVP 
regimen (200 mg) used for the prevention of mother-to-child HIV-1 transmission, no other 
ARV’s were administered to study participants. Most women did however receive a wide 
array of medication used routinely during labour; including anesthetics, analgesics, pitocin, 
antacids and antibiotics.  
 
Actual times of NVP administration were documented for each study participant and her 
respective infant or infants. Using these data, individual time intervals were calculated for 
NVP dosing in relation to maternal delivery and actual sampling. The median time interval 
between maternal dosing and delivery was 16 hours (range 0.5-504 hours). Two (1.8%) of 
women took their NVP dose less than two hours before delivery. All 117 infants (103 
singletons and seven twin pairs) received their single dose of NVP shortly after birth. Median 
time interval between infant birth and NVP dosing was three hours (range: 0.5-48 hours).  
 
Due to logistical constraints, the time of sample collection varied during the peripartum 
period. Among the women who delivered, plasma and CVL samples were collected during 
latent labour 10 (9.0%) or active labour 51 (46.0%) or post-delivery 49 (46.0%). The median 
time interval between maternal NVP administration and pharmacokinetic sampling was 15 
hours (range: 2-717). Of the infants born to these women, a blood sample was drawn within 72 
hours of birth (Table XIII).  
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Table XIII: NVP drug administration and sample collection 
  







Maternal NVP intake and latent labour sampling 10 16.5 5-132 
n = 110 NVP intake and active-labour sampling 51 14.5 0.5-20 
 NVP intake and post-delivery sampling 49 113.5 10-717 
Infant  n = 117* NVP intake and birth sampling 117* 16.5 2-72 
Footnote:* insufficient sample volume did not permit NVP drug analysis in four infants   
 
Pre-NVP dosing: (n = 120) 
An analysis of 120 plasma and 120 CVL samples taken during pregnancy (28-38 weeks) 
revealed an absence of NVP. These baseline data suggests that none of the study participants  
were currently on any NNRTI drug regimen at study entry.  
 
Post-NVP dosing:  
Analysis of 113 maternal plasma and 72 CVL samples obtained during labour or post-delivery 
confirmed the absence of NVP among the three women who did not administer NVP. Among 
the remaining 110 women, NVP was detectable in 82 (74.5%) of plasma samples and in 40 of 
the 72 (55.6%) of CVL samples. The median NVP concentration in the 110 plasma and 72 
CVL samples collected during labour or within 72 hours post-delivery and after sdNVP (200 
mg) administration were 869 ng/ml, (range: 0-3820) and 2.1 ng/ml (range: 0-99.7)  
respectively. This difference in NVP levels between the two compartments was statistically 
significant (p < 0.0001) [unpaired t test] and the ratio of CVL NVP: Plasma NVP 
 
 
- 123 - 
concentration was 0.002. NVP drug levels were below the 100 ng/ml therapeutic target in 39 
(34.5%) of maternal plasma samples and in all 72 (100%) of CVL samples. To further assess 
the level of NVP absorption into the genital compartment, the NVP concentration in CVL 
were correlated with the time interval between NVP administration and specimen collection. 
The Pearson correlation coefficient revealed a negative correlation that was statistically 
significant (Fig 28). 
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Fig 28: Association between CVL NVP concentration and sdNVP administration  
[n = 72, r = -0.43, p < 0.001] 
 
NVP at active labour and intrapartum MTCT  
Due to logistical constraints, the time of sample collection varied during the peripartum 
period. The samples obtained during active labour and within 20 hours of NVP dosing were 
best representative of the intrapartum phase. Hence these data (Table XIV) were selectively 
analysed to determine maternal pharmacokinetics in the systemic and genital compartments 
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when investigated in relation to intrapartum MTCT. Median NVP levels of 1070 ng/ml (range: 
0-3080) and 24.5 ng/ml (range: 0-99.7) were found in the systemic and genital compartments 
respectively. Systemic NVP levels were 44 times more than genital NVP levels. This 
difference between compartments was statistically significant (p < 0.0001) [Unpaired t test]. 
The ratio of CVL NVP was 0.02. NVP levels were below the 100 ng/ml therapeutic target in 
seven (13.7%) of the 51 plasma and in all 39 maternal CVL samples collected at active labour.    
 
Stratification according to transmission indicated that the median time interval between NVP 
intake and delivery was 12.5 hours (range: 3-48) among intrapartum HIV-1 transmitting and 
13 hours (range: 0.5-50) among non-transmitting women (p = 0.1) [Mann-Whitney U test]. 
The median time interval between NVP self-administration and maternal pharmacokinetic 
sampling was 11 hours among intrapartum transmitting (range: 3-20) and 10 hours among 
non-transmitting women (range: 3-20 hours) respectively. 
 
The median plasma NVP concentration among intrapartum HIV-1 transmitting and non-
transmitting were 886 ng/ml (range: 112-1860) and 1060 ng/ml (range: 0-3080) respectively 
and not statistically significant (p = 0.4). The median CVL NVP concentration among 
intrapartum transmitting and non-transmitting women were 2.24 ng/ml (range: 0-15.8) and 
25.7 (0-99.7) respectively and statistically significant (p = 0.02) [Table XIV]. 
 
NVP dosing at 2-48 hours revealed median plasma NVP levels of 886 ng/ml (n = 6) and 1023 
ng/ml (n = 31) among intrapartum and non-transmitting women respectively. CVL samples 
showed median NVP levels of 2.24 ng/ml (n = 4) and 20.4 ng/ml (n = 28) in intrapartum 
transmitting and non-transmitting women dosed at 2-48 hours.  
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Table XIV: Systemic and genital NVP in association with intrapartum MTCT (active labour) 
ACTIVE LABOUR (0.5-20 hours) 
 Maternal plasma (n = 51) Maternal CVL (n = 39) 












Sample size 6 45 4* 35 










p value** 0.4 0.02 
NVP therapeutic target: n (%)  
< 100 ng/ml 0 7 (15.6%) 4 (100%) 35 (100%) 
≥ 100 ng/ml 6 (100%) 38 (84.4%) 0 0 
Footnotes: 
#All in utero transmitters (n=6) excluded from analysis 
*Missing CVL (n=2) 
** Unpaired t test  




3.4.1.2   Infant pharmacokinetic analysis after sdNVP 
Among the 117 infant born to 110 women, 114 (97.4%) of the infants received the standard of 
care sdNVP regimen (0.6 ml) within 72 hours of birth. The three infants, whose mothers did 
not receive NVP in labour, received the two dose regimen according to the standard of care at 
the time of this study. Ninety seven (85.0%) of this infant cohort received their NVP dose 
within six hours of birth. Blood samples were drawn from all 117 infants after NVP dosing. 
The median time interval between birth and NVP dosing was three hours (range: 0-48 hours). 
Of the 117 samples collected, samples from 113 infants were suitable and adequate for LC-
MS-MS analysis. NVP was detectable in 89 (78.8%) of the infant plasma samples collected at 
a median time interval of 16.5 hours (range: 2-72) after dosing. Eighty (71.0%) of the infants 
achieved NVP drug levels above the 100 ng/ml therapeutic target, while 33 (29.2%) fell below 
this target. The median NVP concentration of 828 ng/ml [range: 0-3730] was eight times 
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higher than the therapeutic target and almost 83 times the in vitro inhibitory concentration (10 
ng/ml) against wild-type HIV-1. 
 
The Pearson correlation coefficient was used to determine the relationship between infant and 
maternal plasma NVP levels. A statistically significant association was observed between the 
NVP concentration in the plasma of 100 maternal-infant pairs [r = 0.36, 95% CI: 0.18-0.52, p 
= 0.0002] (Pearson’s correlation coefficient) [Fig 29]. 
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Fig 29: Association between plasma NVP levels in 100 maternal-infant pairs after sdNVP  
[r = 0.36, 95% CI: 0.18-0.52, p = 0.0002]  
 
The median time interval between infant birth and NVP dosing was 2.5 hours (range: 2-28) 
among intrapartum HIV-1 infected infants and three hours (range: 0.5-48) among exposed-
uninfected infants (p = 0.4) [unpaired t test]. NVP was detectable in four (57.1%) of 
intrapartum HIV-infected infants and 78 (78.8%) of exposed-uninfected infants. Table XV 
highlights infant pharmacological dynamics following sdNVP within 2-72 hours of birth. The 
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median NVP level among the intrapartum infected infants [20.3 ng/ml; range: 0-2380] was 
lower than the exposed-uninfected infants [933 ng/ml; range: 0-3730] but not statistically 
significant (p = 0.16) [Mann-Whitney U test]. 
 
Table XV: Infant pharmacological dynamics following sdNVP within 2-72 hours of birth 
 
Footnotes: 
In utero infected infants excluded from analysis (n=6) 
< 100 ng/ml also includes infant samples with undetectable NVP levels 
 
A greater proportion of exposed-uninfected infants (70.1%) had NVP drug levels above the 
therapeutic target, compared to those infected via the intrapartum route of transmission (3.1%) 
(Table XV). This observation was not statistically significant (p = 0.1; RR: 0.45; 95% CI: 
0.22-0.93) [Fishers exact test]. 










< 100 ng/ml 
 
≥ 100 ng/ml 
Exposed-uninfected 90 933 (0-3730) 23 (23.7 %) 67 (70.1%) 
Intrapartum-infected 7 20.3 (0-2380) 4 (4.1%) 3 (3.1%) 
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3.4.2  Virological dynamics and intrapartum MTCT 
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3.4.2.1     Maternal HIV-1 RNA (viral load): Pre vs. post NVP dosing  
Of the 120 patients enrolled, HIV-1 RNA was detectable in 120 (100%) of maternal 
plasma and in 94 (78.3%) of whole unfractionated cervico-vaginal lavage (CVL) samples 
collected from women during pregnancy prior to NVP dosing.  Post-NVP dose sampling of 
113 women indicated that HIV-1 RNA was detectable in 106 (93.8%) of all maternal 
plasma and in 47 (65.3%) of the 72 unfractionated CVL samples collected after dosing.   
                      
3.4.2.2.     Blood contamination of CVL: Pre vs. post NVP dosing 
The presence of HIV-1 as a result of blood contamination was estimated by the use of 
commercially available urine dipsticks (Uricheck, RapiMED Diagnostics, SA) and visual 
estimation of haemoglobin concentration as per previously described method (Hart et al, 
1999). Of the samples assayed before sdNVP, 70 (58.3%) of the maternal CVL samples 
had detectable blood contamination. All (100%) had quantifiable plasma HIV-1 RNA 
levels.  
 
Every effort was made to avoid blood contamination during CVL sampling at the time of 
labour/post-delivery while also trying to collect samples that were closely representative of 
true intrapartum dynamics. Minimal blood contamination was detectable in 53 (73.6%) of 
the 72 maternal CVL samples assayed after NVP dosing. Almost 34 (47.0%) of all assayed 
CVL samples had quantifiable plasma virus loads.  
 
Footnote: *HIV-1 RNA was measured in all 72 CVL samples collected during labour/delivery.
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3.4.2.3      HIV-1 RNA in Plasma and CVL: Pre-NVP vs. Post NVP dose 
Pre and post-NVP maternal plasma samples were available for 113 women (110 deliveries 
and three IUD’s). Pre and post-NVP CVL samples were available for 72 women. 
 
In the presence of maternal STI’s (n = 43), a strong and statistically significant correlation 
in plasma HIV-1 RNA levels [r = 0.70, CI: 0.53-0.86, p < 0.0001] was observed between 
pre and post NVP dosing (Pearson’s correlation coefficient) [Fig 30a]. In the absence of 
maternal STI’s (n = 70), a strong [r = 0.70, 95% CI: 0.56-0.80] and statistically significant 
correlation (p < 0.0001) was found between plasma HIV-1 RNA levels at pre and post-
NVP dosing [Fig 30b].   
 
Similarly [Fig 31a] shows the strong and statistically significant correlation (r = 0.61, 95% 
CI: 0.32-0.80, p < 0.001) that was observed when comparing CVL HIV-1 RNA in pre and 
post NVP dose samples (n = 28) in the presence of maternal STI’s. In the absence of 
maternal STI’s, [Fig 31b] pre and post NVP sampling of the cervicovaginal compartment 
(n = 44) also revealed a strong and statistically significant CVL HIV-1 RNA correlation [r 
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Fig 30a: Scatter-plot showing an association between levels of HIV-1 RNA (viral loads) in paired 
maternal plasma samples (n = 43) collected at pre and post-NVP dosing includes women with 
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Fig 30b: Association between levels of HIV-1 RNA (viral loads) in paired maternal plasma 
samples (n = 70) collected pre and post-NVP dosing in the absence of maternal STI’s [r = 0.70, 





In the absence of maternal STI’s 
In the presence of maternal STI’s 
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Fig 31a: Association between levels of HIV-1 RNA (viral loads) in paired maternal CVL samples 
(n = 28) collected pre and post-NVP dosing includes women with STI’s [r = 0.61, 95% CI: 0.32-
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Fig 31b: Association between levels of HIV-1 RNA (viral loads) in paired maternal CVL samples 
(n = 44) collected pre and post-NVP dosing (in the absence of maternal STI’s) [r = 0.60, 95% CI: 
0.42-0.80, p < 0.0001]  
In the absence of maternal STI’s 
In the presence of maternal STI’s 
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Table XVIIa highlights a general trend of higher levels of HIV-1 RNA in maternal plasma 
when compared to CVL, irrespective of when sampling occurred. While a reduction in 
HIV-1 RNA levels did occur after intrapartum NVP dosing, more than 80.0% of the 
women in this cohort experienced no change (Table XVIIb) to their HIV-1 RNA levels in 
both plasma and CVL samples during active labour. These findings are further supported 
by the strong correlation observed when comparing pre and post-NVP HIV-1 RNA levels 
in both maternal systemic [r = 0.81, p < 0.0001] and genital compartments [r = 0.80, p < 
0.0001] during active labour. This correlation remained strong and statistically significant 
in both plasma [r = 0.75, p = 0.001] and CVL [r = 0.65, p < 0.0001], independent of 
whether the samples were collected during latent labour, active labour or post-delivery 
[Table XVIIb].  
 
Table XVIIa: Effect of NVP on HIV-1 RNA in maternal systemic and genital compartments  
 

















Sample type Plasma CVL Plasma CVL Plasma CVL Plasma CVL 
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Table XVIIb: Overall effect of NVP on HIV-1 RNA after single-dosing 
 
 Active labour Post-delivery ALL post-NVP sampling 
 





n = 51 
 
CVL 
n = 39 
 
Plasma 
n = 49 
 
CVL 
n = 20 
 
Plasma 
n = 113 
 
CVL 
n = 72 












Increased 3  
(5.9%) 
























r = 0.81 
 
 
r = 0.80 
 
r = 0.69 
 
r = 0.57 
 
r = 0.75 
 
r = 0.65 
95% CI 0.71-0.88 0.65-0.89 0.51-0.82 0.23-0.76 0.67-0.83 0.49-0.77 
p value < 0.0001 < 0.0001 < 0.0001 0.0008 0.001 < 0.0001 
**Pearson’s correlation coefficient 
*ALL includes women sampled during the latent phase of labour (n=10) and women with IUD’s (n=3) 
 
 
Pre-NVP dose evaluation (Fig 32a) of maternal plasma-CVL pairs (n = 120) demonstrated 
a moderate and statistically significant correlation between the two variables [r = 0.58; p < 
0.001]. This finding suggests that HIV-1 RNA in CVL was significantly influenced by 
HIV-1 RNA in plasma.  
 
Post-NVP evaluation (Fig 33a) of maternal plasma-CVL pairs (n = 72) continued to 
suggest a similar significant association between systemic and genital compartments (p < 
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Even after controlling for the presence of blood contamination, the dependence of CVL 
HIV-1 RNA on plasma HIV-1 RNA was still evident and statistically significant at both 
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Fig 32a: Association between levels of HIV-1 RNA (viral loads) in paired maternal plasma and 
cervicovaginal lavage (CVL) samples collected pre-NVP dosing (n = 120). [r = 0.58, 95% CI: 0.45-
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Fig 32b: Association between levels of HIV-1 RNA (viral loads) in paired maternal plasma and 
cervicovaginal lavage (CVL) samples collected pre-NVP dosing (n = 50) excluding samples with 
blood contamination. [r = 0.51, 95% CI: 0.27-0.65, p = 0.001]  
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Fig 33a: Association between levels of HIV-1 RNA (viral loads) in paired maternal plasma and 
cervicovaginal lavage (CVL) samples collected post-NVP dosing (n = 72). [r = 0.45, 95% CI: 0.25-
0.62, p < 0.0001]  
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Fig 33b: Association between levels of HIV-1 RNA (viral loads) in paired maternal plasma and 
cervicovaginal lavage (CVL) samples collected post-NVP dosing (n = 19) excluding samples with  
blood contamination [r = 0.50, 95% CI: 0.04-0.77, p = 0.03] 
 
Table XVIII compares HIV-1 RNA levels in plasma and CVL between HIV-1 transmitting 
(intrapartum only) and non-transmitting women at pre and post-NVP dose sampling. 
Firstly, an overall comparison of HIV-1 RNA levels between compartments revealed that 
median HIV-1 RNA levels in plasma remained consistently higher than CVL HIV-1 RNA 
at both pre and post-NVP dosing. This finding was statistically significant in both 
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intrapartum HIV-1 transmitting and non-transmitting women (Table XVII). Secondly, 
compared to non-transmitters, plasma HIV-1 RNA was higher in intrapartum HIV-1 
transmitters at both pre [4.35; range: 3.84-6.27 log10 copies/ml] and post [3.86; range: 
2.61-6.03 log10 copies/ml] NVP dosing. In contrast to plasma, the median CVL viral load 
was comparable between intrapartum HIV-1 transmitting and non transmitting women at 
both pre and post-NVP dosing (Table XVII. The association of viral load and intrapartum 
HIV-1 transmission was statistically significant for maternal plasma (p = 0.02) and not 
CVL (p = 0.7) [unpaired t test]. 
 
HIV-1 RNA classification according to the viral load threshold for the risk of intrapartum 
MTCT is shown in Table XIX. Women with HIV-1 RNA levels above 1000 copies/ml 
demonstrated an increased risk for intrapartum HIV-1 transmission. This finding was 
statistically significant for maternal plasma (p = 0.02, OR: 0.10, 95% CI: 0.01-0.70) and 
not CVL (p = 0.9, OR: 1.23, 95% CI: 0.12-12.60) [Fisher’s exact test]. 
 
An overall 0.33 log10 viral load reduction in plasma (Table XX) following NVP dosing 
was not significant (p = 0.4) among HIV-1 transmitting women. In contrast a 0.45 log10 
viral load reduction in the plasma of non-transmitting women was statistically significant 
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3.4.2.4 Maternal STI’s in relation to viral dynamics in systemic and genital compartments 
as risk factors for intrapartum MTCT  
 
Maternal STI’s were detected in four (66.6%) intrapartum transmitting women and in 38 (38.8%) 
of non-transmitting women. No significant association was observed between the presence of 
maternal STI’s and the risk for intrapartum MTCT (p = 0.2, RR: 2.90, 95% CI: 0.60-15.40). The 
presence of maternal STI’s was associated with higher median viral loads in both systemic and 
genital compartments of all women, independent of intrapartum HIV-1 transmission [Table XXI].  
 









Median HIV-1 RNA 
Intrapartum transmitting 
n = 4 
Non-transmitting 
n = 38 
Intrapartum transmitting 
n = 2 
Non-transmitting 
n = 60 
(log10 copies/ml) 
Pre-NVP Post-NVP Pre-NVP Post-
NVP 
Pre-NVP Post-NVP Pre-NVP Post-
NVP 
Plasma  5.17 4.9 3.8 3.2 4.1 3.9 4.2 3.9 
CVL 4.5 2.7 2.4 1.6 2.0 2.2 2.4 2.5 
 
Footnotes:  
p ≥ 0.2 for all statistical comparisons 
Analysis excludes in utero transmitting women  
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3.4.2.5    Ancillary viral investigations: Describing the presence of NVP drug resistance  
   mutations among intrapartum transmitting women (n = 6)  
 
Maternal plasma samples from the six intrapartum transmitting mothers were evaluated for the 
presence of NVP drug resistance mutations. The median age and gestational age among these 
women was 30 (27-38) years and 40 (33-40) weeks respectively. Median CD4 cell counts and 
median plasma viral loads were 279 (range: 76-957) cells/µl and 3.9 (range: 2.6-6.0) log10 
(copies/ml) respectively. 
 
Drug resistance mutations (NVP
R
) to NNRTI’s were detected in one of the six intrapartum 
transmitting women while five women lacked detectable NVP
R
. Clinical, viral and immune 
characteristics of women in this cohort are summarized in Table XXII. Two NNRTI drug 
resistance mutations; Y181CY and Y188CY were identified in this mother (Appendix 8b). This 
patient transmitted HIV-1 to her second-born twin via the intrapartum route, while her first-born 
twin remained exposed-uninfected. Compared to women without NVP
R
, the patient had a lower 
baseline CD4 cell count and higher viral loads in both systemic and genital compartments. This 
mother delivered twin male infants by an elective C/S within three hours of her sdNVP intake. 
NVP
R
 was detected in a plasma sample obtained seven days post-delivery after sdNVP exposure.  
 
Quality control of all sequence data by phylogenetic tree construction (Fig 34) confirmed the 
absence of contamination. A sequence corresponding to protease amino acids 1-99 and reverse 
transcriptase amino acids 1-312 was obtained for all samples assayed. Drug resistance reports 
(Appendix 8a, 8b) were generated by uploading all sequence data onto the Stanford University 
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drug resistance database. Analysis of patient sequences confirmed a clade C viral subtype HIV 
infection among all of the intrapartum HIV-1 transmitting women that were assayed.  
 
Table XXII: Characteristics of the maternal NVP drug resistance cohort (n = 6) 
 
 









(n = 5) 
Maternal CD4 cell count (cells/ul) 223 336 (76-957) 
Plasma HIV-1 RNA (log10 copies/ml) 5.56 3.86 (2.6-6.0) 
CVL HIV-1 RNA (log10 copies/ml) 3.95 3.1 (2.7-3.5) 
Plasma NVP level (ng/ml) 0 886 (112-1860) 
Interval between sdNVP and delivery (hours) 3  47 (16-132) 
Mode of delivery (n = 6) 
Elective C/S (n = 3) 1 (33.3%) 2 (66.7%) 
NVD (n = 3) 0 3 (100%) 
Gestational age at delivery (weeks) 40 40 (39-43) 
Viral subtype in mum Clade C Clade C 
Maternal CCL3-L1 gene copy (p.d.g) 2 5 (4-7) 
Intrapartum infected infants (n = 7)*   
Infant birth weight (kg)  2.2 3.3 (1.8-3.8) 
Infant gender  
Male (n = 4) 1 (25.0%) 3 (75.0%) 
Female (n = 3) 0 3 (100%) 
Infant CCL3-L1 gene copy (p.d.g) 4 4 (4-7) 
    Footnotes: * includes twins 
 
 











Fig 34: Phylogenetic analysis of the PIVD drug resistance subset. (*) denotes all intrapartum 
transmitting women (n = 6). Reference sequences were obtained from the Los Alamos database and 
can be accessed at (http://www.hiv.lanl.gov). Sequences were aligned using Clustal X software and 
corrected manually. Phylogeny construction and evaluation were performed by the neighbour-joining 
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3.4.3.1  Maternal CD4 cell counts  
 
CD4 cell counts were available for 120 women during pregnancy (GA: 28-39 weeks). The 
median and interquartile range (IQR) of CD4 cell counts for these women was 530 cells/µl 
(IQR: 246-497) cells/µl. Of the 120 women, 19 (15.8%), 35 (29.2%), 37 (30.8%) and 29 
(24.2%) presented with CD4 cell counts of ≤ 200 cells/µl, 200-350 cells/µl, 350-500 cells/µl 
and ≥ 500 cells/µl respectively.  
 
3.4.3.2  CD4 cell counts in relation to viral dynamics in systemic and genital compartments as  
 risk factors for intrapartum MTCT 
 
The relationship between maternal CD4 cell counts and HIV-1 RNA (viral loads) in the 
systemic and genital compartments of women was determined by using the Pearson 
correlation coefficient [Figs 35a, 35b, 35c, and 35d]. A higher maternal viral load during 
pregnancy and labour/delivery was associated with lower CD4 cell counts during pregnancy. 
This finding was statistically significant in maternal plasma (p < 0.001; p < 0.001) and CVL (p 
< 0.001; p = 0.04).  
Footnote: 
Paired t testing revealed similar statistically significant relationships between plasma HIV-1 RNA and maternal CD4 cell counts at 
pre (p < 0.0001) and post-NVP dosing (p < 0.0001). Similarly associations between CVL HIV-1 RNA and maternal CD4 cell counts 
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Although not statistically significant, intrapartum transmitting women had a lower median 
CD4 cell count than their non-transmitting counterparts (p = 0.7) [Mann Whitney U test]. 
Further stratification of maternal CD4 cell counts according to the WHO CD4 classification 
criteria (Table XXIV) did not reveal any statistically significant associations between both 
groups (p = 0.4) [Fisher’s exact test]. 
 
Table XXIV: CD4 cell counts among HIV-1 transmitting and non-transmitting women 
 
















Median (range) 279 (76-957) 402 (55-974) 0.7**








2 (3.5%) 57 (96.5%) 0.4
#
 n = 57 
 Footnotes: All in utero transmitting women (n=6) were excluded from the above analysis  
                  *WHO classification criteria (WHO, 2006c) 
                 **Mann-Whitney U test; #Fisher’s exact test 
 
Stratification according to intrapartum HIV-1 transmission revealed no significant association 
between pre-NVP CD4 cell counts and pre-NVP viral loads in the systemic [r = 0.20; 95% CI: 
0.25-4.69, p = 0.7] and genital compartments [r = - 0.51, 95% CI: -0.94 to 0.51; p = 0.3] of 
women. A similar correlation analysis of pre-NVP CD4 cell counts and post-NVP viral loads 
was not significant in the systemic compartment [r = -0.05; 95% CI: -0.26-4.69, p = 0.6] but 
significant for the genital compartment [r = - 0.36, 95% CI: -0.57 to 0.12; p = 0.001], 
following stratification according to intrapartum HIV-1 transmission. 
 
 
- 151 - 
3.4.3.3  Ancillary immunological investigations: Effect of host genetics on viral  
dynamics and intrapartum MTCT 
 
A summary of data analysis for this study component is shown in Table XXV. 
 
Table XXV:  Summary of data analysis for ancillary study investigations and findings 
 
 
RESEARCH AREAS WOMEN INFANTS ENDPOINTS ILLUSTRATION 
 BASELINE    
 
1. Immunological:  
Describing host genetics 
(CCL3 and CCL3-L1) in 

























2: Immunological:  
Describing haplotype 













relation to CCL3-L1 
gene 








3. Birth Outcomes:   
Describing multiple 
pregnancies (twins) in 
relation to MTCT  



















Footnotes: NTM: non-transmitting mother; TM: transmitting mother; 
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Case-controlled subsets of maternal and infant pairs, based on demographic and clinical 
characteristics were selected for genotypic investigation. This group of maternal-infant pairs 
included seven intrapartum infected infants and their corresponding “transmitting mothers” 
and 28 exposed-uninfected infants and their corresponding “non-transmitting” mothers. As 
reported in the previous section, HIV-1 transmitting women had a higher viral load in both the 
systemic [median: 4.36 log10 copies/ml] and genital [median: 3.47 log10 copies/ml] 
compartments and a lower CD4 cell count [median: 280 cells/µl] [Table XXVI].   
 






(n = 6) 
Non-transmitting 
women 
(n = 28) 
 
p value* 
Characteristics Median (range) Median (range)  
Maternal age (years) 30 (27-33) 26 (19-39)  0.09 
Gestational age (weeks) 36 (28-37) 33 (28-39) 0.4 
Parity 2 (0-3) 1 (0-5) 0.2 
CD4 cell count (cells/µl) 280 (76-957) 420 (85-1013) 0.47 
Plasma HIV-1 RNA  
log10 (copies/ml) 
4.36 (3.8-6.3) 3.93 (1.74-5.2) 0.03 
CVL HIV-1 RNA  
(log10 (copies/ml) 
3.47 (1.0-5.4) 1.72 (1.0-4.12) 0.04 
Infant cohort Intrapartum infected 
(n = 7)  
Exposed-uninfected 
(n = 28) 
 
Birth weight (kg) 3.25 (1.8-3.8) 3.1 (1.6-3.6) 0.83 
        
                             Footnotes: * Mann-Whitney U test 
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CCL3 and CCL3-L1 gene copies 
 
Genotypic analysis confirmed the presence of the CCL3 gene at two gene copies per diploid 
genome (p.d.g) in all 34 (100%) mothers and 35 (100%) infants selected for this sub-study. 
The detection frequency of CCL3-L1 gene copies per diploid genome ranged from 2-8 in the 
infants and 2-7 in the mothers of these infants (Fig 36). The overall population median in the 
maternal cohort was determined to be four gene copies (p.d.g) among intrapartum HIV-1 
transmitting (median 4, range 2-6) and non-transmitting (median 4, range 2-7) women [Table 
XXVII] (p = 0.9). The overall population median in the infant cohort was similar among the 
intrapartum infected (4, range: 4-7) and exposed-uninfected infants (4, range: 2-8) [p = 0.4]. 

























Infant 5.7 14.3 42.9 14.3 5.7 11.4 5.7
Maternal 14.7 11.8 32.4 20.6 11.8 8.8 0
2 3 4 5 6 7 8
 
 
Fig 36: Distribution of CCL3-L1 gene copy numbers among the maternal-infant subset
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(n = 6)  
 
Non-transmitting 
(n = 28) 
 n (%) n (%) 
2 1 (16.7) 4 (14.3) 
3 0 4 (14.3) 
 4*  2 (33.3) 9 (32.1) 
5 2 (33.3) 5 (17.9) 
6 1 (16.7) 3 (10.7) 
7 0 3 (10.7) 
Median (range) 4 (2-6) 4 (2-7) 
 










(n = 28) 
 n (%) n (%) 
2 0 2 (7.1) 
3 0 5 (17.9) 
 4* 4 (57.1) 11 (39.3) 
5 1 (14.3) 4 (14.3) 
6 1 (14.3) 1 (3.6) 
7 1 (14.3) 3 (10.7) 
8 0 2 (7.1) 
Median (range) 4 (4-7) 4 (2-8) 
 
                    Footnote: 
                   (*) indicates CCL3-L1 population medians in maternal and infant subsets 
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The median CD4 cell count among intrapartum transmitting and non-transmitting women 
were 279 cells/µl [range 76-957] and 421 cells/µl [range 85-1013] respectively. A correlation 
analysis of CCL3-L1 gene copy expression in the maternal subset did not reveal any 
significant relationship with maternal CD4 cell counts (n = 40, r = -0.20, p = 0.3) or maternal 
viral load (n = 40, r = 0.10, p = 0.4). Likewise no significant associations were observed 
between infant CCL3-L1 gene copy expression and maternal CD4 cell counts (n = 41; r = 
0.10, p = 0.5) or maternal viral loads (n = 41, r = 0.10, p = 0.7) [Table XXVIII]. 
 
Table XXVIII: Maternal and infant immune and virological dynamics in relation to  
                        CCL3-L1 gene expression as a marker for intrapartum MTCT 
 
Comparisons n r p values 
Maternal CD4 vs. Maternal CCL3-LI    
Maternal CD4 vs. Maternal CCL3-LI (IP) 6 0.20 0.6 
Maternal CD4 vs. Maternal CCL3-LI (EU) 28 0.10 0.7 
Maternal viral load vs. maternal CCL3-L1    
Maternal viral load vs. maternal CCL3-L1 (IP) 6 -0.70 0.1 
Maternal viral load vs. maternal CCL3-L1 28 0.02 0.9 
Maternal CD4 vs infant CCL3-L1     
Maternal CD4 vs infant CCL3-LI (IP) 7 -0.20 0.7 
Maternal CD4 vs infant CCL3-LI (EU) 28 0.10 0.8 
Maternal viral load and infant CCL3-L1    
Maternal viral load vs. infant CCL3-L1 (IP) 7 -0.20 0.7 
Maternal viral load vs infant CCL3-L1 (EU) 28 0.20 0.3 
 
 
Footnotes : r (Pearson correlation coefficient) ; IP (intrapartum) ; EU (exposed-uninfected) 
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Haplotype (Hap-1) characterization and intrapartum MTCT 
 
CCL3-Hap-1 allelic representation was observed in two (33.3%) of the intrapartum 
transmitting women and four (14.3%) of the 28 non-transmitting women (Table XXIX). This 
finding was not statistically significant [p = 0.23; OR: 3.60; 95% CI: 0.62-11.40] (Fishers 
exact test). No significant relationships were observed between allelic Hap-1 representation 
and maternal plasma HIV-1 RNA (p = 0.5) or maternal CD4 cell count (p = 0.9).  
 
CCL3-L1 Hap-1 allelic representation was detected in six (21.4%) of the exposed-uninfected 
infants. The absence of allelic representation among the intrapartum-infected infants did not 
permit statistical comparisons of CCL3-Hap-1 expression and susceptibility to intrapartum 
MTCT.  
 
Table XXIX: Maternal and infant CCL3-Hap-1 allelic proportions in relation to intrapartum MTCT 
 
Group CCL3-Hap 1 proportions p value* 
2 (33.3%) Intrapartum (n = 6) 
vs. 
non-transmitting women (n = 28) 4 (14.3%) 
 
0.23 
0 (0%) Intrapartum infected (n = 7) 
vs. 
Exposed- uninfected infants (n = 28) 6 (21.4%) 
 
n/a 
* Fishers exact test
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3.5.   Ancillary study findings:  
 
3.5.1 Twin cohort observations 
Seven pairs of twins were born during the course of this study. A summary of their clinical 
and laboratory characteristics are shown in Table XXX. Following two separate DNA PCR 
tests, nine (64.3%) of the fourteen infants were classified as exposed-uninfected, while five 
(35.7%) were established as HIV-1 infected. Intrapartum transmission accounted for two 
(40.0%) of these HIV-1 infections, while three (60.0%) were in utero infections. One case of 
discordant HIV-1 transmission was observed, whereby the first-born twin was HIV-1 negative 
and the second-born twin became HIV-1 infected through the intrapartum route of 
transmission. 
 
The median interval between maternal NVP administration and delivery was 5 hours (range: 
2-16). Median time interval between infant birth and NVP dosing was 2 hours [range: 1.5-3]. 
No statistically significant association was found between MTCT and maternal NVP dosing (p 
= 0.1) or infant NVP dosing (p = 0.4). Median age among the multiparous women was 27 
years [range: 20-38] and median gestational age was 38 weeks [range: 33-38]. No statistically 
significant association was observed between MTCT and maternal age (p = 0.1) or gestational 
age (p = 0.13). Four (57.1%) twin deliveries occurred at full-term (37-41 weeks) while three 
(42.9%) were pre-term (< 37 weeks). While one women (16.7%) delivered by an emergency 
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The median maternal CD4 cell count among this multiparous cohort was 290 cell/ul [range: 
160-458]. No statistical significance (p = 0.7) was found when comparing CD4 cell counts 
between HIV-1 transmitting [n = 3, median: 223 cell/ul, range: 218-290] and non-transmitting 
women [n = 4, median: 253 cell/ul, range: 160-458]. Similarly no association was found 
between perinatal transmission and maternal plasma HIV-1 RNA at pre-NVP (p = 0.1) and 
post-NVP dosing (p = 0.43). At birth sampling, the median plasma NVP concentration among 
HIV-1 infected infants was 1930 ng/ml [range: 0-2380], while exposed-uninfected infants had 
a median plasma NVP concentration of 674 ng/ml [range: 0-1640] (p = 0.3). No statistically 
significant associations were found when comparing median plasma NVP concentration of 
exposed-uninfected vs. intrapartum infected (p = 0.8) or exposed-uninfected vs. in utero 
infected (p = 0.19) infants.  The Mann Whitney U test was used to test all associations.  
 
At least one type of STI was detected in 67.0% of the HIV-1 transmitting women during 
antenatal screening. Approximately four (80.0%) of HIV-1 infected twins were also exposed 
to at least one type of maternal STI.  
 
Infant birth weight ranged from 1.7-3.2 kg [median = 2.4 kg]. Birth weight among HIV-1 
infected twins [median = 2.1 kg, range: 1.7-2.5] was significantly lower than exposed-
uninfected infants [median = 2.8 kg, range: 2.1-3.2] (p = 0.01, 95% CI: 0.20-1.10) (unpaired t 
test). Although eleven (78.6%) infants of the PIVD twin cohort were of male gender, 
stratification according to HIV-1 transmission did not reveal any statistical significance (p = 
0.2). Oral thrush (Candidias) was the most commonly diagnosed infection among the in utero 
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One pair of HIV-1 infected twins demised as a result of respiratory-related illnesses. In 
addition to a low CD4 cell count, the mother of these twins had a Trichomonas vaginalis 
infection during pregnancy. Both infants had extremely low birth weights (Table XXX). This 
dichotomous HIV-1 transmitting mother infected one twin during pregnancy (in utero) and the 
other via the intrapartum route of transmission. To minimize any confusion during data 
analysis, this mother was classified as an “in utero” HIV-1 transmitting mother. 
 
Compared to singletons, twin pregancies were significantly associated (p=0.01) with HIV-1 
transmission (Table XXXb). 
 
Table XXXb: Effect of twin pregnancy on HIV-1 transmission 
 HIV-1 infected HIV-1 uninfected 
Twins (n=14) 5 9 
Singletons (n=103) 9 94 
p value 0.01 
OR 5.8 (95% CI: 1.34-25.1) 
*Fishers exact test 
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CHAPTER FOUR:  DISCUSSION     
 
During the period of the PIVD study (April-December 2006), a regimen of intrapartum 
maternal sdNVP and postpartum neonatal sdNVP was provided to all HIV-1 infected 
pregnant women and their HIV-exposed infants, as the standard of care for PMTCT at 
KEH, Durban. The overall HIV-1 MTCT rate at six weeks in this sdNVP-exposed and 
exclusively formula-fed cohort of maternal-infant pairs was 11.9% [95% CI: 6.70-19.00] 
with similar rates of in utero and intrapartum transmission (5.9% and 5.9% respectively). 
During active labour, the median NVP concentration in the maternal systemic compartment 
[1070 ng/ml] was almost 44 times higher than the NVP levels detected in the genital 
compartment [24.5 ng/ml] (p < 0.001). NVP drug levels were below the 100 ng/ml 
therapeutic target in seven (13.7%) of 51 plasma and in all 39 CVL samples. The median 
plasma NVP level detected among infants at birth was 83 times above the IC50 WT (10 
ng/ml) and eight times higher than the 100 ng/ml therapeutic target for NVP.  More than 
71.0% of the infants achieved NVP drug levels above the therapeutic target. These findings 
confirm that the role of sdNVP in PMTCT was primarily one of infant prophylaxis. This 
was further supported by relatively unchanged maternal HIV-1 RNA (viral load) at the time 
of active labour, in both systemic and genital compartments. HIV-1 transmitting women had 
significantly higher viral loads than their non-transmitting counterparts in systemic and 
genital compartments, before and after intrapartum sdNVP administration. In terms of 
perinatal transmission this observation was only statistically significant for plasma (p = 
0.02) and not CVL (p = 0.7). For clarity and ease of comparison with other studies, the 
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Pharmacokinetic assessment using the LC-MS-MS quantitation method in this PIVD study of 
women, who received the single dose NVP (200 mg) regimen as standard of care to prevent 
mother-to-child transmission of HIV-1 in the South African PMTCT program, demonstrated 
that the median NVP concentration of 1070 ng/ml, [range 0-3080] in maternal plasma 
collected from 51 women during active labour and within 20 hours of NVP dosing. NVP fell 
within the range detected in controlled phase II clinical trials that employed either HPLC or 
LC-MS-MS quantitation methods. Mirochnick and others first reported a median maternal 
plasma NVP concentration of 1663 ng/ml [range: 447-2639] in the first pharmacokinetic study 
investigating the potential of single dose NVP (200 mg) in prevention of MTCT among 18 
HIV-1 infected pregnant women and their neonates (Mirochnick et al, 1998).  Similar median 
plasma NVP concentration were reported in subsequent phase II clinical trials; 1644 ng/ml 
(Musoke et al, 1999), 1742 ng/ml (Harms et al, 2005) and 1695 ng/ml (Creesey et al 2005).  
 
Known to be readily absorbed after oral administration in adults, NVP readily crosses the 
placenta and has been an excellent candidate for single-dose (200 mg) ARV intervention 
during labour because of its potent antiviral effect (an IC50 or in vitro inhibitory concentration 
of 10 ng/ml) (Musoke et al, 1999; Mirochnick et al, 1998). In the PIVD study, NVP drug 
levels failed to reach the 100 ng/ml therapeutic target in just 13.7% of women at active labour 
(0.5-20 hours). In contrast, the median NVP concentration found in maternal CVL (24.5 
ng/ml, range: 0-99.7) was significantly lower than plasma NVP levels during active labour [p 
< 0.0001]. This finding was consistent with the observations by several researchers who found 
that the NNRTI group of compounds did not penetrate well into cervicovaginal fluids 
(Ellerbrock et al, 2001; Tirado et al, 2004 and Kwara et al, 2008). A group of researchers 
from the University of North Carolina used novel methods to profile various ARV drugs based 
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on intracellular and intracellular genital tract exposure relative to plasma. They found that the 
penetration of ARV agents into the genital tract was strongly dictated by the degree of protein 
binding and the drug’s affinity for α1-acid glycoprotein. In comparison to plasma, more than 
80.0% of high-protein bound drugs were recovered at a much lower concentration within the 
genital tract. The relative extent of drug penetration into the genital tract was similar between 
males and females. In the PIVD study, NVP in CVL failed to meet the 100 ng/ml therapeutic 
target in all 39 women studied at active labour (0.5-20 hours). Despite high plasma NVP 
levels, the corresponding female genital tract concentration of high protein bound NNRTI 
drugs like NVP remained remarkably low (Kashuba, 2006; Cohen et al, 2007). It was 
therefore not surprising that median NVP levels in active labour were almost  44 times higher 
in maternal plasma (1070 ng/ml) compared to CVL (24.5 ng/ml) in the PIVD study. These 
findings were consistent with previous reports of poor NNRTI drug penetration into the 
genital compartment (Ellerbrock et al, 2001; Tirado et al, 2004; Kashuba, 2006; Cohen et al, 
2007 and Kwara et al, 2008).  
 
The CVL NVP: Plasma NVP ratio [0.02] observed during active labour in this PIVD study 
was within the range observed in a recent study (Kwara et al, 2008). While no statistically 
significant association was attained between perinatal transmission and NVP concentration in 
the systemic compartment (p = 0.4), this relationship was significant in the genital 
compartment (p = 0.02). The observation of sub-therapeutic drug levels during active labour in 
the female genital tract despite optimal NVP dosing remains clinically relevant. Since sdNVP 
for the indication of PMTCT does not reduce maternal viral load, other ARV’s are therefore 
required for optimal absorption and viral reduction in genital fluids and hence also reducing 
infant exposure to HIV-1 during labour and delivery. Studies by Kashuba and others have 
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demonstrated that excellent ARV drug penetration (within the female genital tract) was 
achievable through the use of the nucleoside reverse transcriptase inhibitors or NRTI class of 
compounds. NRTI’s like ZDV, 3TC and Tenofovir were found to accumulate very 
successfully in genital secretions [Kashuba, 2006; Dumond et al, 2007; Kwara et al 2008]. 
The efficacy of NRTI drugs like ZDV (in PMTCT) have already been demonstrated by the 
successful outcomes of clinical drug trials like the PACTG 076 (Connor et al, 1994) and 
PHPT (Lallemant et al, 2000), in addition to field efficacy studies (Dabis et al, 1999; 2005). 
Unlike other drugs, ZDV becomes fully active within the placenta, enters the fetal circulation 
and has the ability to rapidly achieve drug levels comparable to those in maternal blood 
(Kumar et al, 1994). 
 
A dual ARV regimen of (ZDV and sdNVP) is currently a WHO recommended option for 
PMTCT. This dual regimen will not only be beneficial for prevention of drug resistance 
(associated with sdNVP) but several studies have demonstrated that short-course ZDV 
regimens are also more efficacious in achieving optimal HIV-1 RNA (viral load) suppression 
in maternal genital secretions in addition to reducing MTCT. Chuachoowong and others 
reported a substantial and rapid reduction of HIV-1 RNA levels in maternal CVL with as little 
as one to two weeks of ZDV administered near the end of pregnancy (Chuachoowong et al, 
2000). Similarly following short-course ZDV treatment, both plasma and genital secretions 
showed a reduction in HIV-1 RNA. Compared to plasma, a more rapid virus clearance was 
observed in genital secretions (Mbori-Ngacha et al, 2003). These reports are encouraging and 
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Almost 71.0% of the infants in PIVD study were able to achieve plasma NVP drug levels 
(birth) above the 100 ng/ml therapeutic target within 72 hours of birth. The median NVP 
concentration of 828 ng/ml in infant plasma was eight times higher than the therapeutic target 
(100 ng/ml) and almost 83 times above the in vitro [IC50 WT] (10 ng/ml). In a phase I/II safety 
and toxicity trial performed in Uganda, a single dose of intrapartum maternal and postpartum 
infant NVP, resulted in infant serum NVP levels of more than 150 times the in vitro [IC50 WT] 
(Musoke et al, 1999). This trial also reported a median cord blood NVP concentration of 1175 
ng/ml which exceeded the 100 ng/ml therapeutic target in 100% of their infant cohort. Median 
infant serum or plasma NVP levels from other phase II clinical trials were 925 ng/ml [64-
2030] (Mirochnick et al, 1998) and 1291 ng/ml [114-2910] respectively (Harms et al, 2005). 
While the median infant plasma NVP level (828 ng/ml) observed in the present PIVD study 
was slightly lower than previously described, this level was within the range described in 
previous studies (Mirochnick et al, 1998, Harms et al, 2005).  
 
A statistically significant relationship was observed between the NVP concentration in the 
plasma of a 100 maternal-infant pairs [r = 0.36, 95% CI: 0.18-0.52, p = 0.0002] (Pearson’s 
correlation coefficient). These findings concurred with similar observations by (Harms et al, 
2005) and confirm the transplacental passage of NVP (Mirochnick et al, 1998). In the PIVD 
study, median plasma NVP levels of exposed-uninfected infants of 933 ng/ml fell within the 
drug concentration range (875-1471)] of exposed-uninfected infants at 6-8 weeks reported by 
Jackson and others (Jackson et al, 2006) in a phase III (HIVNET 012) clinical trial. The 
median NVP concentration of 20.3 ng/ml (range: 0-2380) found among intrapartum infected 
infants in the PIVD study was far below the expected therapeutic target and below the NVP 
concentration range described by (Jackson et al, 2006). Phase I studies of safety and 
 
 
- 166 - 
pharmacokinetics of NVP in Ugandan and American women demonstrated that a 200 mg/ml 
dose of NVP administered to HIV-1 infected women in labour was rapidly absorbed and 
achieved NVP drug levels of more than 10 times the concentration required to inhibit antiviral 
activity by 50% (IC50) in the newborn at delivery. When the infant received an additional dose 
of 2 mg/kg (48-72 hours of birth), infant NVP concentration was maintained at greater than 
the 100 ng/ml target for up to seven days postnatally (Mirochnick et al, 1998; Musoke et al, 
1999). Recommended dosing of sdNVP has been 2-48 hours for women and 6-72 hours for 
infants (Guay et al, 1999). While sdNVP is easily self-administered, there has been wide 
variability regarding the timing of the drug dose in relation to delivery. In the current study, 
more than 70% of women self-administered their NVP dose within 2-48 hours and more than 
80.0% of this infant cohort received their NVP dose less than six hours of birth. No 
association was found between sdNVP dosing and intrapartum HIV-1 transmission (p = 0.4). 
While some studies reported a decreased cord blood concentration when maternal dosing took 
place at less than two hours of delivery (Mirochnick et al, 2003), Chi and others found that 
MTCT was unaffected by the timing of the maternal or infant NVP dose, provided dosing 
occurred within reasonable proximity to the time delivery (Chi et al, 2005).  
 
The HIVNET 012 (Guay et al, 1999; Jackson et al, 2003) and SAINT (Moodley et al, 2003) 
trials evaluated the provision of intrapartum sdNVP and postpartum maternal NVP and 
postpartum neonatal sdNVP. In the NVAZ trial, a post-exposure prophylactic regimen of 
sdNVP and one week of Zidovudine or ZDV was administered to the infants of untreated 
mothers (Taha et al, 2003). In the South African PEP study, investigators compared two post-
exposure prophylaxis regimens (sdNVP vs. 6 weeks of ZDV) administered to the infants of 
untreated mothers (Gray et al, 2005). Authors of the NVAZ study strongly recommended that 
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when it is not possible to administer intrapartum NVP to the mother, it might still be beneficial 
to provide this intervention to the infant. The infant could also be afforded additional 
protection by a second ARV such as ZDV. This study indicated that dual therapy of sdNVP 
coupled with one week of ZDV given to the infant was far superior to a single dose of NVP 
alone (Taha et al, 2003). In slight contrast, the PEP study investigators reported that an infant 
only sdNVP regimen was as efficacious as six weeks of ZDV therapy (Gray et al, 2005). Both 
the South African PEP (Gray et al, 2005) and the Malawian NVAZ (Taha et al, 2003) studies 
provided compelling evidence for the safe and efficacious implementation of an infant only 
PEP strategy as an alternate intervention to reduce MTCT.   
 
Since April 2008 a dual regimen of ZDV starting from 28 weeks gestational age and sdNVP in 
labour has now been prescribed as the standard of care for HIV-1 infected pregnant women 
(PMTCT programme). Their subsequently HIV-exposed infants also receive sdNVP at birth, 
followed by a seven day course of ZDV (WHO, 2006b). This new development is extremely 
positive as findings from this and several other studies underscore the need for dual ARV 
regimens. 
 
Using an ultra-sensitive HIV-1 RNA quantitation method [COBAS AmpliPrep/Cobas TaqMan 
system, 2006], HIV-1 RNA detection rates of 78.3% and 65.3% were observed in the analysis 
of maternal CVL samples collected at pre and post-NVP dosing respectively. CVL HIV-1 
RNA detection rates reported in this study concur with several other studies (Kovacs et al, 
1999; Hart et al, 1999; Goulston et al, 1998; Iversen et al, 1998; Fiore et al, 2003). The 
variable detection rates reported across these studies have been attributed to CVL collection 
procedures and HIV-1 RNA quantitation methods. The COBAS system (used in this study) 
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has only been validated (FDA approved) in human plasma samples. Detection rates from this 
study demonstrate the potential application of this assay in the quantitation of CVL HIV-1 
RNA. Besides a high throughput, this commercial COBAS assay offers increased detection 
sensitivity with a lower limit of detection of 40 vs. 400 copies/ml typically achieved when 
using conventional Roche Amplicor assays (Liegler, 2006). Despite the presence of blood 
contamination in some CVL samples collected during labour sampling, all 72 CVL samples 
that were collected at post-NVP dosing were assayed for HIV-1 RNA. This was undertaken as 
several published studies have shown that minimal blood contamination of genital samples 
does not significantly affect genital viral load levels (Hart et al, 1999; Reichelderfer et al, 
2000 and Cu-Uvin et al, 2006). 
 
Median maternal plasma HIV-1 RNA (viral loads) did not vary significantly between 
pregnancy (4.1 log10 copies/ml), active-labour (3.9 log10 copies/ml) or post-delivery (3.7 log10 
copies/ml) sampling. Likewise median CVL HIV-1 RNA during pregnancy, active labour and 
post-delivery were 2.8; 2.4 and 1.9 (log10 copies/ml) respectively.HIV-1 transmitting women 
had significantly higher viral loads than their non-transmitting counterparts in systemic and 
genital compartments, before and after intrapartum sdNVP administration. A general trend of 
higher HIV-1 RNA levels in maternal plasma as compared to CVL was consistently observed 
independent of sampling. This finding concurs with similar observations by Cu-Uvin et al, 
2006. Overall, women who transmitted HIV-1 had significantly higher HIV-1 RNA levels 
than their non-transmitting counterparts at pre and post-NVP dosing in their systemic 
compartments. Maternal genital viral load (CVL HIV-1 RNA) was comparable between both 
groups at pre and post-NVP dosing. In terms of intrapartum MTCT, these findings were only 
significant for maternal plasma (p = 0.02) and not for CVL (p = 0.7). This observation 
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supports previous reports wherein plasma was seen as a much stronger predictor for MTCT 
(Mofenson, 1997; Quinn et al, 2000; Kovacs et al, 2001). Women with viral loads above the 
threshold for mother-to-child transmission (> 1000 copies/ml) only demonstrated an increased 
risk of intrapartum HIV-1 transmission in their plasma samples (p = 0.02) and not CVL (p = 
0.9). 
 
In their study of patterns and predictors of genital tract HIV-1 RNA levels over a 36-month 
period, Cu-Uvin and others reported that plasma HIV-1 RNA correlated strongly with genital 
tract HIV-1 RNA (Cu-Uvin et al, 2006). They also found plasma HIV-1 RNA to be the 
strongest predictor of CVL fluid HIV-1 RNA detection. Even though cases of discordance are 
known to occur (Rasheed, 1998), genital tract HIV-1 RNA is unlikely to be found when 
plasma HIV-1 RNA is undetectable. 
 
In the PIVD study, both intra [e.g. pre-NVP dose vs. post-NVP dose] and inter-compartmental 
[plasma vs. CVL] HIV-1 RNA comparisons have revealed strong and statistically significant 
relationships. These positive associations remained constant even after controlling for 
confounding variables such as CVL blood contamination and detection of sexually transmitted 
infections. The PIVD study findings of moderate to strong correlation between systemic and 
genital HIV-1 RNA were consistent with other studies of HIV-1 infected women who either 
received or didn’t receive ARV drug therapy (Andréoletti et al, 2003; Si-Mohamed et al, 
2000; Iversen et al, 1998; Kovacs et al, 1999; Hart et al, 1999; Cu-Uvin and Caliendo, 1997; 
Cu-Uvin et al, 2006; Goulston et al, 1998) and in studies of pregnant and non-pregnant HIV-1 
infected women (Shaheen et al, 1999). This finding suggests that HIV-1 RNA in CVL was 
significantly influenced by HIV-1 RNA in plasma (Kovacs et al, 2001; Cu-Uvin and Caliendo, 
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1997; Cu-Uvin et al, 2006; and Fiore et al, 2003). In contrast, some studies have demonstrated 
a lack or poor viral load correlation (Rasheed, 1998; Shepard et al, 2000 and Garcia-Bujalance 
et al, 2004) between both compartments. Similar to the reports of variable HIV RNA detection 
rates, discrepancies between published studies could be due to patient selection bias, 
methodological differences in respect of CVL sample collection or even choice of HIV-1 
RNA quantitation assay. 
 
Findings of strong correlation between pre and post-NVP dose HIV-1 RNA levels in both 
systemic [r = 0.81, p < 0.0001] and genital compartments [r = 0.80, p < 0.0001] further 
supports another crucial observation wherein no viral load reduction took place in more than 
80.0% of study women (at the time of active labour). Interestingly, this relationship remained 
strong and statistically significant in both compartments, even during a combination analysis 
that included active labour, post-delivery and latent labour maternal CVL samples. While 
unchanged viral loads were indicative of the lack of maternal effect, these findings serve to 
confirm the role of sdNVP as being primarily a function of prophylaxis for infants. These 
findings are important in elucidating the role of sdNVP (for prevention of mother-to-child 
HIV-1 transmission), particularly due to current concerns over NVP-related drug resistance 
selection. This observation supports studies of “infant only” post-exposure prophylaxis. 
Researchers from the South African PEP study (Gray et al, 2005) concluded that sdNVP acted 
purely as infant prophylaxis. Initial reports from the benchmark HIVNET 012 trial almost a 
decade ago, found no significant difference between maternal plasma HIV-1 RNA levels at 
baseline and delivery. Even then, HIVNET 012 investigators postulated that the efficacy of 
sdNVP in prevention of vertical HIV-1 transmission was unlikely to be caused by a reduction 
of maternal viral load (Musoke et al, 1999).  
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In the PIVD study, CD4 cell counts were available for 120 women during pregnancy (GA: 28-
39 weeks). The median and interquartile range (IQR) of CD4 cell count of these women was 
530 cells/µl (IQR: 246-497) cells/µl. Of the 120 women, 19 (15.8%), 35 (29.2%), 37 (30.8%) 
and 29 (24.2%) presented with CD4 cell counts of ≤ 200 cells/µl, 200-350 cells/µl, 350-500 
cells/µl and ≥ 500 cells/µl respectively. Nineteen (15.8%) of these women had a CD4 count of 
< 200 cells/µl and were eligible for antiretroviral therapy in admission into the ARV rollout 
programme at KEH. The median CD4 cell count among these women was 142 cells/µl [range: 
21-198].  All nineteen women were referred to the ARV rollout clinic (Philani Family Clinic, 
KEH) and commenced on a comprehensive eight-week ARV drug adherence training 
programme prior to labour and delivery. As at the final postnatal study visit at six weeks, ARV 
treatment (3TC, d4T and NVP) was reported to have been initiated in four (21.0%) of the 
women prior to delivery, while the remaining 15 (78.9%) women had not commenced ARV 
treatment. The WHO currently recommends that all patients with a CD4 cell count of ≤ 350 
cells/µl be given access to HAART (WHO, 2006c). Early identification of pregnant women in 
need of ARV drugs and initiation of therapy as early as possible in pregnancy would greatly 
reduce MTCT rates in developing regions. ARV treatment of these women not only benefits 
their own health but more significantly remains the best prophylaxis against MTCT (McIntyre, 
2007). 
 
In the present study, a higher maternal viral load during pregnancy and labour/delivery was 
associated with lower CD4 cell counts during pregnancy. This finding was statistically 
significant in maternal plasma (p < 0.001; p < 0.001) and CVL (p < 0.001; p = 0.04). Despite 
the absence of statistical significance, intrapartum transmitting women had a lower median 
CD4 cell count than their non-transmitting counterparts (p = 0.7). Maternal immune depletion 
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has been shown to correlate with vertical HIV-1 transmission. An increased risk of vertical 
transmission was noted with lowered CD4 T cell counts (European Collaborative study, 1994; 
Mofenson et al, 1999b; Luzuriaga, 2007). In the South African PEP study, a CD4 cell count of 
≤ 500 cells/µl was associated with a two-fold increase in transmission (Gray et al, 2005). 
Increased maternal HIV-1 RNA (viral load) was associated with decreased or lower CD4 cell 
counts. This finding was statistically significant in maternal plasma and CVL. Women with 
high plasma HIV-1 RNA and low CD4 cell counts were more likely to also have high CVL 
HIV-1 RNA. Similar relationships were described by Kovacs and others (Kovacs et al, 1999). 
In concordance with a report from an Italian study (Fiore et al, 2003); maternal CD4 cell 
counts in this current study also correlated negatively with plasma and CVL HIV-1 RNA, 
even after stratification according to intrapartum transmission. 
 
The overall mother-to-child transmission rate observed in this study at six weeks was 11.9% 
[95% CI: 6.70-19.00]. While direct comparison to other studies is difficult due to variable 
study designs and settings, the MTCT rate observed here was comparable to transmission rates 
reported by several clinical trials and studies performed on the African continent (that 
investigated treatment arms/regimens containing sdNVP): HIVNET 012 (Uganda) [11.8%; 
95% CI: 8.20-15.50] (Guay et al, 1999; Jackson et al, 2003); SAINT (South Africa) [12.3%; 
95% CI: 9.70-15.00] (Moodley et al, 2003); NVAZ (Malawi) [15.3%; 95% CI: 12.10-18.50] 
(Taha et al, 2003) and PEP (South Africa) [11.9%, 95% CI: 8.80-15.00] (Gray et al, 2005). 
 
In the PIVD study, the MTCT in utero rate was 5.9% [95% CI: 1.68-10.28]. Likewise the 
intrapartum MTCT rate was 5.9% [95% CI: 1.68-10.28]. Without any ARV intervention or 
breastfeeding exposure, perinatal HIV-1 transmission rates have been documented to range 
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from 5-10% in utero and 10-20% intrapartum (De Cock et al, 2000). MTCT rates in this study 
were comparable with rates described in several studies/clinical trials investigating sdNVP-
containing treatment arms/regimens. The in utero MTCT rates reported from such studies 
included; 8.2% (HIVNET 012, Guay et al, 1999); 8.5% (SAINT, Moodley et al, 2003); 10.2% 
(NVAZ, Taha et al, 2003) and 7.0% (PEP, Gray et al, 2005). The intrapartum MTCT rates 
included; 11.8% (HIVNET 012, Guay et al, 1999); 8.9% (SAINT, Moodley et al, 2003); 
12.1% (NVAZ, Taha et al, 2003) and 11.9% (PEP, Gray et al, 2005). 
 
Advanced maternal age is a well-known risk factor for poor pregnancy outcome and increased 
MTCT (Mayaux et al, 1995). To control for this confounding factor, all antenatal attendees 
aged ≥ 39 years were excluded from participation in the present study. As a result, no 
statistically significant association was observed between maternal age and intrapartum MTCT 
(p = 0.24).  
 
In contrast to other MTCT studies (Fang et al, 1995; Stratton et al, 1999), no association was 
observed between maternal gestational age at labour and intrapartum MTCT in this study (p = 
0.7). An infant birth weight of less than 2500 grams was significantly associated with 
intrapartum MTCT (p = 0.04). This finding was consistent with findings in numerous MTCT 
studies (Landesman et al, 1996; Stratton et al, 1999, Jourdain et al, 2007). The observation of 
infant gender not being a significant risk factor for intrapartum MTCT (p = 0.13, OR: 3.20) 
was in agreement with the findings from the meta-analysis of nine African studies where no 
association between infant gender and early perinatal transmission (Breastfeeding and HIV 
International Transmission Study Group, 2004).  
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Mode of delivery (NVD vs. C/S) was equally distributed in the current study and was not 
associated with an increased risk of intrapartum MTCT [p = 0.7]. Comparisons for deliveries 
by emergency C/S were not possible due to a lack of statistical power. While the use of an 
elective  C/S prior to the onset of labour and rupture of membranes has been widely advocated 
as an effective intervention for protection against intrapartum HIV-1 transmission (European 
mode of delivery collaboration, 1999), there have also been conflicting reports regarding its 
clinical utility among HIV-1 infected women. In the meta-analysis review undertaken by Read 
and colleagues, the use of an elective C/S over a NVD translated to a 50.0% reduction of 
MTCT risk among women with high plasma viral load or those who were not on HAART 
(Read and Newell, 2006). However, data from the WITS study highlighted an association 
between maternal morbidity and use of an elective C/S (Read et al, 1999) among HIV-1 
infected women. Similarly the ACTG 185 trial reported an increased rate of infectious 
maternal complications among HIV-1 infected women undergoing surgical deliveries 
(Mofenson et al, 1999a). Despite its potential risks, an elective C/S negates any likelihood of 
the premature rupture of membranes and also minimizes an infant’s contact with contaminated 
maternal cervicovaginal fluids during a normal delivery. Taking this into consideration, the 
CDC issued guidelines stating that the risk of infectious maternal complications was not of 
significant frequency or severity to outweigh the potential benefits of reduced transmission 
with the use of elective caesarean section. The CDC also recommended that the elective C/S 
be offered as an option to all HIV-1 infected women provided they were aware of the potential 
risks and benefits (CDC 2002; Luzuriaga, 2007).   
Findings from the Mandelbrot, Landesman and Magder research groups have found 
statistically significant associations between a rupture of membranes of greater than four hours 
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and the risk of intrapartum MTCT (Mandelbrot et al, 1996; Landesman et al, 1996 and 
Magder et al, 2005). Due to a lack of statistical power, this comparison was not possible in the 
present study. While some large cohort studies have reported an association between 
intrapartum MTCT and preterm labour (Landesman et al, 1996; Mandelbrot et al, 1996; 
European collaborative study, 1992 and Kuhn et al, 1999), this was not the occurrence in the 
present  study (p = 0.31,  OR = 1.70). 
In spite of two decades of research on MTCT and HIV-1, there has been very little study of 
the risks of multiple pregnancies among women with HIV-1 infection. The twinning rate 
observed in the PIVD study was 6.4%. Nine (64.3%) of the twin infants were exposed-
uninfected, while five (35.7%) were confirmed to be HIV-1 infected. Among those infected, 
intrapartum MTCT accounted two (40.0%), while the remaining three (60.0%) were infected 
in utero. Intriguingly, more than 80.0% of the HIV-1 infected twins were also exposed to at 
least one type of maternal STI. While 78.6% of the twin infants were of male gender, this 
finding was not associated with perinatal HIV-1 transmission (p = 0.2). Likewise findings 
from a large French perinatal cohort (Scavalli et al, 2007) also reported no relationship 
between gender and twin HIV-1 transmission.  Similar to findings from the singleton cohort, 
low birth weight among the PIVD twin cohort was also significantly associated with MTCT (p 
= 0.01). All twin deliveries occurred by elective C/S, with the exception of one emergency 
C/S. The birth order of twins has long been associated with a variable risk of HIV-1 infection. 
Studies by Goedert and associates as well as Duliège and colleagues have shown that the 
majority of twin pairs were concordant in terms of HIV-1 infection (Goedert et al, 1991; 
Duliège et al, 1995). Those two groups also found first-born twins to be at an increased risk 
for MTCT, compared to second-born twins. In the PIVD cohort seven women delivered twins. 
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Of these, three (42.9%) also transmitted HIV-1 to their infants. One mother transmitted HIV-1 
via the in utero mode to both her babies. The occurrence of a dichotomous transmitting mother 
with one in utero-infected twin and one intrapartum-infected twin in this study was also quite 
unusual. One case of discordant HIV-1 transmission was also observed. This mother 
transmitted HIV-1 to her second-born twin via the intrapartum mode, while her first-born twin 
remained inexplicably HIV-1 exposed-uninfected until the end of this study at six weeks. The 
precise mechanism for the increased risk of HIV-1 acquisition among first-born twins remains 
an unsolved mystery. Compared to singletons, twin pregnancies were highly associated with 
HIV-1 transmisson (p = 0.01) in this study.  
A high prevalence rate of multiparous pregnancies is not uncommon within the African 
setting. This together with the high MTCT rates of this region, merits further investigation into 
the pregnancy-related outcomes of multiparous HIV-1 infected women. 
Tremendous research efforts and progress have resulted in the WHO’s current support and 
recommendation of more efficacious prophylactic regimens for PMTCT (in resource-
constrained settings) such as the dual regimen of sdNVP and ZDV, in the absence of maternal 
HAART (WHO, 2006b). However due consideration must be given to the challenges 
associated with large scale implementation of such programmes in these resource-limited 
settings. Studies have shown that ZDV and sdNVP are not easy to apply in Africa (Msellati et 
al, 2001; Temmerman et al, 2003; Stringer et al, 2003a). While combined use may not be 
more complex, universal ARV coverage still remains a huge challenge. A recent UNAIDS 
report revealed that in 2007, ~49.0% of women received single-dose NVP, ~26.0% received a 
combination of two ARV drugs and ~8.0% received a combination of three ARV drugs 
(UNAIDS/WHO/UNICEF, 2008b).  
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Despite more efficacious ARV combinations (as demonstrated from various clinical drug 
trials), few low-resourced country programmes have yet been able to go beyond single dose 
NVP or even achieve good coverage with this regimen. In 2007, reasonable ARV coverage 
(for PMTCT) was observed in some African countries including SA (57.0%), Kenya (69.0%), 
Mozambique (46.0%), however ARV coverage in countries like India (14.0%) and  
Democratic Republic of Congo, Ethiopia and Nigeria (<10.0%) was extremely inadequate 
(UNAIDS/WHO/UNICEF, 2008). More concerning was the observation that many of the 
countries with poor ARV coverage were also geographically located within well-known HIV-
1 epicenters (Africa and Asia) of the world. ARV coverage among HIV-exposed infants was 
less than 20.0% in 2007 (UNAIDS/WHO/UNICEF, 2008b).  
  
Deficiencies in various MTCT components such as VCT uptake, receipt of results, uptake of 
ARV drugs and post-delivery follow up were cited as reasons for the sub-optimal 
implementation of PMTCT programmes in some African countries (Colvin et al, 2007).  
When the present PIVD study was undertaken, ARV drug adherence training was conducted 
for a period of eight weeks. While this was the standard of care, this unusually long training 
process for antenatal HAART did not prove beneficial to some women. Despite their 
eligibility for antenatal HAART, some women were either still in the process of training or 
were too far along in their pregnancy (> 34 weeks) to attain the optimal benefit of antenatal 
HAART. While there is a substantial body of literature from clinical trials regarding the 
efficacy of short-course ARV prophylaxis in reducing transmission from mother to child, data 
pertaining to the operational effectiveness (most especially sub-Saharan Africa) of national 
programmes remains sparse. Proportions of women who were somehow missed by their 
PMTCT programmes have been reported as Kenya (17.0%); Ethiopia (57.0%) and Zimbabwe 
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(59.0%) (Bolu et al, 2007). Data regarding operational efficacy has also been conflicting. 
While a Kenyan study found that the sdNVP regimen to have low efficacy (Quaghebeur et al, 
2004), a South African study demonstrated the feasibility and effectiveness of implementing  
large scale PMTCT programmes in an urban public sector setting (Coetzee et al, 2005). Colvin 
and others also found PMTCT programmes (using sdNVP) to be efficacious in reducing early 
transmission of HIV-1 in operational settings (Colvin et al, 2007). Fear, discrimination and 
stigma remain some of the main impediments to participation of women in the PMTCT 
programme. A study carried out in Botswana highlighted the negative attitudes of healthcare 
workers, lack of partner support and stigma associated with infant feeding choice as some of 
the barriers which led to poor PMTCT uptake (Kebaabetswe, 2007). 
 
Use of sdNVP and postpartum prophylaxis (PEP) in infants still has a significant role to play 
in PMTCT and will continue to be of benefit in settings where women: a) do not access 
routine antenatal care services, b) are not offered antenatal counseling and testing, c) arrive at 
hospital in advanced labour neither counseled nor tested, d) refuse to take their intrapartum 
NVP or miss their dose or e) where babies are born at home/or en-route to hospital and f) 
where healthcare workers wish to avoid maternal NVP dosing (Gray et al, 2005). PEP serves 
as an alternative post-delivery strategy to improve the uptake of VCT, attendance of infant 
feeding counseling and access to ARV therapy. Apart from the sdNVP PEP regimen being 
simpler to implement, it also abates concerns of NVP drug resistance in the mother. NVP- 
associated drug resistance does however remain a significant challenge among HIV-1 infected 
infants (Martinson et al, 2004). Infant only PEP is an effective means of reaching, counseling 
and treating women who missed opportunities for the commonly practiced voluntary 
counseling and HIV-1 testing during pregnancy or antenatal VCT. Postpartum VCT or PP-
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VCT has been reported as being a valuable option (Chersich et al, 2002) among women who 
missed antenatal counseling and testing opportunities. A recent study (n = 493) offering HIV 
testing to women who accessed immunization or acute infection services at child health clinics 
in Kenya was viewed as an acceptable and valuable option by many of the clinic attendees. 
Approximately 472 (95.7%) of women cited a keen interest in the benefits regular HIV testing, 
point of care testing, infant feeding counseling and access to treatment to prevent MTCT. A 
large proportion of women 98 (79.0%) who did not access antenatal care services were tested 
in the study by Chersich and others (Chersich et al, 2008). The best strategy for attaining the 
MTCT rates of (< 2.0%) often only seen in developed countries remains “universal access to 
ARV drugs”. For PMTCT, this means urgent early identification of HIV-1 infected pregnant 
women in need of ARV therapy and initiation of therapy in these high-risk women as early as 
possible in pregnancy. “ARV treatment of these women not only benefits their own health but 
remains the best prophylaxis against MTCT” (McIntyre, 2007). 
 
While the sdNVP regimen is a successful and cost-effective treatment option for prevention of 
mother-to-child HIV transmission in many resource-constrained countries, there has however 
been much controversy surrounding its use for this purpose due to the rapid emergence of 
NVP-associated drug resistance mutations (NVP
R
). While these resistance mutations may 
disappear over time (Eshleman et al, 2001), there has been concern that administration of NVP 
to HIV-1 infected pregnant women may permit selection of NNRTI drug resistance mutations 
which could compromise the success of a patient’s future therapeutic options with ARV drugs 
like NNRTI’s (Sullivan, 2002; Kantor et al, 2003; Eshleman et al, 2004; Jourdain et al, 2004). 
Eshleman and others have also shown that avoidance of maternal intrapartum sdNVP and 
provision of (sdNVP and ZDV) to infants only was effective in eliminating the development 
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of maternal NNRTI drug resistance and reducing the occurrence of NVP
R
 among infants 
(Eshleman et al, 2006). Compared to a regimen of maternal and infant sdNVP, development 
of NVP
R
 among infants occurred less frequently in infants exposed to “infant only PEP” (Gray 
et al, 2005). Alternatively the development of NVP
R
 could also be reduced in infants when 
both mother and infant received a short course of combivir (ZDV and 3TC) in addition to 
sdNVP (McIntyre et al, 2005). 
 
NVP drug resistance testing was only undertaken among the intrapartum HIV-1 transmitting 
women to determine plausible reasons for the intrapartum HIV-1 transmission occurring in 
this group, independent of sdNVP dosing at labour. While five HIV-1 transmitting women 
lacked detectable resistance to NNRTI, NVP
R
 was observed in one HIV-1 transmitting 
woman. Compared to women who lacked NVP
R
, the patient with drug resistant mutations had 
a lower baseline CD4 cell count and higher viral load in both systemic and genital 
compartments. In keeping with findings from the analysis of two local PMTCT cohorts in 
Soweto and KZN (Martinson et al, 2004), two commonly occurring NNRTI resistance 
mutations (Y181CY and Y188CY) were also detected in this HIV-1 transmitting mother. 
Furthermore, sub-typing of the virus confirmed a clade C infection among all intrapartum 
transmitting women. This finding was consistent with the viral subtype, known to dominate in 
the Sub-Saharan region (Spira et al, 2003). 
 
In addition to ARV therapy, prevention and elimination of biological risk factors like STI’s 
are simple and effective PMTCT interventions. In a study by Wilkinson and others in the rural 
Hlabisa district (KZN), investigators observed that on any given day, 29.4% of the resident 
female population had one or more detectable STI and that more than 48.0% of the women 
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were asymptomatic (Wilkinson et al, 1999). While screening for STI’s in the PIVD cohort was 
carried out mainly to rule out confounding risk factors, it was rather concerning to note that 47 
(39.2%) of the maternal cohort had at least one or more STI detected at antenatal screening. 
This finding underscores the need for ongoing STI-related counseling and education 
throughout the duration of pregnancy. In addition, two (2.5%) of women had two types of 
STI’s. Independent of the type of STI, detection of these preventable and curable infections 
during pregnancy remains clinically relevant due to the resulting adverse maternal (e.g. 
infertility, puerperal sepsis, chorioamniotis) and neonatal complications (e.g. pneumonia, 
conjunctivitis) (Moodley and Sturm, 2000). The deadly synergy between HIV-1 and STI’s 
presents a dual dilemma and further complicates this equation. Researchers have shown strong 
epidemiological evidence of an increased risk of HIV-1 acquisition and transmission in the 
presence of STI’s (Pham-Kanter et al, 1996; Kharsany et al, 2006). HIV-1 infected pregnant 
women with untreated STI’s continue to act as viral reservoirs of infection for both horizontal 
and vertical HIV-1 transmission (Wilkinson et al, 1997; Sturm et al, 1998).  
 
Although the number of Bacterial vaginosis infection cases reported in the present study was 
lower compared to global estimates by the World Health Organization (WHO, 2001), the 
prevalence rate of other STI’s such as; Treponema pallidum (0.83%), Trichomonas vaginalis 
(15%) and Candida albicans (20.8%) concurred with reports from local and international 
studies (WHO, 2001; Pham-Kanter et al, 1996; Kharsany et al, 1997 and Johnson et al, 
2005b). No statistically significant association was found between STI detection and 
intrapartum MTCT in the present study [p = 0.2, RR: 2.90, 95% CI: 0.60-15.40]. The presence 
of any STI was however found to increase HIV-1 RNA levels in both systemic and genital 
compartments of HIV-1 transmitting women at the time of labour/delivery. These findings 
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were in accordance with numerous other reports of increased viral shedding in STI presence 
and a strong association with increased HIV-1 transmission risk (Ghys et al, 1997; Pham-
Kanter et al, 1996; Moodley and Sturm, 2000; Moodley et al, 2002; Taha et al, 1998; Coombs 
et al, 2003; Mbopi-Kéou et al, 2000; Cu-Uvin et al, 2001). 
 
In South Africa, STI’s are still managed syndromically (Department of Heath, 1999), however 
studies on MTCT risk factors have found the treatment of such infections at the onset of 
prenatal care to be quite ineffective for prevention for perinatal HIV-1 transmission (Fawzi et 
al, 2001). The investigators cited treatment failure, re-infection of treated individuals or 
incident infections after onset of antenatal care, as important predictors of HIV-1 transmission 
due to ascending infection (Fawzi et al, 2001). In the PIVD study all 47 women with 
detectable STI’s were contacted to return for appropriate clinical management. Only 19 
(40.6%) of these women sought treatment before delivery. Likewise Wilkinson and others 
found that 98.0% of symptomatic women in their study also failed to seek treatment. A 
substantial proportion of STI’s, therefore, remain untreated as health-seeking behaviors are 
influenced by recognition of symptoms, access to health services, attitudes of service 
providers and gender (Wilkinson et al, 1997, 1999; Sturm et al, 1998 and Frohlich et al, 
2007).   
 
Ongoing STI counseling, intensive screening and testing (including partners), promotion of 
condom usage, safe sex practices and aggressive STI treatment are simple interventions with 
tremendous impact. Along with enhancing antenatal care and improving pregnancy and 
neonatal outcomes (Moodley and Sturm, 2000), this simple and cost-effective strategy has 
great potential in also reducing and preventing both horizontal and vertical HIV-1 
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transmission. Given that STI treatment is provided at no cost to all attendees in most public 
health settings, this presents healthcare workers with an invaluable opportunity for 
strengthening HIV-1 prevention and STI management. In addition, the integration of STI 
services with family planning and antenatal services could potentially have a huge impact on 
both epidemics (Frohlich et al, 2007).    
 
Novel findings of increased HIV-1 susceptibility with reduced CCL3-L1 gene copy numbers 
prompted the investigation of this unique immune marker in the PIVD study. A case-control 
subset of maternal-infant pairs was selected for CCL3-L1 gene copy determination, 
identification of single nucleotide polymorphisms and haplotype-1 characterization. The 
observed population median of four in HIV-1 transmitting and non-transmitting women of the 
PIVD study fell within the range determined by a large international study (Gonzalez et al, 
2005) and was consistent with reports from local studies (Meddows-Taylor et al, 2006; Kuhn 
et al, 2007). In their landmark study, Gonzalez and others observed wide variability in the 
median number of CCL3-L1 gene copies across various human populations that extended 
across various continents. Adults and children bearing a higher number of CCL3-L1 gene 
copies relative to their population median were at a lower risk of acquiring HIV-1 infection, 
while those individuals possessing a lower gene copy number than the population median 
displayed marked enhanced HIV/AIDS susceptibility (Gonzalez et al, 2005). Similar to 
findings by Meddows-Taylor and others, no relationship was found between maternal CD4 
cell counts and infant CCL3-L1 gene copy number (Meddows-Taylor et al, 2006). In contrast 
to the same study, a statistically significant association between infant CCL3-L1 gene copy 
numbers and maternal viral loads was observed in the PIVD study. There are two plausible 
reasons as to why the PIVD study was unable to detect any significant association between 
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increased CCL3-L1 gene copy numbers and reduced HIV-1 susceptibility in both mothers (p = 
0.9) and infants (p = 0.4). The small sample size of the genotyping subset may have not been 
statistically powered to adequately address this relationship. Another possible explanation 
could be attributable to the use of NVP itself. In keeping with the observations by Gonzalez et 
al, 2005, local researchers at the NICD (Kuhn et al, 2007) successfully confirmed a similar 
association between high infant CCL3-L1 gene copy numbers and reduced HIV-1 
susceptibility within the context of the South African black population. Their finding was 
however limited to detection “only in the absence of maternal NVP” or high maternal viral 
load (Kuhn et al, 2007). Coincidentally the cohort genotyped by Tiemessen and others 
included mother-infant sample pairs from the previously described South African PEP study 
wherein mothers were untreated (Gray et al, 2005). The investigators postulated that NVP 
could possess antiviral or immunomodulatory effects that may partially alter the role of CCR5 
and its ligands during HIV-1 transmission (Kuhn et al, 2007). In the PIVD study, 94.7% of 
women and 100% of infants received sdNVP as PMTCT standard of care. Kuhn and others 
found that sdNVP influenced CCL3 production and have suggested that ARV drugs used for 
PMTCT could possibly obscure genotype-transmission relationships (Kuhn et al, 2007). The 
CCL3-L1 gene dose may be an important genetic correlate of vaccine responsiveness 
(Gonzalez et al, 2005). ARV drugs may also affect the immunogenicity of vaccines that rely 
on appropriate support from this component of innate immunity. In light of current evidence, 
sdNVP still remains the cornerstone of therapy for PMTCT in many resource-poor settings 
and further investigation into the indirect consequences of ARV drugs used for this purpose 
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Paximadis and others investigated the role of a unique CCL3 haplotype (CCL3-Hap-1) in 
respect of HIV-1 susceptibility and MTCT (Paximadis et al, 2008). They found a lower Hap-1 
representation among in utero infected infants as opposed to intrapartum infected infants. In 
the PIVD study, CCL3-L1 Hap-1 allelic representation was detected in six (21.4%) of the 
exposed-uninfected infants. The absence of allelic representation among the intrapartum-
infected infants (n = 7) did not permit a statistical comparison between CCL3-Hap-1 
expression and susceptibility to intrapartum MTCT. Consistent with observations by 
Paximadis and others, no significant relationship was observed between CCL3-Hap-1 
presence and maternal CD4 cell counts or maternal viral loads (Paximadis et al, 2008). The 
role played by CCL3-Hap-1 in MTCT is very novel and further investigation in larger 
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CONCLUSION 
Detectable CVL HIV-1 RNA (viral load) that correlated well with plasma HIV-1 RNA, in 
conjunction with sub-optimal NVP drug concentration in maternal CVL during active labour 
suggests that HIV-1 infected women continue to act as reservoirs for both vertical and 
horizontal HIV-1 transmission throughout the duration of pregnancy. Early identification of 
women who need HAART and initiation of such therapy as early as possible during pregnancy 
not only benefits maternal health but remains the best prophylaxis against mother-to-child 
HIV-1 transmission. Universal access to HAART and improving strategies to optimize 
coverage of the current dual ARV regimen of sdNVP and ZDV for PMTCT remain urgent 
research priorities for several resource-limited settings. Early diagnosis and aggressive 
treatment of maternal STI’s are simple, cost-effective interventions that not only enhance 
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STUDY LIMITATIONS 
 
1) This study was limited by the use of cervicovaginal lavage (CVL) fluid. This 
method results in the dilution of mixed cervicovaginal secretions. All CVL 
samples were analyzed as whole unfractionated samples. While all HIV-1 RNA 
(viral loads) [copies/ml] were log10 transformed before statistical analysis, the 
dilution factor known to result during the CVL sample collection procedure was 
not taken into consideration during the analysis of HIV-1 RNA in this study. This 
widely-accepted practice has been noted in several publications and was also 
corroborated through personal communication with several research experts 
(Williamson, 2007; Puren, 2007; Hart, 2007; Kovacs, 2007; Cu-Uvin, 2007 and 
Reichelderfer, 2007).   
 
2) While all maternal (labour) samples were only collected after maternal sdNVP 
dosing, data reported in this study represents sampling during active labour and 
post-delivery. 
 
3) CVL labour sampling was not undertaken among women who had: 1) already 
progressed well into their labour upon arrival at labour ward; 2) bulging or 
ruptured membranes or 3) signs of excessive blood contamination. 
 
4) Wet mount microscopy was the screening method employed to detect STI’s, as 
opposed to gram staining, culture or molecular PCR techniques. Wet mount 
microscopy is also a valid method for STI screening recommended by the World 
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Health Organisation (WHO, 2005). While the prevalence rates reported in this 
study could have been under-estimated, the main purpose of undertaking 
antenatal STI screening was to rule out possible confounding factors which may 
have influenced detection of HIV-1 RNA (viral load) in maternal CVL.    
 
5) The small number of HIV-1 infected infants (n = 14) in this study, resulted in a 
smaller subset for CCL3-L1 genotyping analysis. This may have reduced the 
power of statistical analysis to adequately address relationships observed 
elsewhere. 
 
6) The Tandem Mass spectrophotometry method used to quantify NVP in maternal 
CVL has only been validated for use in plasma samples at the UCT host 
laboratory. 
 
7) The drug reference standard (NVP) used at the UCT host laboratory was a generic 
drug obtained from Aspen Pharmacare. 
 
8) The Cobas AmpliPrep/Cobas TaqMan system utilized for HIV-1 RNA (viral 
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RECOMMENDATIONS 
 
• Further investigation into ARV pharmacology and the effects of drug interaction, 
drug penetration and drug affinity in various bodily fluids and viral compartments. 
• Earlier identification of HIV-1 infected, pregnant women and commencement of 
HAART in these women as soon as possible to improve overall maternal health 
and prevent MTCT. This strategy prevents the unnecessary exposure of infants to 
ARV drugs. 
• Improve access and optimize coverage of the current dual regimen of ZDV and 
sdNVP for PMTCT [where HAART is unavailable]. This regimen reduces the 
likelihood of the development of NNRTI drug-resistant mutations typically 
associated with NVP monotherapy. 
• Promotion of the infant PEP strategy among healthcare workers as a valuable 
alternate strategy for reaching those women who: a) were missed by PMTCT, b) 
booked late for antenatal visits, c) arrived in advanced labour with unknown HIV 
status, d) refused or missed their intrapartum sdNVP dosing and also in instances 
where infants are born at home or on route to hospital. 
• Due consideration should be given to CCL3-L1 and other immune markers, in light 
of their implications in vaccine development. 
• Further exploration into the antiviral and immunomodulatory effects of NVP as 
well as other ARV drugs. 
• Continued STI screening by wet mount microscopy and aggressive treatment of 
STI’s during the course of pregnancy, with partner involvement where possible.  
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Appendix 5: Patient case report form (CRF) 
 
PHARMACO-IMMUNOLOGICAL-VIROLOGICAL DYNAMICS IN INTRAPARTUM 
HIV-1 TRANSMISSION (PIVD STUDY) 
 
PRE-NVP DOSING (BASELINE ANTENATAL VISIT)  
 
 
Study ID:           PIVD                                            
 
 
Patient Initials:                                      …   . 8         
 
 
ANC No:           8           888                  88  8        
 
 
Hospital No:      988                                8    88        
       
 
Informed consent obtained: Yes/no                  Enrolment date:         /    /   2   
 
 
Age:            (yrs)    Gestational age at visit:   NN           N       
 
 
Parity: NN          N    Gravida:  NN   N WR:  NN           N            Rh:  NN           N           
 
 
HIV status: NN          N     
 
 
Was NVP tab dispensed: Yes/no    Date of NVP issue:    /     / 200 5   
 
 





























CD4 cell count 
                                                              
                                       cells/ml 
 
HIV-1 ELISA 
   
 
FBC 
  Hb 
WCC 
Platelets 
SAMPLE COLLECTION    
 
CVL (10 ml) 
   
 
Blood (x2 EDTA) 
   
CVL volume collected    
CVL pH @ collection    
CVL blood level    
 
SAMPLE STORAGE 
   
Whole blood aliquoted    No of 1ml (WB) aliquots stored: 
Plasma spun & aliquoted    No of 1ml (P) aliquots stored: 











Wet mount microscopy    
 
CVL HIV RNA PCR 
                                                             
                                    copies/ml 
 
Plasma HIV RNA PCR 
                                                             
                                    copies/ml 
 
Plasma NVP concentration 
                                                             
                                         ng/ml 
 
CVL NVP concentration 
                                                    
                                         ng/ml 
 
CCL3 gene copy no 
   
                                copy/pdg 
 
CCL3L1 gene copy no 
   
                                copy/pdg 
 
OTHER 




- 238 - 
POST-NVP DOSING (LABOUR/DELIVERY) 
 
 
Date of onset of labour:          /      /2000          Time 12::0 0 am/pm    
 
NVP administered? Yes/no     Date:        /      /2000         Time 12::0 0 am/pm    
 
Was more than one dose given? yes/no        Time 12::0 0 am/pm    
 
Date of rupture of membranes:           /      /2000           Time 12::0 0 am/pm    
 
Mode of delivery:    NVD  MM   M Emergency C/S  MM   o       Other  MM              o 
   
Episiotomy: Yes/No                                     Instrumental delivery: Forceps/vacuum extraction 
 
No of live infants born::     SSS                            Gestational age at delivery: SS       SS      
 
Apgar score:  MM  M  (1min)    MM   M   (5min) 
 
 







Baby Study ID:                       
 
 
Date of birth:        /      /            Time of birth:       /      /           Sex:   Male/ Female     
 
 
Birth weight:              kg     OFC:                      cm    Length:  M    cm             
 
 




 dose given? Yes/No     Date:         /      /                 Time:        am/pm                
 
 


























FBC    
SAMPLE COLLECTION     
(MUM) 
CVL (10 ml) 
   
Blood (X2 EDTA)    
Total volume CVL collected     
pH of CVL     
Blood level of CVL     
(INFANT) 
Blood (X1 EDTA)   
   
SAMPLE STORAGE    
Mum whole blood aliquoted    No of 1ml (WB) aliquots stored: 
Mum blood spun & plasma 
aliquoted   
  No of 1ml (P) aliquots stored: 
CVL vortexed & aliquoted    No of 1ml (CVL) aliquots stored: 
Infant blood spun & plasma 
aliquoted  
  No of 200ul aliquots stored: 






Mum CVL  
HIV-1 RNA PCR 
                                                             
            
copies/ml 
Mum Plasma  
HIV-1 RNA PCR 
                                             
                                  copies/ml 
Mum Plasma  
NVP concentration 
                                                                  
                                        ng/ml 
Mum CVL  
NVP concentration 
                       
                                        ng/ml 
Mum CCL3 gene copy no   copy/p.d.g 
Mum CCL3-L1 gene copy    copy/p.d.g 
Infant plasma  
HIV-1 RNA PCR  
   
copies/ml 
Infant plasma  
NVP concentration 
   
ng/ml 
 
Infant HIV-1 DNA PCR 






- 240 - 
INFANT FOLLOW-UP ASSESSMENTS 
 
 
4-WEEK POST DELIVERY:  
 
 
Date of visit:        /     /            Baby weight:                   kg    
 
 
Is baby still being formula-fed? Yes/No 
 
 




















   
 
Blood (X1 EDTA)  




   
Blood spun and 
plasma aliquoted 









HIV DNA PCR 
   
 
HIV RNA PCR  
   
copies/ml 
 
NVP concentration  
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INFANT FOLLOW-UP ASSESSMENTS 
 
6-WEEKS POST DELIVERY:  
 
 
Date of visit:        /     /            Baby weight:                    kg    
 
 
Is baby still being bottle-fed? Yes/No 
 
 












LABORATORY EVALUATIONS DONE 
Y/N 
DATE RESULT 
INFANT SAMPLE COLLECTION    
Blood (X1 EDTA)    
 
SAMPLE STORAGE 
   
Whole blood aliquoted for host 
genetics 
  No of 200ul (P) aliquots stored: 
Blood spun & plasma aliquoted   No of 200ul (P) aliquots stored: 






HIV DNA PCR 
   
 
NVP concentration 
   
ng/ml 
 
CCL3 gene copy no 
   
copy/p.d.g 
 
CCL3-L1 gene copy no 
   
copy/p.d.g 




End of study 
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Appendix 6: Reagents and solutions – NVP quantitation assay 
 
A)  Nevirapine stock solution: 
A Nevirapine stock solution was first prepared by weighing out 0.001 grams of 
Nevirapine powder (drug reference standard) obtained from Aspen Pharmacare, South 
Africa). A calibrated analytical balance (Satorius) was used for accuracy. The 
Nevirapine powder was dissolved in one milliliter (1000 µl) of HPLC grade 
Acetonitrile (MERCK, Germany) to obtain a final concentration of 1 mg/ml. All stocks 
were stored at -80
o
C after use. 
 
B) Reserpine stock solution:  
0.001 grams of Reserpine powder (Sigma, St Louis, MO) was weighed out using a 
calibrated analytical balance (Satorius). Reserpine powder was reconstituted with one 
milliliter (1000 µl) of HPLC grade Acetonitrile (MERCK, Germany) and served as the 
internal standard in the assay. 
 
C)  100 µg/ml Nevirapine working standard: 
1 ml of Acetonitrile (MERCK, Germany) was added to a clean eppendorf tube. A 100 
µl volume of Acetonitrile was removed and discarded. This was replaced with 100 µl 
of Nevirapine stock (1 mg/ml) [from A above]. The eppendorf tube was vortexed 
thoroughly and labeled appropriately.  
 
D)  10 µg/ml Nevirapine working standard: 
1 ml of Acetonitrile (MERCK, Germany) was added to an eppendorf. A 100 µl volume 
of Acetonitrile was removed and discarded. This was replaced with 100 µl of 
Nevirapine Working standard (100 µg/ml) [from C above]. The eppendorf tube was 
vortexed thoroughly and labeled appropriately.  
 
E)  Nevirapine calibration standards [S1- S10] for plasma samples: 
Calibration standards contained ten non-zero calibrators. A calibration curve was run 
with every batch of samples run throughout the analysis period to evaluate the 
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calibration status of the assay and to also calculate the concentration of each unknown 
study sample within the batch. Calibration standards were made up in drug-free plasma 
obtained from the blood bank at Groote Schuur Hospital, Cape Town. Calibration 
standards were spiked to the final concentrations of 100, 200, 500, 800, 1000, 1300, 
1500, 2000, 5000, and 10 000 ng/ml respectively. 
 
F) Quality Control Samples for plasma samples 
Three quality control samples, [C1 (low), C2 (medium), and C3 (high)] with  
concentrations of 300 ng/ml (C1), 1800 ng/ml (C2) and 9000 ng/ml (C3) respectively 
were used to monitor the performance of the Nevirapine quantitation assay. These 
quality control samples were equally interspersed among unknown patient samples 
during each sample run. 
 
G)  Protein Precipitation Solution: 
Protein Precipitation contained 80% Methanol: 20% 0.2 M Zinc Sulphate (v: v) 
 
For a 250 ml volume of protein precipitation solution: 
Measure 200 ml of HPLC grade Methanol (MERCK, Germany). Add 50 ml of 0.2 M 
Zinc Sulphate (Sigma, St Louis, MO), followed by 150 µl of Reserpine (1 mg/ml) 
[from B]. Mix thoroughly and store in cold room when not in use. 
 
H)  0.2 M Zinc Sulphate 
Weigh out 28.75 grams of Zinc Sulphate (Sigma, St Louis, MO). Add 450 ml of 
deionised water (MERCK, Germany). Place onto a mixer until dissolved. Pour mixture 
into a measuring cylinder and top up to the 500 ml mark. 
 
I) Mobile Phase: 
Consisted of two bottles of reagents: 
Bottle A: 10% Methanol 
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Bottle A: 10% Methanol                     
Pour 100 ml of Methanol (MERCK, Germany) into a measuring cylinder. Add 900 ml of deionised 
water (MERCK, Germany). Cover with parafilm. Invert gently. Filter using vacuum filter apparatus. 
Sonnicate solution for ten minutes. Label appropriately and store at room temperature. 
 
Bottle B: (preparations) 
0.1% Glacial Acetic Acid 
Pour 1000 ml of deionised water (MERCK, Germany) into a clean bottle. Remove 1 ml and discard. 
Add 1 ml of concentrated analytical grade Glacial Acetic Acid (Pal Chemicals). Re-cap the bottle, 
invert to mix and label appropriately. 
 
10 mM Ammonium Acetate in 0.1% Glacial Acetic Acid 
Weigh out 0.38544 grams of Ammonium Acetate (MERCK, Germany). Measure 450 ml of 0.1% of 
Glacial Acetic Acid from above. Add Ammonium Acetate (MERCK, Germany) to it. Mix until 
dissolved. Top up to 500 ml with 0.1% Glacial Acetic Acid from above and label appropriately. 
 
Bottle B: (final) 
Measure 970 ml of Methanol (MERCK, Germany). Add 30 ml of 10 mM Ammonium Acetate in 
0.1% Glacial Acetic Acid from above. Mix and filter using vacuum filter apparatus. Sonnicate 
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       Appendix 8a: Drug resistance report for study patient without NNRTI drug resistant mutations 
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Appendix 8b: Drug resistance report for study patient with  
                   detectable NNRTI drug resistant mutations 
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Appendix 9: Preparation of a mini agarose gel (1%) 
 
A gel casting tray was rinsed and dried. The ends of the casting tray were sealed with tape 
before the tray was placed onto a level surface. The level of the comb was adjusted so that it 
rested with a few millimeters of space between the teeth and the tray. This allowed for the 
formation of wells in the agarose gel.  
 
An agarose gel (1%) was prepared by combining 50 ml of 1x Tris-Borate-EDTA or TBE 
buffer [Bulk 10x TBE buffer, Invitrogen, UK] and 1 tablet (0.5 grams) Agarose (Bioline, 
USA) in a glass bottle. The bottle was capped loosely and the agarose solution was placed into 
a microwave for two minutes on high power (or until agarose solution was clear). The agarose 
solution was gently swirled to mix, and then allowed to stand on the work bench for five 
minutes. Once the solution had cooled, 0.5 µg/ml Ethidium Bromide (Sigma, St Louis, MO), 
was added into the agarose solution and the entire solution was carefully poured into the 
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